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ABSTRACT OF DISSERTATION

METABOLISM REPROGRAMMING IN HEXAVALENT CHROMIUM-INDUCED
HUMAN LUNG CARCINOGENESIS
Hexavalent chromium, Cr(VI), is an established human carcinogen that is a
worldwide environmental health concern. It is well understood that reactive oxygen
species, genomic instability, and DNA damage repair deficiency are important contributors
to Cr(VI)-induced carcinogenesis. After decades of research some cancer hallmarks remain
understudied for the mechanism of Cr(VI) carcinogenesis. Dysregulated cellular energetics
have been established as a hallmark of cancer. Energy pathways that become dysregulated
in cancer include mitochondrial respiration, lipogenesis, pentose phosphate pathway, one
carbon metabolism, and increased anaerobic glycolysis in the presence of oxygen or
‘Warburg effect’.
To investigate metabolism changes in Cr(VI) carcinogenesis, we exposed
human lung epithelial cells (BEAS-2B cells) to Cr(VI) for six months and isolated a colony
from soft agar. To confirm the results in the BEAS-2B cells, we used two other sets of
Cr(VI)-transformed cells, human lung epithelial cells (BEP2D cells) and human lung
fibroblasts (WTHBF-6 cells).
We found increased lipogenesis related protein expressions including: ATP
citrate lyase (ACLY), acetyl-CoA carboxylase 1 (ACC1), and fatty acid synthase (FASN)
in Cr(VI)-transformed cells as compared to passage-matched control cells. We also
observed increased palmitic acid levels, confirming that Cr(VI)-transformed cells were
making more lipids. Cr(VI)-transformed BEAS-2B cells had decreased colony formation
in soft agar and decreased cell growth when treated with a FASN inhibitor (C75). ACLY,
ACC1, and FASN protein expressions were also increased in chromate-induced lung
tumors in human tissue samples.
We also observed that Cr(VI)-transformed human lung cells (BEAS-2B, BEP2D,
and WTHBF-6 cells) had no major changes in their mitochondrial respiration as measured
by the Seahorse Analyzer when compared to their passage-matched control cells.
Conversely, xenograft tumor-derived cells had mitochondrial respiratory dysfunction.
Interestingly, we also found that Cr(VI)-transformed human lung cells (BEAS-2B,
BEP2D, and WTHBF-6 cells) had no major changes in their glycolytic function as
measured by the Seahorse Analyzer when compared to their passage-matched control cells.
Similarly, these cells did not have changes in glycolytic enzymes or extracellular L-lactate

levels. Moreover, xenograft tumor-derived cells showed no changes in glycolytic endpoints
or L-lactate levels. This indicates these cells did not undergo the ‘Warburg effect’.
These data demonstrate that increased lipogenesis is important to Cr(VI)-induced
lung carcinogenesis and are consistent with the cancer literature which reports that
increased lipogenesis proteins occur during carcinogenesis. Additionally, our results
indicate mitochondrial respiratory dysfunction is likely a result of the tumor
microenvironment and a later step during Cr(VI) carcinogenesis. Lastly, we observed the
‘Warburg effect’ is not required for Cr(VI)-induced carcinogenesis in vitro. However, it
remains to be shown if the ‘Warburg effect’ is still a consequence or contributing factor
for tumorigenesis. Future studies are needed to investigate other metabolic pathways in
Cr(VI)-induced carcinogenesis. In conclusion, some metabolism pathways are important
to Cr(VI)-induced carcinogenesis, while others appear not to be.
KEYWORDS: Cellular Energetics, Hexavalent Chromium, Lung Cancer, Lipogenesis,
“Warburg effect”.

James Tate Fortin Wise

02/22/2019
Date

METABOLISM REPROGRAMMING IN HEXAVALENT CHROMIUM-INDUCED
HUMAN LUNG CARCINOGENESIS

By
James Tate Fortin Wise

Dr. Xianglin Shi
Director of Dissertation
Dr. Howard Glauert
Director of Graduate Studies
02/22/2019
Date

DEDICATION
I would like to dedicate this to my grandparents, Jane M. Fortin, Roger T. Fortin,
Kathleen Harrigan, Steve Seekins, and Francis Wise, Ph.D. Each has had their own
battle with cancer. I would also like to dedicate this to two of my uncles, Franklin D.
Wise and Mark C. Wise, both who passed during my time as a Ph.D. Student.

ACKNOWLEDGMENTS
I am grateful for all of the support from my first-rate committee members. I thank
Dr. Xianglin Shi, my mentor for his scientific leadership and insight in the area of metal
toxicity and carcinogenesis. I thank Dr. Jia Luo and Dr. Gang Chen for their expertise in
environmental health and carcinogenesis, and Dr. Yvonne Fouette-Mittendorf for her
expertise in molecular biology and epigenetics. Each of you have contributed significantly
through the years to make my education and research an excellent and enjoyable
experience. I would also like to thank Dr. Chenfeng Yang for acting as my external
examiner.
I thank all members of the Shi and Zhuo Zhang laboratories, past and present, who
helped me to make our labs a great place to study, work, and thrive scientifically. I
especially thank: Hong Lin for administrative support; Dr. Naglame Olive Ntube for her
support; and Dr. Lei Wang, for project start up support; and my fellow graduate students
Kourtney Schumann and J. Andrew Hitron. I would also like to thank Michael C. Alstott
of the Redox Metabolism Shared Resource Facility for his support with the Seahorse
Analyzer.
There are many other I would like to thank at a professional and education level:
Dr. Douglas Currie, my undergraduate advisor; Dr. Hong Xie, my undergraduate research
mentor who first trained me in environmental health and cell culture; Dr. John F. Lechner
for his continued insight into carcinogenesis (from in my undergraduate years and
continuing to this day), and his encouragements, and a special note on his development of
the culture of lung epithelial cells (without which this project would not be possible).

iii

At a personal level, I would like to thank my parents Dawn, Sandra, and John.
You all have always been supportive of my higher education goals. I especially thank, my
father, John for his continued support and for introducing me to the world of
environmental health and carcinogenesis back in high school, and my step-mother, Sandra
for her continued support and both her and my Dad taking me on adventures while in
graduate school. I would also like to thank my aunts and uncles: Tina, Cathy, Carole,
Michael, Mark, Franklin, Cheryl, Blaine, Lisa, and Richard. You all have been so
supportive, and loving over the years. I would also like to thank all my cousins. I specially
thank my grandparents Jane and Roger for always engaging me with discussions about
my graduate project and my continued success (even though they have no background in
science). I would also like to thank Jamie Young and Yosuke Sakamachi for their love,
support, and help.
I thank my siblings, Ashley, Catherine, and Johnny. Cathy and Johnny know the
trials and tribulations of graduate school and have been very supportive of my goals as
they go through the experiences and as we raise our Puerto Rican Terriers (Bucky, Pepper,
and Simbaa), and for our continued debates on science! I look forward to our continued
family adventures together, science discussions, and project collaborations.
I would like to thank all of my close friends for their love and support: Matthew
Braun, Tyler Davidson, Peter Hecker, Randall Hobbs, Hannah Kaltenbach, Jordan
Kennedy, Katie Lewis, Rachel Mowl, Tayler Croom-Pérez, Adam Pérez, Molly Reese,
Jim Slayer, Michael Stansfield, Kendra Stearns, Kamil Suja, Peter van Wie, Yongchao
Wang, Tongzhang Zheng, and Kai Zhang.

iv

For samples: I thank Dr. John P. Wise, Sr., University of Louisville, for the use of
the WTHBF-6 Cells; and Dr. Curtis Harris, National Institute of Health, for the use of the
BEP2D cells; and Kazuya Kondo, University of Tokushima Graduate School (Tokushima,
Japan) for the chromate lung tumor samples. This research was supported by National
Institutes of Health [(R01ES021771, R01ES020870, R01ES025515, R01ES28984,
R01ES21771, and P30ES026529) and the Redox Metabolism Shared Resource Facility of
the University of Kentucky Markey Cancer Center (P30CA177558).

v

TABLE OF CONTENTS

ACKNOWLEDGMENTS ................................................................................................. iii
LIST OF TABLES .............................................................................................................. x
LIST OF FIGURES ........................................................................................................... xi
CHAPTER 1. Introduction.................................................................................................. 1
1.1 Overview ................................................................................................................. 1
1.2 Chromium Exposure ............................................................................................... 3
1.2.1 Chromium is an Important Element ................................................................ 3
1.2.2 Chromium Exposure: Who is Exposed? ......................................................... 6
1.2.2.1 Occupational Exposure ............................................................................ 6
1.2.2.2 Exposure in the General Public................................................................ 8
1.2.2.2.1 Water ......................................................................................... 9
1.2.2.2.2 Air ........................................................................................... 10
1.3 Chromium is a Human Carcinogen....................................................................... 12
1.3.1 Evidence in Chromium Exposed Workers.................................................... 13
1.3.2 Evidence from Animal Studies ..................................................................... 16
1.3.3 Evidence in Cell Culture ............................................................................... 16
1.4 Physico-Chemical Factors in Cr(VI) Carcinogenesis ........................................... 17
1.4.1 The Role of Valence ..................................................................................... 17
1.4.2 The Role of Reactive Oxygen Species.......................................................... 17
1.4.3 The Role of Reducing Agents ....................................................................... 20
1.4.4 The Role of Solubility................................................................................... 22
1.4.5 A Physico-Chemical Mechanism for Cr(VI) ................................................ 23
1.5 Cr(VI) Genotoxicity .............................................................................................. 26
1.5.1 Oxidative DNA Damage ............................................................................... 27
1.5.2 DNA Adducts and Crosslinks ....................................................................... 27
1.5.3 DNA Single Strand Breaks ........................................................................... 27
1.5.4 DNA Double Strand Breaks.......................................................................... 28
1.5.5 Microsatellite Instability ............................................................................... 29
1.5.6 Mechanisms of DNA Repair of Cr(VI)-Induced Lesions DNA Repair ....... 30
1.5.7 Chromosome Instability ................................................................................ 32
1.6 Models for Cr(VI) Carcinogenesis........................................................................ 33
1.6.1 Characteristics of Cr(VI)-Induced Lung Tumors ......................................... 33
1.6.2 Characteristics of Cr(VI)-Transformed Cells ............................................... 36
1.6.3 Cr(VI) and Epigenetic Modificaiton ............................................................. 36
1.6.4 Cr(VI) and Multistage Carcinogenesis ......................................................... 40
vi

1.6.5

Cr(VI) and Genomic Instability .................................................................... 43

1.7 Dysregulated Cellular Energetics and Cancer ...................................................... 48
1.7.1 Increased Anaerobic Glycolysis or the “Warburg Effect” ............................ 48
1.7.2 Increased de novo Lipogenesis in Cancer ..................................................... 52
1.7.3 Pentose Phosphate Pathway in Cancer ......................................................... 55
1.7.4 One-Carbon Metabolism and Nucleotide Synthesis in Cancer..................... 55
1.7.5 Mitochondria and Cancer .............................................................................. 56
1.8 Chromium and Cellular Energetics ....................................................................... 56
1.9 Study Overview .................................................................................................... 58
1.10 Summary ............................................................................................................... 59
. Materials and Methods ................................................................................................... 61
2.1 Materials ............................................................................................................... 61
2.1.1 Cell Culture ................................................................................................... 61
2.1.2 Metals and Metal Preparation ....................................................................... 61
2.1.3 Drug Preparation and Treatment ................................................................... 61
2.1.4 Antibodies ..................................................................................................... 61
2.1.5 Protein Preparation and Quantification ......................................................... 62
2.1.6 Immunoblotting............................................................................................. 62
2.1.7 Immunofluorescence ..................................................................................... 63
2.1.8 Oil Red O Staining ........................................................................................ 63
2.1.9 Growth Curve................................................................................................ 63
2.1.10 Metabolism Kits ............................................................................................ 63
2.1.11 Seahorse Analyzer ........................................................................................ 63
2.1.12 Soft Agar Transformation Assay and Colony Isolation................................ 64
2.1.13 Xenograft Tumor Studies .............................................................................. 64
2.1.14 Cell Line Development ................................................................................. 64
2.1.15 Statistics ........................................................................................................ 64
2.1 Materials ............................................................................................................... 64
2.2.1 Cell Culture ................................................................................................... 64
2.2.2 Metals and Metal Preparation ....................................................................... 65
2.2.3 Inhibition Compound Preparation and Treatment ........................................ 65
2.2.4 Chronic Chromium Treatment ...................................................................... 65
2.2.5 Protein Preparation and Quantification ......................................................... 66
2.2.6 Immunoblotting............................................................................................. 66
2.2.7 Patient Lung Sample Collection ................................................................... 67
2.2.8 Immunofluorescence ..................................................................................... 67
2.2.9 Oil Red O Staining ........................................................................................ 68
2.2.10 Growth Curve................................................................................................ 68
2.2.11 Metabolism Kits ............................................................................................ 69
2.2.11.1 L-Lactate Acid Levels................................................................. 69
vii

2.2.12

2.2.13
2.2.14
2.2.15
2.2.16

2.2.11.2 Palmitic Acid Levels ................................................................... 69
Seahorse Analyzer ........................................................................................ 69
2.2.11.1 Fatty Acid Oxidation................................................................... 69
2.2.11.2 Glycolytic Rate Assay................................................................. 70
2.2.11.3 Glycolytic Stress Test ................................................................. 70
2.2.11.4 Mitochondrial Stress Test ........................................................... 71
Soft Agar Transformation Assay and Colony Isolation................................ 72
Xenograft Tumor Studies .............................................................................. 72
Cell Line Development ................................................................................. 73
Statistics ........................................................................................................ 73

CHAPTER 3. De novo Lipogenesis Is Important for Hexavalent Chromium-Induced
Lung Carcinogenesis......................................................................................................... 74
3.1 Overiew ................................................................................................................. 74
3.2 Prolonged Cr(VI) Exposure Induces Lipogenesis-Related Protein Expressions in
Human Lung Cell Lines ................................................................................................ 74
3.3 Chromium(VI)-Transformed BEAS-2B Cells Have Increased de novo
Lipogenesis ................................................................................................................... 77
3.4 Chromium(VI)-Transformed BEP2D Cells Have Increased de novo Lipogenesis
82
3.5 Chromium(VI)-Transformed WTHBF-6 Cells Have Increased de novo
Lipogenesis ................................................................................................................... 87
3.6 Increased de novo Lipogenesis is Important for Chromium(VI)-transformed Cels
93
3.7 Chromate-Induced Lung Tumors Show Increased Lipogenesis Protein
Expressions ................................................................................................................... 97
3.8 Importance .......................................................................................................... 101
CHAPTER 4. Elucidating a Role of Mitochondrial Respiratory Dysfunction During
Hexavalent Chromium-Induced Lung Carcinogenesis ................................................... 102
4.1 Overview ............................................................................................................. 102
4.2 Chromium(VI)-Transformed BEAS-2B Cells Do Not Exhibit Mitochondrial
Respiratory Dysfunction ............................................................................................. 102
4.3 Chromium(VI)-Transformed BEP2D Cells Do Not Exhibit Mitochondrial
Respiratory Dysfunction ............................................................................................. 108
4.4 Chromium(VI)-Transformed WTHBF-6 Cells Do Not Exhibit Mitochondrial
Respiratory Dysfunction ............................................................................................. 113
4.5 Cr(VI)-Transformed Cells Grow Tumors in Nude Mice .................................... 118

viii

4.6 Cr(VI)-Lung Fibroblast Xenograft Tumor-Derived Cells Have Mitochondrial
Respiratory Dysfunction ............................................................................................. 125
4.7 Importance .......................................................................................................... 134
CHAPTER 5. Anaerobic Glycolysis or the ‘Warburg Effect’ Is Not Important for
Hexavalent Chromium-Induced Lung Carcinogenesis ................................................... 135
5.1 Overview ............................................................................................................. 135
5.2 Chromium(VI)-Transformed BEAS-2B cells Do not exhibit the ‘Warburg effect’
137
5.3 Cr(VI)-Transformed BEP2D Cells Do Not Exhibit the ‘Warburg Effect’ ......... 143
5.4 Cr(VI)-Transformed WTHBF-6 Cells Do Not Exhibit the ‘Warburg Effect’ .... 150
5.5 Cr(VI)-Transformed WTHBF-6 Xenograft-Derived Cells Do Not Exhibit the
“Warburg Effect” ........................................................................................................ 157
5.6 Chromate-Induced Lung Tumors Do Not Show Increased Lactate Dehydrogenase
A Protein Expression .................................................................................................. 165
5.7 ATP Production .................................................................................................. 167
5.7 Importance .......................................................................................................... 174
CHAPTER 6. Disscussion .............................................................................................. 175
6.1 Overview ............................................................................................................. 175
6.2 Chromium and Lipid ........................................................................................... 177
6.3 Chromium and Mitochondria.............................................................................. 184
6.4 Chromium and ‘Warburg Effect’ ........................................................................ 190
6.5 Overall Role of Dysregulated Cellular Energetics in Cr(VI) Carcinogenesis .... 195
6.6 Proposed Cr(VI) Carcinogenesis Mechanism ..................................................... 196
6.7 Potential Future Directions ................................................................................. 203
6.8 Importance .......................................................................................................... 203
6.9 Conclusions ......................................................................................................... 204
APPENDICES ................................................................................................................ 205
APPENDIX A. COPYRIGHT PERMISSION LETTERS ......................................... 205
REFERENCES ............................................................................................................... 214
VITA ............................................................................................................................... 233

ix

LIST OF TABLES
Table 1.1
Table 1.2
Table 1.3
Table 6.1
Table 6.2
Table 6.3

Uses of Chromium Compounds......................................................................... 5
Occupations with Potential Chromium Exposure .............................................. 7
List of Chromate Epidemiology Studies in the United States ......................... 15
Results of Lipogenesis Experiments .............................................................. 183
Results of Mitochondria Respiration Experiments ........................................ 189
Results of Anaerobic Glycolysis Experiments .............................................. 194

x

LIST OF FIGURES
Figure 1.1 Cr-mediated Haber-Weiss Reactions ............................................................. 19
Figure 1.2 Mechanisms of Intracellular Cr(VI) Reduction.............................................. 21
Figure 1.3 Cr(VI) Cellular Uptake ................................................................................... 25
Figure 1.4 Mechanisms of Numerical and Structural CIN in Cr(VI) Carcinogenesis ..... 46
Figure 1.5 Glycolysis Overview ...................................................................................... 51
Figure 1.6 De novo Lipogenesis ...................................................................................... 54
Figure 3.1 Prolong Exposure to Cr(VI) Induces Lipogenesis-related Protein Expressions
in Human Lung Cells ........................................................................................................ 75
Figure 3.2 Chromium(VI)-Transformed BEAS-2B Cells Have Increased de novo
Lipogenesis Enzymes........................................................................................................ 78
Figure 3.3 Chromium(VI)-Transformed BEAS-2B Cells Have Increased Palmitic Acid
Levels ................................................................................................................................ 79
Figure 3.4 Chromium(VI)-Transformed BEAS-2B Cells Do Not Have Increased Fatty
Acid Oxidation .................................................................................................................. 80
Figure 3.5 Chromium(VI)-Transformed BEAS-2B Cells Do Not Have Increased Lipid
Droplets ............................................................................................................................. 81
Figure 3.6 Chromium(VI)-Transformed BEP2D Cells Have Increased De Novo
Lipogenesis Enzymes........................................................................................................ 83
Figure 3.7 Chromium(VI)-Transformed BEP2D Cells Have Increased Palmitic Acid
Levels ................................................................................................................................ 84
Figure 3.8 Chromium(VI)-Transformed BEP2D Cells Do Not Have Increased Fatty Acid
Oxidation........................................................................................................................... 85
Figure 3.9 Chromium(VI)-Transformed BEP2D Cells Do Not Have Increased Lipid
Droplets ............................................................................................................................. 86
Figure 3.10 Chromium(VI)-Transformed WTHBF-6 Cells Have Increased De Novo
Lipogenesis Enzymes........................................................................................................ 88
Figure 3.11 Chromium(VI)-Transformed WTHBF-6 Cells Have Increased Palmitic Acid
Levels ................................................................................................................................ 89
Figure 3.12 Chromium(VI)-Transformed WTHBF-6 Cells Do Not Have Increased Fatty
Acid Oxidation .................................................................................................................. 90
Figure 3.13 Chromium(VI)-Transformed WTHBF-6 Cells Do Not Have Increased Lipid
Droplets ............................................................................................................................. 91
Figure 3.14 Drug Inhibition Decreased FASN Protein Expression in Cr(VI)-Transformed
BEAS-2B Cells ................................................................................................................. 94
Figure 3.15 Increased De Novo Lipogenesis Is Important for Cr(VI)-transformed Cells
Growth .............................................................................................................................. 95
Figure 3.16 Increased de novo Lipogenesis Is Important for Cr(VI)-transformed Cells
Growth in Soft Agar.......................................................................................................... 96
Figure 3.17 Chromate Lung Tumors Show Increased ACLY Protein Expression .......... 98
Figure 3.18 Chromate Lung Tumors Show Increased pACLY and ACC1 Protein
Expressions ....................................................................................................................... 99
xi

Figure 3.19 Chromate Lung Tumors Show Increased FASN Protein Expression ........ 100
Figure 4.1 Chromium(VI)-Transformed Bronchial Airway Epithelial Cells (BEAS-2B)
Do Not Have Mitochondrial Respiratory Dysfunction ................................................... 104
Figure 4.2 Chromium(VI)-Transformed Bronchial Airway Epithelial Cells (BEP2D) Do
Not Have Mitochondrial Respiratory Dysfunction ......................................................... 109
Figure 4.3 Chromium(VI)-Transformed Human Lung Fibroblasts (WTHBF-6) Do Not
Have Mitochondrial Respiratory Dysfunction ................................................................ 114
Figure 4.4 Chromium(VI)-Transformed Human Lung Bronchial Cells (BEAS-2B) Grow
Tumors in Nude Mice ..................................................................................................... 119
Figure 4.5 Chromium(VI)-Transformed Human Lung Bronchial Cells (BEP2D) Grow
Tumors in Nude Mice ..................................................................................................... 121
Figure 4.6 Chromium(VI)-Transformed Human Lung Fibroblasts (WTHBF-6) Grow
Tumors in Nude Mice ..................................................................................................... 123
Figure 4.7 Xenograft Tumor-derived Cells Have Dysfunctional Mitochondrial
Respiration ...................................................................................................................... 127
Figure 5.1 Chromium(VI)-Transformed BEAS-2B Cells Do Not Exhibit the ‘Warburg
Effect’ ............................................................................................................................. 137
Figure 5.2 Chromium(VI)-Transformed BEP2D Cells Do Not Exhibit the ‘Warburg
Effect’ ............................................................................................................................. 144
Figure 5.3 Chromium(VI)-Transformed WTHBF-6 Cells Do Not Exhibit the ‘Warburg
Effect’ ............................................................................................................................. 151
Figure 5.4 Xenograft Tumor-Derived Cells Do Not Exhibit the ‘Warburg Effect’ ...... 158
Figure 5.5 Chromate Lung Tumors Compared Do Not Show Increased LDHA Protein
Expression ....................................................................................................................... 166
Figure 5.6 ATP Production of Chromium(VI)-Transformed Cells ............................... 169
Figure 5.7 ATP Production of Xenograft Tumor-Derived Cells ................................... 172
Figure 6.1 Chromium(VI) Transformation Changes ..................................................... 198
Figure 6.2 Updated Cr(VI) Carcinogenesis Mechanism................................................ 201

xii

Chapter 1 Introduction
1.1. Overview
Chromium is a naturally occurring element found ubiquitously worldwide. It was
first discovered by Louis-Nicholas Vauquelin in Siberian red lead (crocoite) in 1797.
Chromium is a transition metal found in group 6 of the periodic table. It has a ground state
electron configuration of [Ar]3d54s1 and its abbreviation is Cr, and has an atomic number
of 24 with an atomic mass of 51.9961 (IARC, 1990). Chromium occurs in various valence
states, with the most common and stable being Cr(0), Cr(III), and Cr(VI). Cr(0), or metallic
chromium, is a steel-gray solid that has a high melting point and is used to make steel and
other metal alloys. There are other unstable valance states that occur in biological systems
[e.g., Cr(IV) and Cr(V)]. Cr(III) was considered for a long time as an essential element but
has recently been deemed by the European Union and experts in the field as non-essential
and subsequently has been removed from the United States Dietary Associations’ 20152020 dietary guidelines (USDA, 2017; Vincent, 2010;). Trivalent chromium is generally
considered safe at pharmacological and dietary exposure levels (Vincent, 201; Wise et al.,
2018b). Meanwhile, Cr(VI) is an established human and animal carcinogen and is the most
toxic form of Cr.
The first suspected documented case of Cr(VI)-induced cancer was reported in
1890, a Cr(VI)-pigment worker was diagnosed with adenocarcinoma of the nasal turbinate
bone (Newman, 1891). Following this finding, there have been countless studies
demonstrating a correlation between occupational exposures to Cr(VI) and cancers. Most
of these reported cancers being lung and nasopharyngeal in origin, suggesting that
inhalation is the primary route of exposure (Wise et al., 2008). Furthermore, epidemiologic
studies of chromate-exposed workers have estimated a 2 to 80-fold increased risk in
1

respiratory system cancers (Langard, 1990; Leonard and Lauwerys, 1980; OSHA, 2006).
In conjunction with these studies, animal studies have supported the epidemiologic data,
and further implicated Cr(VI) in respiratory cancers (IARC, 2012; Levy 1986a, 1986b).
Cr(VI) found in the environment is largely due to industrial activity and it is
considered stable when there are no available reducing agents. Most of the serious adverse
health effects documented for chromium are attributed to its hexavalent form as other
valence states, namely Cr(III), have not been shown to be carcinogenic; however, the latter
has shown some negative health effects, including contact dermatitis and kidney and liver
damage (EPA, 1984; NIOSH, 2006).
Cr(VI) is the most potent form of chromium due to its ability to be transported
through the cell membrane, Cr(III) is unable to penetrate the cell membrane and has poor
passive absorption. Once inside the cell Cr(VI) is rapidly reduced to Cr(III) while the
extracellular Cr(VI) is slowly reduced and contributes to a chronic exposure to Cr(VI).
Prolonged exposure to Cr(VI) is key to its toxic and carcinogenic effects (Wise et al.,
2008). It has been established that either chronic or repeated prolonged exposures to Cr(VI)
leads to neoplastic transformation (Kim et al., 2015; Kim et al., 2016; Wise J et al., 2018a;
Wise S et al., 2018). Additional changes include: redox imbalances, imbalance of
numerous proteins, growth signal changes, and DNA repair inhibition that results in
chromosome instability (Wise S et al., 2018). We hypothesize that Cr(VI)-transformed
cells will have cancer cell properties (i.e., dysregulated energy metabolism).
Here we summarize the significance of chromium exposure and the exposed
populations. We also discuss the known physico-chemical mechanisms of Cr(VI) exposure
which contribute to its carcinogenesis. Next, we discuss the current models of Cr(VI)2

induced carcinogenesis. Then we discuss dysregulated energy metabolism in cancer.
Lastly, we discuss how dysregulated energy metabolism may have a role in Cr(VI)-induced
lung carcinogenesis.
1.2. Chromium Exposure
Chromium has several unique properties that make it a unique metal and thus
when addressing the exposure of Cr(VI) it is important to understand its complexity. It
is also important to understand the relevance of this complexity for exposed human
populations.
1.2.1 Chromium is an Important Element
Chromium is a common abundant element found in the Earth’s crust. Elemental
chromium is a steel grey, hard metal with a high melting point. Since chromium is highly
resistant to corrosion and heat, it is widely used in the metallurgic industry. The name
chromium is derived from the Greek word “chroma”, meaning color. When chromium is
combined with other chemicals it can produce compounds of a variety of colors, making
these compounds highly attractive for producing pigments and dyes.
Chromium can exist in oxidation states from -2 to +6 (ATSDR, 2012). The most
commonly occurring stable oxidation states are 0, 3, and 6. Other states are occasionally
found but, are considered highly unstable and rapidly oxidized or reduced to more stable
states. In the natural environment, pH and oxidative states of the environment (soil and
water) will greatly influence which species of chromium will predominate. The bulk of
Cr(VI) found readily available in the environment is from anthropogenic causes (ATSDR,
2012).
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The major uses for Cr(VI) include chemical industries, metallurgic, refractory, and
the leading use is in stainless steel. Stainless steel consists of 12 to 30 percent chromium
(the higher quality of stainless correlates with more chromium). Other major uses include
anticorrosive applications, chrome plating, leather tanning, paints, and dyes (including
tattoo ink), as well as a wood preservative. Table 1.1 provides a list of some of the
chromium compounds and their major uses.
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Table 1.1 Uses of Chromium Compounds
Activity/Use

Type of Chromium Exposure

Chromate production and
smelting

Sodium, potassium, calcium, and ammonium chromates and
dichromates; alkaline chromates, chromic sulfate, sodium chromate,
sodium dichromate

Chrome plating

Chromium trioxide, chromic chloride, chromic sulfate

Pigment production and use

Zinc chromate, lead chromate, chromic hydroxide, chromic acid,
chromic oxide, chromic phosphate, calcium chromate, chromium
trioxide, potassium dichromate, sodium chromate, barium chromate,
strontium chromate

Corrosion inhibition

Calcium chromate, chromic oxide, chromic nitrate, chromic chloride,
chromium trioxide, barium chromate, strontium chromate, zinc chromate

Stainless steel and alloy
production

Metallic chromium, cobalt chromium, ferrochromium, chromic oxide,
strontium chromate

Welding

Alkaline chromates, chromic oxide

Tanning

Chromic acetate, chromic hydroxide, chromic sulfate, potassium
chromic sulfate, ammonium dichromate, sodium chromate, sodium
dichromate

Dyeing

Chromic acid, potassium chromic sulfate, ammonium dichromate,
potassium chromate, potassium dichromate, sodium chromate, sodium
dichromate

Adapted from IARC, 1990
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1.2.2. Chromium Exposure: Who is Exposed?
1.2.2.1. Occupational Exposure
Chromate ore is used to produce hexavalent chromium for industrial purposes.
Around 14 million tons of chromate ore are mined yearly, with the majority of chrome
ore mined in India, Kazakhstan, Russia South Africa, and Turkey (IARC, 1990; Wise et
al., 2008). The production method affects the final form for Cr(VI). For example, the
final product can be primarily insoluble Cr(VI) when using lime in production or soluble
Cr(VI) when using soda ash in production.
Occupational exposures to Cr(VI) is of major health concern and is the top source
of high dosage human exposure. The main routes of exposure are dermal contact and
inhalation. Recently ingestion has become an exposure concern, given the prevalence in
drinking water of Cr(VI). It is estimated that workers in industries that involved Cr(VI)
typically have exposure rates that are two orders of magnitude higher than the general
population (ATSDR, 2012). OSHA (2006) estimates that approximately 558,000 U.S.
workers are exposed to Cr(VI). Table 1.2 is a list of occupations in which workers may
be exposed to Cr(VI).
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Table 1.2 Occupations with Potential Chromium Exposure
Abrasives manufacturers
Jewelers
Acetylene purifiers
Laboratory workers
Adhesives workers
Leather finishers
Aircraft sprayers
Linoleum workers
Alizarin manufacturers
Lithographers
Alloy manufacturers
Magnesium treaters
Aluminum anodizers
Match manufacturers
Anodizers
Metal cleaners
Battery manufacturers
Metal workers
Biologists
Milk preservers
Blueprint manufacturers
Oil drillers
Boiler scalers
Oil purifiers
Candle manufacturers
Painters
Cement workers
Palm-oil bleachers
Ceramic workers
Paper water proofers
Chemical workers
Pencil manufacturers
Chromate workers
Perfume manufacturers
Chromium-alloy workers
Photoengravers
Chromium-alum workers
Photographers
Chromium platers
Platinum polishers
Copper etchers
Porcelain decorators
Copper-plate strippers
Pottery frosters
Corrosion-inhibitor workers
Pottery glazers
Crayon manufacturers
Printers
Diesel locomotive repairmen
Railroad engineers
Drug manufacturers
Refractory-brick manufacturers
Dye manufacturers
Rubber manufacturers
Dyers
Shingle manufacturers
Electroplaters
Silk-screen manufacturers
Enamel workers
Smokeless-powder manufacturers
Explosives manufacturers
Soap manufacturers
Fat purifiers
Sponge bleachers
Fireworks manufacturers
Steel workers
Flypaper manufacturers
Tanners
Furniture polishers
Textile workers
Fur processors
Wallpaper printers
Glass-fiber manufacturers
Wax workers
Glass frosters
Welders
Glass manufacturers
Wood-preservative workers
Glue manufacturers
Wood stainers
Histology technicians
Adapted from IARC, 1990
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In occupational settings, airborne Cr(VI) concentrations can range from 5 µg/m3
to 600 µg/m3 depending on the industry (Stern, 1982). Occupational setting levels are
significantly higher than the Cr concentrations in ambient air in industrial cities which
generally ranges from 0.01 to 0.03 µg/m3 (Fishbein, 1981). Blood levels of chromium
in occupationally exposed workers are also increased and chromium lung burdens are
higher (Gerhardsson et al., 1988; McAughey et al., 1988). It has been reported that
workers at a British pigment factory exposed to strontium and lead chromates had
chromium levels in their blood from 3-216 µg/L, while in non-occupationally exposed
workers chromium levels were less than 1 µg/L (McAughey et al. 1988). The chromium
lung burden was higher in occupationally exposed workers was 2.3 to 4 times higher
than both urban and rural residents (Gerhardsson et al., 1988). Given the high level of
health effects (including lung cancer), in 2006, the National Institute for Occupational
Safety and Health (NIOSH) lowered the permissible exposure limit in ambient air for an
8 hour period from 52 µg/m3 to 5 µg/m3 Cr(VI). Still, studies report that industrial air
Cr(VI) concentrations frequently exceed the occupational exposure limits (Blade et al.,
2007). Therefore, despite permissible limits being set, workers in industries using Cr(VI)
compounds are often exposed to high levels of Cr(VI) and are still at a higher risk for
developing adverse health effects.
1.2.2.2. Exposure in the General Public
Cr(VI) mainly enters the environment from anthropogenic sources. The
anthropogenic sources of Cr(VI) include industrial waste streams from electroplating,
leather tanning, and textile industries, and factories making dyes and pigments.
Typically, Cr(VI) is in soils as a result of the disposal of commercial products containing
chromium, coal ash from electric utilities, and chromium waste from industry. Cr(VI)
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generally enters the air largely as particulate from the manufacturing and use of metal
chromates. Cr(VI) can also enter the environment in lesser amounts from cement
production, the combustion of fossil fuels, industrial cooling towers, and municipal
incinerators. Chromium has been found in at least 1,127 of the 1,699 hazardous waste
sites listed on the EPA’s National Priorities List (ATSDR, 2012).
The majority of high-dose chromium exposures occurs in the industrial settings,
however, there is still a risk to the general populations. The general population is
exposed to chromium via inhalation or ingestion of contaminated food and water. Levels
of Cr(VI) in food are generally lower (IARC 2012). Interestingly, in salt water
environments, chromium predominates as Cr(VI). Thus, given this and that chromium
bioaccumulates in marine organisms, it is possible that chromium exposure may also
occur due to consumption of seafood containing a high dose of bioaccumulated
chromium. Air quality values of Cr(VI) for U.S. urban and nonurban areas were reported
to be 5-525 ng/m3 (ATSDR 2012). More precise levels for the different regions of the
United States can be found from the Environmental Protection Agency (EPA).
1.2.2.2.1 Water
Chromium predominates as Cr(VI) in the public drinking water systems (Moffat
et al., 2018; Zhitkovich 2011). Members of the general population that reside near
industrial facilities and waste sites will have a higher risk of exposure. A well-known
example of chromium exposure to a general human population, is Hinkley, California,
where the legal case against Pacific Gas and Electric Company’s contamination of the
drinking water was documented in the movie Erin Brockovich. Another example is
Hudson County, New Jersey, where it is estimated that 2 million tons of industrial waste
were produced by local chromium industries (ATSDR, 2012). This waste contamination
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has been documented as a contributor to occasional blooms of particulate Cr(VI) on the
ground’s surface. Given that Cr(III) can be oxidized by chlorine to Cr(VI), it is possible
that Cr(III) contamination of drinking water sources can result in Cr(VI) in the water
supply (Zhitkovich, 2011). The level of chromium in U.S. freshwaters ranges from <130 μg/L and U.S. drinking water contains total chromium levels of 0.2–35 μg/L (ATSDR
2012). In California (CA) drinking water supplies, it was reported that 86% of the
sources tested reported levels of Cr(VI) below 10 μg/L (Moffat et al., 2018). A recent
epidemiological report of individuals living near industrial waste sites in CA has shown
lasting reproductive and developmental impacts on the non-occupationally exposed
population (Remy et al., 2017).
1.2.2.2.2 Air
Roughly 60-70% of the atmospheric chromium emissions are from human
activities (ATSDR, 2012). Sources of chromium contamination in the air can be from
industrial processes and waster, municipal water incineration, cement dusts, cigarette
smoke, and e-cigarettes, and brake lining dust (ATSDR, 2012; Farsalions and Rodu,
2018). Cigarette smoke can significantly increase chromium levels in indoor air. More
data are still needed to determine the public significance of environmental Cr(VI)
exposure as the likelihood of adverse health effects are not limited to occupational
exposures.
Roughly 2,700 to 2,900 tons of chromium is released into the atmosphere in the
U.S. and about a third can be hexavalent (ATSDR, 2012). Total chromium in ambient
air in the U.S. is estimated to be 0.005 to 0.525 µg/m3 (ATSDR, 2012) while the
concentrations in ambient air within the vicinity of ferrochrome industries can be 10 to
100-fold higher. Cr(VI) particles half-life in the atmosphere varies on the particle size
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and density. The smaller, more aerodynamic particles (less than 10 µm) remain longer
in the air ATSDR, 2012). These smaller particles are also potentially more likely to
negatively impact human health due to this smaller size enabling them to pass through
the larger areas of the lung and nose. The particles can then deposit and possibly
accumulate in the bifurcation sites within the lung rodents (Speer and Wise, 2018; Wise
et al., 2008).
Some urban cities are known to have high levels of fine particulate matter (PM2.5),
which may contain chromium, specifically in Mexico City. Residents in this city are
exposed to year-round air pollution concentrations above the United States’ National Air
Ambient Air Quality Standards. (1) In a study by Calderón-Garcidueñas et al. (2013), the
lungs of polluted air-exposed young adults of Mexico City contained chromium
equivalent to 2524 ± 581 µg/g dry weight whereas in the control reference lungs it was
368 ± 179 µg/g dry weight. In the same study, the frontal lobe of the brain had chromium
levels of 910 ± 63 µg/g dry in adults and 527 ± 85 µg/g dry weight in the reference
individuals. The chromium levels in the lungs of the Mexico City adults was higher than
the study’s control group was not statistically significant, but the levels in the brains were.
(2) However, chromium levels were higher in both the control and high exposed young
adults than those reported in chromate workers (21.3 µg/g wet weight) (Tsuneta et al.,
1980). (3) Adjusting for wet weight versus dry weight (assuming a 75% moisture), the
adjusted mean values for the Mexico City residents is 3367 µg/g wet weight and the
reference residents is 1824 µg/g wet weight and the chromate workers levels would be
15.98 µg/g dry weight. Thus, these values show us that the Mexico City residents had a
150 to 160-fold increase in chromium levels compared to workers that died of chromate
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induced lung tumors, while the fold increase for the Mexico City resident paper was 85115 times higher than in chromate workers. While the authors did not measure any known
health effects from Cr(VI), these data are important as it shows that urbanites exposed to
particulate matter in the city can accumulate chromium in their tissues and environmental
exposures may be of health concerns.
1.3. Chromium is a Human Carcinogen
Multiple regulatory agencies have classified Cr(VI) as a human carcinogen. The
International Agency for Research on Cancer (IARC) lists Cr(VI) as a human
carcinogen. IARC listing is based on sufficient evidence from humans and animals
studies on the carcinogenicity of Cr(VI) compounds (IARC, 2012). More specifically,
for humans, the risk of respiratory cancers is high for workers in chromate production,
chromate pigment production, and chromium plating industries. The EPA lists airborne
Cr(VI) as a Group A or a human carcinogen via inhalation exposure (EPA, 1984).
Furthermore, the Agency for Toxic Substances and Disease Registry (ATSDR) states
that occupational exposure to Cr(VI) compounds are associated with increased
incidences of lung cancers (ATSDR, 2000). Lastly, the NIOSH considers that all Cr(VI)
compounds are potential occupational carcinogens (NIOSH, 2006).
Most of the epidemiological studies have implicated Cr(VI) as a respiratory tract
carcinogen and some studies provide evidence to suggest that Cr(VI) may also play a
role in other cancers. Chromium-exposed workers have been reported to have higher
incidences of digestive tract cancer, but these results were not statically significant
(Enterline, 1974; Machle and Gregorius, 1948; Royle, 1975; Sheffet et al., 1982).
Recent data have indicated that Cr(VI) exposure in drinking water can cause
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gastrointestinal carcinomas in mice and rats (Moffat et al., 2018; NTP, 2008; Stout et
al., 2009). Although there is no data on these cancer types in Cr(VI) contaminated
drinking water human exposed population, studies indicate Cr(VI) may cause
gastrointestinal tract cancers. Interestingly, oral exposure to Cr(VI) in combination with
UV exposure increases the levels of chromium in the skin and increases skin
carcinogenesis (Davidson et al., 2004; Uddin et al., 2007). Yet, Cr(VI) effects on the
respiratory system remain the primary health concern and thus studies focus on Cr(VI)
role as a human lung carcinogen. While, chromium has been found above permissible
limits in tattoo inks, it remains unclear if there is a higher incidence in skin cancer rates
of individuals with tattoos (Bocca et al., 2018).
1.3.1. Evidence in Chromium Exposed Workers
The first reported epidemiologic studies in Cr(VI)-exposed workers was in 1948.
Table 1.3 highlights some early epidemiologic studies in Cr(VI)-exposed workers in the
U.S. The 1948 study reported that 22 percent of the chromate production workers died
of respiratory cancers compared to less than 2 percent of an unexposed reference
population. These chromate workers had an 18 to 50-fold increased risk of death due to
lung cancer (Machle and Gregorius, 1948). A similar study reported lung cancer death
rates among chromate workers were 15 times higher than the general population
(Mancuso, 1951). Subsequent studies have provided supporting data showing the
insoluble Cr(VI) compounds produced from the high lime production process are more
carcinogenic than the soluble Cr(VI) forms (Alderson et al., 1981; Baetjer, 1950; Hayes
et al, 1979; NIOSH, 2006).
The chromate pigment production industry also has a high rate of occupational
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exposures to chromium. These industries rely heavily on the use of insoluble forms of
Cr(VI), for example, lead chromate and zinc chromate. Epidemiological studies of
chromate pigment workers have showed similarly high lung cancer risk as those works
in the chromate production industry (Langard, 1990; NIOSH, 2006). The first chromate
pigment epidemiologic study calculated a risk ratio of 38 in exposed workers (Langard
and Norseth, 1975). Epidemiological studies from countries other than the U.S. have
also shown a two- to three-fold increased risk of developing respiratory cancer in
chromate workers (Davies, 1979, 1984; Frentzel-Beyme, 1983; Sheffet et al., 1982).
Additionally, chronic exposure in the pigment industry is associated with a higher risk
of lung cancers (Hayes et al., 1989).
Recent epidemiological studies reported an improvement in the risks posed to
chromate workers. This is due to the increased hazard awareness and improved
protection procedures for those at highest risk; however, the risk remains elevated
compared to control populations (Luippold et al., 2003; Mancuso, 1997; Proctor et al.,
2016). A key factor to the observed decline of lung cancers in chromate workers is due
to the elimination or reduction of lime usage during the production process. In 2006, the
United States’ Occupational Safety and Health Admiration (OSHA) reduced their 8 h
permissible exposure limits (PEL) from 52 µg/cm3 to 5.0 µg/cm3 (OSHA, 2009) and
thus future studies may show an additional reduction in respiratory cancers in chromaterelated employments.
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Table 1.3 List of Chromate Epidemiology Studies in the United States
Study
Population

Years of
Exposure

Reference
Population

Major
Endpoints

6 chromate
plants; 156
deaths

4-17 years
before 1948

Oil refining
company

bronchial
and lung
cancers

1940-1948

US male;
white and
black

1950, 1953
and 1958

1940-1949 and
1950-1959

7 United
States
chromate
factories
3 United
States
chromate
producing
plants
United
States
chromium
plant

Estimated
Relative Risk

Reference

32

26

Machle
and
Gregorius,
1948

Lung cancer

10

14.3

Galafer,
1953

Males

lung cancer

71

3.6

Taylor,
1966

Baltimore
City

lung cancer

59

2

15

No. of
Cases

Hayes et
al., 1979

1.3.2. Evidence from Animal Studies
Many animal studies have assessed the carcinogenicity of chromium and these
studies support the epidemiological data. These studies indicate that Cr(VI) is the cancercausing form of chromium. Furthermore, these studies support that the more potent
carcinogenic forms of Cr(VI) are the insoluble forms (IARC, 1990). Inhalation,
intrabronchial instillation or implantation exposures of calcium chromate in mice and
rats induced lung tumors (Nettesheim et al., 1971; Steinhoff et al., 1986; Levy 1986a,
1986b). Chromium trioxide as a mist induced tumors in mice (Adachi et al., 1986); the
same result was seen with inhalation and intratracheal administrations (Adachi et al.,
1986; Levy 1986a, 1986b). Intrabronchial implantation of either lead chromate or
strontium chromate led to lung tumors in rats (Levy 1986b). Other insoluble forms of
chromium, for example, sodium dichromate, have been shown to induce lung tumors in
animals (Glaser et al., 1986; Steinhoff et al., 1986).
1.3.3

Evidence in Cell Culture

Numerous cell culture studies have provided invaluable data for the mechanisms of
Cr(VI)-induced carcinogenesis. Cellular transformation studies also support the
epidemiologic and animal studies and further demonstrate that the particulate forms of
Cr(VI) are the more potent carcinogenic form of Cr(VI) (Patierno et al., 1988; Elias et
al., 1989; IARC, 1990). Cell culture studies demonstrated that extracellular dissolution
of Cr(VI) particles is important for the genotoxic effects of chromium (Wise et al.,
2004a). Cell culture studies in human cell lines also showed that acute/prolonged (less
than 120 h) high dose exposures or chronic (6 months) environmentally relevant dose
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exposures can induce neoplastic transformation (Kim et al., 2015; Pratheeshkumar et
al., 2106; Wise J et al., 2018a; Wise S et al., 2018; Xie et al., 2007).
1.4. Physico-Chemical Factors in Cr(VI) Carcinogenesis
1.4.1. The Role of Valence
The carcinogenic potency differences between Cr(III) and Cr(VI) are due to their
cellular uptake differences, being a result of their valence states. Cr(III) is poorly
absorbed by cells as it forms large bulk molecules with ligands such as water, cysteine,
glutathione, sulfates or organic acids (Costa and Klein 2006; EPA 1990; Wise J et al.,
2018b). Whereas Cr(VI) forms a chromate (CrO42-) anion, which structurally resembles
phosphate (PO43-) and sulfate (SO42-), that readily allow cell internalization via
facilitated diffusion (De Flora and Wetterhahn, 1989). Intracellular Cr(VI) does not
directly interact with DNA or proteins (evidenced in cell-free systems) (Fornace et al.,
1981). Cr(VI) is rapidly reduced intracellularly to Cr(III) by a variety of mechanisms
that are dependent on the reducing agents, like glutathione and ascorbate (De Flora and
Wetterhahn, 1989). Major results of this intracellular reduction of Cr(VI) to Cr(III)
include highly reactive intermediates such as Cr(IV), Cr(V) (De Flora and Wetterhahn,
1989; Wise J et al., 2018b). Cr(III) is not readily excreted from the cells and can lead to
high intracellular chromium concentrations. It is still unknown if Cr(III) or its reactive
intermediates are the ultimate carcinogen, as all three have the ability to react with and
damage DNA and cellular proteins (De Flora and Wetterhahn, 1989).
1.4.2. The Role of Reactive Oxygen Species
In regards to Cr(VI)-induced carcinogenesis, the reactive oxygen species produced
from the reduction of Cr(VI) to Cr(III) is considered important to the mechanism
underlying the carcinogenesis of Cr(VI) (Shi et al., 1998, 1999). Cr(III) from this reduction
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can interact with various cellular components (discussed in section 1.5). Reactive oxygen
species (ROS) are generated by Cr(VI) and Cr(III). These ROS occur from a Haber-Weiss
reaction (Figure 1.1). In the classical reactions (Haber-Weiss and Fenton) involving iron,
O2•- mediates •OH generation from H2O2 and also participates in the reduction of Fe(III)
leading to the Fenton reaction. In the case of Cr(VI) and Cr(III), both species can replace
Fe(II) to produce •OH. The Haber–Weiss reaction may also involve the different valence
states of chromium, such as Cr(IV) and (V). The Haber–Weiss-type mechanism of •OH
generation is likely to be more predominant in vivo than other reaction (Shi et al., 1998,
1999).

18

Figure 1.1. Cr-mediated Haber-Weiss Reactions.
This figure shows a schematic of the reactive oxygen species produced by Cr(III) and
Cr(VI), the intermediate chromium species produced, and the various reactive oxygen
species produced during these processes.
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1.4.3. The Role of Reducing Agents
Multiple intracellular components, like ascorbate, cysteine, glutathione,
NADPH, ribose, fructose, and cytochrome P450, as well as certain cellular organelles,
can act as cellular reductants for Cr(VI) (Figure 1.2) (Shi et al., 1999; Wise J et al.,
2018b). Studies suggest that ascorbate may be the principal reductant in vivo (Standeven
and Wetterhahn 1991, 1992; Zhitkovich 2011); however, these studies were carried out
by exposing extracted cytosolic fractions to Cr(VI) and did not use whole animals (Wise
et al., 2008). Unlike rodents, humans are not able to synthesize ascorbate like rodents.
Rodents may have evolved a system that overemphasizes ascorbate as a primary
mechanism for pro-oxidant reductions. Subsequent studies have relied on these rat
studies and presume that ascorbate is the principal reductant and ascorbate is
supplemented to the media in cell culture studies. Interestingly, addition of ascorbate to
cell culture media resulted in higher mutation frequencies (base substitutions and
deletion mutations) (Quievryn et al., 2003, 2006; Reynolds et al., 2007a). The
physiological levels of ascorbate in human lung tissues are relatively low and thus the
pro-oxidant activity of ascorbate may not be the primary contributing mechanism for
Cr(VI) reduction in human lung tissue and cells (Slade et al., 1985; Yavorsky et al.,
1934). This possibility is further supported by the low levels of mutations seen in Crinduced human lung cancers. Further, whole animal studies utilizing electron
paramagnetic resonance (EPR) analysis revealed that Cr(VI) is preferentially reduced
by NADPH, producing high valent chromium species, that are believed to be
responsible for reactions with DNA (Liu et al., 1995). Unfortunately, the principal
reductant for Cr(VI) in human lung tissue still remains unknown at this time.
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Figure 1.2. Mechanisms of Intracellular Cr(VI) Reduction.
This figure shows the mechanisms by which Cr(VI) is reduced to Cr(III) inside the cell.
Glutathione can reduce Cr(VI) in a one- or two-electron reaction whereas cysteine is
almost exclusively considered to reduce Cr(VI) in a one-electron reaction with NADPH
providing electrons. Ascorbate reduces Cr(VI) in a two-electron reaction skipping the
Cr(V) intermediate and immediately forming Cr(IV). As a result of all of these
reductions. ROS are formed which can lead to oxidative damage to nucleic acids,
proteins, and lipids. Reprinted from Reference Module in Chemistry, Molecular
Sciences and Chemical Engineering, 2018, Speer RM and Wise, JP Sr. Current Status
on Chromium Research and Its Implications for Health and Risk Assessment, Pages No.
3, Copyright (2018), with permission from Elsevier [OR APPLICABLE SOCIETY
COPYRIGHT OWNER]." Also, Lancet special credit - "Reprinted from The Lancet,
2018, Speer RM and Wise, JP Sr. Current Status on Chromium Research and Its
Implications for Health and Risk Assessment, Pages No. 3, Copyright (2018), with
permission from Elsevier."
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1.4.4. The Role of Solubility
Solubility plays a key role in the carcinogenic potential of chromium compounds.
Animal studies and human epidemiologic studies demonstrate particulate (or waterinsoluble forms) of Cr(VI) are potent carcinogens. Studies of soluble chromium
compounds showed relatively small effects in the increases of lung tumors and these
results are linked to the fact that soluble forms of Cr(VI) are rapidly reduced (De Flora
et al., 1997; IARC, 1990). Additionally, these results in rodent studies were attributed
to the much higher level of ascorbate in rodents (Speer and Wise, 2018; Wise et al.,
2008).
Many studies have established that the more insoluble forms of Cr(VI), e.g.
calcium chromate, lead chromate, strontium chromate, and zinc chromate, cause
significant increases in lung tumor formation (IARC, 1990). Similarly, workers who
died of Cr(VI)-induced lung cancer had Cr(VI) deposits at their lung bifurcations sites,
where the particles are likely to impact pathology and cancer (Ishikawa et al., 1994a,
1994b). Given the slow rate of clearance for particulate Cr(VI), these deposits can
efficiently produce a prolonged exposure of Cr(VI) to lung tissue. Prolonged exposure
to particulate Cr(VI) in human lung cell culture studies further support this conclusion
resulting in increased levels of aneuploidy, chromosome damage, DNA damage repair
deficiency, and neoplastic transformation (Holmes et al., 2006a, 2006b, 2010; Wise S et
al., 2018; Xie et al., 2007; Xie et al., 2015). Interestingly, recent studies of chronic
exposure to soluble Cr(VI) showed that chronic exposure results in neoplastic
transformation (Kim et al., 2015, 2016; Pratheeshkumar et al., 2016, 2017; Wise J et
al., 2018). Even through prolonged exposure to soluble Cr(VI) can induce
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transformation in cell culture, animal, cell culture and human studies still show that the
particulate form is a more potent carcinogen.
1.4.5. A Physico-Chemical Mechanism for Cr(VI)
Extracellularly, particulate Cr(VI) dissolves releasing the chromate oxyanion,
which then enters the cell by facilitated diffusion (Wise et al., 1994; Wise S et al., 2004a)
(Figure 1.3). While the cation and the particle can be taken into the cell, studies report
that these internalized particles do not dissolve intracellularly and thus both the particle
and cation have no reported cellular effects (Wise S et al., 2004a; Xie et al., 2004;
Holmes et al., 2005). On the other hand, soluble Cr(VI) compounds make the chromate
oxyanion directly available to enter the cell through facilitated diffusion. After the
Cr(VI) ion is in the cell it is rapidly reduced by intracellular reductants to Cr(III) (De
Flora and Wetterhahn, 1989). Cr(III) or the reactive Cr intermediates then interact with
intracellular molecules and induce the observed damaging effects. Studies have
demonstrated that Cr can bind to DNA directly altering its conformation or in the event
of DNA replication, leading to a DNA break (Cupo and Wetterhahn, 1985;
Madhusudanan et al., 1999; Standeven and Wetterehahn, 1992; Tsapakos et al., 1983;
Zhitkovich et al., 1996). Interestingly, studies on the binding of Cr with DNA reveal
there are inconsistencies in our understanding of the binding mechanism and exactly
where Cr binds DNA remains elusive. Recently, it was observed that Cr(III) binds
weakly to the DNA phosphate backbone in a reversible interaction likely through
electrostatic forces (Zhou et al., 2016). Cr(III) also interacted with nucleobases and
formed stable cross-links. When neutral or high pH was restored in these experiments,
Cr(III) gradually lost its DNA binding ability which was likely due to hydrolysis. While
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this study reveals some information about Cr-DNA binding kinetics, the physiological
relevance remains elusive. There are limited other studies regarding the direct interaction
of Cr with cellular molecules. This part of the Cr(VI) carcinogenesis mechanism still
remains unclear.
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Figure 1.3. Cr(VI) Cellular Uptake.
This figure shows a model for the cellular uptake of chromate (VI) anion. Following
exposure to Cr(VI) (insoluble or soluble), Cr(VI) anion is the key species and not the
cation. The chromate anion is taken into the cell (via facilitated diffusion mimicking sulfate
and phosphate ions) and reduced to reactive intermediates, Cr(IV) and Cr(V), and lastly to
Cr(III). While, the particulate Cr(VI) enters the cell typically through phagocytes and has
no contribution to Cr(VI) carcinogenic mechanism.
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1.5. Cr(VI) Genotoxicity
It is well accepted that Cr(VI) can induce DNA damage. Specifically, Cr(VI) can
cause DNA single and double strand breaks; DNA adducts and crosslinks; oxidative
lesions of DNA bases; and chromosome instability. Cr(VI) itself does not directly react
with DNA but Cr(III) and the same intermediates (produced during intracellular
reduction) have a high level of reactivity toward DNA (O’Brien et al., 2002; Speer and
Wise, 2018). Chromium can also form covalent and electrostatic bonds with intracellular
molecules (e.g., amino acids, ascorbate, cysteine, histidine, and glutathione) and then can
lead to DNA adducts (O’Brien et al., 2002; Speer and Wise, 2018). In support of this
concept, lymphocytes from Cr(VI)-exposed workers had increased levels of DNA-protein
crosslinks (Medeiros et al., 2003). The Cr-DNA adducts and crosslinks are considered
important in Cr(VI)-induced carcinogenesis, by causing cell cycle arrest, mutations, gene
expression changes, and polymerase arrest (Patierno and Landolph, 1989; Manning et al.,
1992; Yang et al., 1992; Bridgewater et al., 1994; Chen and Thilly 1994; Speer and Wise,
2018).

1.5.1. Oxidative DNA Damage
The ROS from the reduction of Cr(VI) leads to oxidative DNA damage and
produces alterations in DNA including abasic sites, base and sugar lesions, DNA-protein
cross-links, and strand breaks. If these damages are left unrepaired, they can lead to
biological consequences that are detrimental to an organism, including cell death,
mutations and ultimately malignant transformation (Wise et al., 2008). Studies have
shown Cr(VI) damages both purines and pyrimidines (Blasiak and Kowalik, 2000; Qi et
al., 2000; Slade et al., 2005; Sugden and Martin, 2002). Studies have provided evidence
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that the main lesion of nucleobases is on the guanine residue and forms 7,8-dihydro-8oxoguanine (8-oxoG) (Slade et al., 2005). Oxidative DNA damage from Cr is not limited
to the guanine residues, but, can also occur at adenine bases in Cr(VI)-treated lung cells
(Arakawa et al., 2012). Another study suggested that the 8-oxoG lesion is susceptible to
additional oxidation by Cr and forms the lesion spiroiminodihydantoin (Sp) and may be
capable of carcinogenic initiation following Cr(VI) exposure and toxicologically more
important than the 8-oxoG lesion (Slade et al., 2005). However, these lesions have not
been explored after particulate Cr(VI) exposure and additional investigations are needed.
1.5.2. DNA Adducts and Crosslinks
Cr(VI) is able to cause Cr-DNA adducts, Cr-DNA crosslinks and DNA-protein
crosslinks, which can lead to additional cellular injuries (e.g. DNA polymerase arrest, gene
expression changes, and mutagenesis) (Singh et al., 1998). Macfie et al., 2010 proposed a
stepwise mechanism for the formation of protein-Cr-DNA crosslinks. Cr(VI) is reduced to
Cr(III) and Cr(III) then binds to DNA. Following the slow capture of proteins by the binary
Cr-DNA adduct, a ternary protein-Cr-DNA crosslink forms. Additionally, the repair of
these lesions may cause DNA single and double strand breaks. The isolation and detection
of a specific Cr-DNA adduct have proven difficult despite a robust effort from many
laboratories and the isolation of the exact lesion remains elusive. It remains unclear if Cr
is binding directly to DNA bases or is electrostatically associating with the phosphate
backbone. The Cr interactions with DNA are important because these interactions lead to
the various consequences of DNA strand breaks and ultimately chromosomal aberrations.
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1.5.3. DNA Single Strand Breaks
Insoluble and soluble forms of Cr(VI) have been reported to induce DNA single
strand breaks (Hodges et al., 2001; Sugiyama et al., 1986; Yang et al., 2005). Animal
Cr(VI) exposure studies have shown single strand breaks occurred in lymphocytes and
somatic cells of the brain, kidney, liver, lung, and spleen (Kleinsasser et al., 2001; Ueno et
al., 2001). It remains unclear if the single strand breaks are formed by direct DNA damage
or are formed indirectly as a byproduct of excision repair. Cell-free system studies suggest
that they are indirect (Messer et al., 2006), but more studies are warranted. It is possible a
DNA double strand break may occur from the conversion of single strand break to a double
strand break (Speer and Wise, 2018).
1.5.4. DNA Double Strand Breaks
In addition to single strand breaks, both particulate and soluble forms of Cr(VI)
have been shown induce DNA double strand breaks in animals a n d i n cultured human
cells (Ha et al., 2004; Reynolds et al., 2007a; Wakeman et al., 2004; Wang et al., 2006;
Wise et al., 2010; Xie et al., 2005, 2009;). These double strand breaks were detected by
increased migration of broken DNA in an agarose gel electrophoresis (comet assay) and
gamma-H2A.X (g-H2A.X) foci. DNA double strand breaks can arise from the collapse
of a replication for, the conversion of a single strand break to a double strand break during
replication, and a stalled replication fork (as their formation is limited to the late S- and
G2-phases of the cell cycle) (Ha et al., 2004; Reynolds et al., 2007a; Speer and Wise,
2018).
1.5.5. Microsatellite Instability
Cr(VI)-induced tumors have shown microsatellite instability (MIN) at two or more
loci and longer Cr(VI) exposures have a greater frequency of MIN (Hirose et al., 2002;
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Takahashi et al., 2005b). MIN and Cr(VI) has been investigated in only one cell culture
study. Human lung epithelial (BEAS-2B) cells were transformed by a chronic low dose
of soluble Cr(VI). One Cr(VI)-transformed cell line was isolated which had an increased
expression of a mismatch repair gene but had no evidence of microsatellite instability
(Rodrigues et al., 2009). This Cr(VI)-transformed cell line did display a high degree of
chromosomal instability. The results from these suggest that MIN may not be a driving
factor in Cr(VI)-induced carcinogenesis but may be a result of later stages or a potential
consequence from other genomic changes.
1.5.6. Mechanism of DNA Repair of Cr(VI)-Induced Lesions DNA Repair
Cr(VI) is a well-known genotoxicant agent and can produce several types of DNA
damage and unchecked these damage can lead to apoptosis, cytotoxicity, growth arrest,
and mutations. In normal basal conditions, cells are able to swiftly and proficiently repair
damage. If damages are left unrepaired or misrepaired, it can lead to neoplastic
transformation and ultimately tumorigenesis. Therefore, scientists have been
investigating how Cr(VI) interferes with different DNA repair mechanisms for decades.
Base excision repair (BER) is the primary pathway used to repair DNA alkylation,
oxidation lesions, and single strand breaks. Data indicate that BER and single strand break
repair occur after Cr(VI) exposure (Speer and Wise, 2018; Wise and Wise, 2018; Wise et
al., 2018). Further, the specific mechanisms involved in repairing these lesions are still
poorly understood. Currently, it is too difficult to formulate a repair pathway for Crinduced lesions and more investigations are required to identify these specific repair
mechanisms after Cr(VI) exposures (Speer and Wise, 2018; Wise and Wise, 2018; Wise et
al., 2018).
Single-strand breaks are generally detected by poly [ADPribose] polymerase 1
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(PARP1), and this detection is followed by processing of the DNA ends. These steps are
coordinated by the enzyme X-ray repair cross-complementing protein 1(XRCC1).
XRCC1 acts as recruiter and scaffold for other proteins required for repair (Caldecott,
2008). Cell culture studies have shown that XRCC1 appears to be involved in the repair
of Cr(VI)-induced lesions and these data are supported from an epidemiological study in
Cr(VI) workers (Zhang et al., 2012). Additionally, failed single-strand break repair after
Cr(VI) exposure leads to more complex forms of damage (Bryant et al., 2006; GrlickovaDuzevik et al., 2006a, 2006b; Zhang et al., 2006).
Nucleotide excision repair is used to repair chemically modified bases and helical
distortions in the DNA (Gillet and Scharer, 2006). Data indicate that nucleotide excision
repair occurs after Cr(VI) exposure, which is consistent with the observations that these
lesions are produced by Cr(VI). To date, the specific mechanism for repairing these
lesions after Cr(VI) exposure is still uncertain. More studies are needed to formulate a
repair pathway for these lesions. Interestingly, studies have shown evidence that
nucleotide excision repair may be pro-mutagenic or anti-mutagenic after Cr exposures,
but more studies are necessary (Speer and Wise, 2018; Wise and Wise, 2018; Wise et al.,
2018).
Mismatch repair functions to recognize and repair mispaired bases and
insertion/deletion loops generated during DNA replication. Cr-induced lung cancer
patients have shown higher rates of replication errors than lung cancer patients lacking Cr
exposures and some mismatch repair proteins are repressed at a higher rate (Takahashi et
al., 2005b). Likewise, Cr(VI)-exposed cancer patients with alterations in mismatch repair
proteins (MLH1) were at a higher risk for lung cancer development (Halasova et al.,
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2016). Additionally, these results are supported by cell culture studies, which have
provided further evidence that mismatch repair (MMR) proteins may increase the
genotoxicity of Cr-DNA adducts by causing replication fork collapse thus leading to DNA
double strand breaks (Peterson-Roth et al., 2009; Reynolds et al., 2007a; Reynolds and
Zhitkovich, 2007) Mismatch repair proteins were able to recognize ternary Cr-DNA
adducts, but did not recognize binary Cr-DNA adducts. The generation of Cr-induced
chromosomal breaks and double strand breaks was dependent on the ternary Cr-DNA
adducts, as they were mistakenly processed by MMR proteins as mismatches and
consequently processed into these DNA breaks (Reynolds et al., 2009). These studies
show that mismatch repair is active after Cr(VI) exposure but the specific repair
mechanism remains unclear. Studies provide evidence that both MLH1 and MSH2 are
candidate genes involved. Remarkably, as was observed for nucleotide excision repair;
proficient mismatch repair seems to be more genotoxic than deficient repair, this is
additionally interesting as the Cr-induced human tumors appear MMR-deficient. This
further suggests that obtaining a state of mismatch repair-deficiency is likely a later event
in Cr(VI)-carcinogenic process and that Cr(VI)-induced mismatch damage is likely
acquired after other carcinogenic changes have occurred.
The two primary DNA double strand break repair pathways are homologous
recombination (HR) and non-homologous end joining (NHEJ). Non-homologous end
joining is considered a low fidelity pathway due to the loss of genetic material during its
repair process. A study reported NHEJ is not critical in protecting cells against Cr(VI)
exposure (Camyre et al., 2007). Unlike NHEJ, homologous recombination is considered
to be a high-fidelity repair mechanism and is critical in preventing chromosome
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instability. Multiple groups have found homologous recombination is impaired following
Cr(VI) exposure and recently observed a loss of RAD51 protein expression and function
(Browning et al., 2016; DeLoughery et al., 2015; Qin et al., 2014; Reynolds et al., 2007).
DNA crosslink repair is utilized to repair adducts that tether both strands of DNA
together. Interstrand crosslinks cause a stalled DNA replication fork. Studies report that
Cr does induce DNA crosslink repair but the components of the crosslinks remain
uncertain but are likely to involve amino acids, DNA, and/or proteins (Savery et al., 2007;
Vilcheck et al., 2002, 2006). The specific mechanisms involved in repairing these cross
link regions remain elusive and inadequate to formulate a repair pathway for these Crinduced lesions. Future studies are still required to elucidate the specific crosslink repair
mechanisms.
1.5.7. Chromosome Instability
Particulate and soluble Cr(VI) have also been reported to damage chromosome
structure, which can manifest as chromosomal aberrations. Numerous studies have
extended these findings to human lung epithelial cells and fibroblasts and demonstrate that
damage occurs in both a concentration- and time-dependent manner (Holmes et al., 2006a,
2006b, 2010; Kost et al., 2012; Wise et al., 2002, 2004a, 2004b, 2004c, 2004d, 2006b,
2018; Wise and Wise, 2012; Xie 2004, 2008, 2009, 2015). Cr(VI) has also been shown to
affect mismatch repair which is used to repair Cr-DNA adducts (discussed above) (Zecevic
et al., 2009). Additionally, failure of this process can lead to a stalled replication fork and
ultimately double strand breaks (Barbour and Xiao, 2003). These double strand breaks
occur during late S and G2 (DeLoughery et al., 2015; Reynolds et al., 2004; Xie et al.,
2009). If DNA double strand breaks are unattended to, they can lead to chromosomal
instability (CIN) (Masuda A and Takahashi, 2002). CIN is a common occurrence in lung
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cancers and has been observed in chromate-induced tumors (Maeng et al., 2004). CIN can
occur in multiple forms, including in the form of numerical CIN (change in chromosome
number), structural CIN (form of translocations), or DNA breaks contributing to Cr(VI)
carcinogenesis (Figure 1.4) (Albertson et al., 2003; Speer and Wise, 2018). Improper
chromosomal segregation after Cr(VI) exposures appears to due to supernmumerary
centromeres. Centromeres are important for the chromosomal separation during cell
division (Holmes et al., 2010; Martino et al., 2015).
These studies provide significant evidence that both structural and numerical CIN
play a key role in the mechanism of Cr(VI)-induced carcinogenesis. The abnormal
chromosome numbers or deletions/insertions in whole chromosomes or genes can result in
aberrant gene expression. These changes can then lead to more carcinogenic outcomes.
The complete pathways involved in maintaining fidelity in these mechanisms are still being
examined. There is significant evidence that genomic instability is a key driver of Cr(VI)induced carcinogenesis.
1.6. Models for Cr(VI) Carcinogenesis
Although, various mechanisms for Cr(VI)-induced carcinogenesis have been
established, the ultimate mechanism of Cr(VI)-induced carcinogenesis remains elusive.
Currently, there are three well-recognized paradigms for chemical carcinogenesis that can
be applied to a probable model of Cr(VI)-induced carcinogenesis. These models are
epigenetic modification, multistage carcinogenesis, and genomic instability.
1.6.1. Characteristics of Cr(VI)-Induced Lung Tumors
Chromium accumulates high concentrations at lung bifurcation sites in chromateexposed workers (Ishikawa et al., 1994a). Another study showed multiple tumors at these
bifurcation sites, mainly squamous cell carcinomas (Ishikawa et al., 1994b). Additionally,
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in these workers with lung cancer, the levels of chromium were higher than workers who
did not have lung cancer (Ishikawa et al., 1994b). It has been reported that there is no
correlation between chromium accumulation in the lungs, but there was a correlation
between chromium accumulation and the malignancy stage of the lung cancer (Kondo et
al., 2003). This finding was further supported in animal studies (Takahashi et al., 2005a).
Studies have reported there are very few mutations in key oncogenes or tumor
suppressor genes in chromium-induced tumors. There were fewer mutations found in p53
in Cr(VI)-induced lung tumors when compared to lung tumors with no Cr(VI) exposure
and those tumors with mutations in p53 had no association with the length of chromium
exposure (Kondo et al., 1997). Additionally, Katabami et al. (2000) reported there was no
difference in p53 protein expression in Cr(VI)-induced lung tumors. Likewise, there were
no point mutations found in the ras oncogene (Ewis et al, 2001).
Chromate-induced lung tumors have been characterized by features that are
associated with genomic instability. Microsatellite instability markers were found in 79%
of Cr(VI) induced tumors compared to only 15% of non-Cr(VI) exposed tumors (Hirose et
al., 2002). Microsatellite instability markers were increased proportionally with chromium
exposure (Hirose et al., 2002) and further correlated with a decrease in the hMLH1
(mismatch repair gene) protein expression but microsatellite instability was not associated
with the hMSH2 (mismatch repair gene) repression (Takahashi et al., 2005b). Furthermore,
Hirose et al. (2002) also reported a higher level of methylation in CpG islands in the MLH1
gene was present in the tumors of Cr(VI) exposed tumors when compared to non-Cr(VI)
tumors. However, this change in CpG islands in the gene was not correlated with the
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observed decreased in protein expression. These studies suggest a mechanism for MIN in
Cr(VI)-induced lung cancers that does not involve a loss of mismatch repair proteins.
Studies have also revealed that Cr(VI)-induced lung tumors exhibit chromosome
instability. Loss of heterozygosity was reported at 6 different loci in 50-75% of Cr(VI)induced lung tumors but this result was not significantly different from non-Cr(VI) lung
tumors (Hirose et al., 2002). These findings could implicate loss heterozygosity may be a
general mechanism for lung carcinogenesis given that most lung cancers exhibit significant
chromosome instability (Masuda and Takahashi, 2002). No further studies have
investigated chromosome instability in Cr(VI)-induced lung tumors and no examinations
of chromosome complement have carried out on.
Other characteristics reported of Cr(VI)-induced lung tumors include alterations in
cyclin D1 and p16 protein expressions (Katabami et al., 2000; Kondo et al., 2006),
methylation of the APC (adenomatosis polyposis coli) gene (Ali et al., 2011), alterations
in the surfactant protein B (SP-B) gene (Ewis et al., 2006), and changes to EGFR and Nrf2
(Kim et al., 2015, 2016). However, the EGFR and Nrf2 were only examined in one
chromate worker lung tumor. APC is the gene that has been reported to be mutated in
patients with familial adenomatous polyposis coli (colon cancer). Further, the silencing of
this gene activates the Wnt signaling pathway which could lead to excessive cell
proliferation and eventual tumor development (Nusse, 2005). Alterations of the SP-B gene
may potentially lead to abnormal clearance ability in these individuals and enhance
susceptibility to particulates in Cr(VI)-exposed workers. Both cyclin D1 and p16 are
important cell cycle regulators (Katabami et al., 2000; Kondo et al., 2006) and changes of
these protein expressions could allow for otherwise damaged cells to escape the normal
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cell cycle arrest and continue to proliferate. Increased activate EGFR protein expression
could lead to further cancer cell growth and tumor proliferation and increased Nrf2 and
downstream antioxidant proteins could protect the cell against the harsh pro-oxidant
environment (Kim et al., 2015, 2016).
1.6.2. Characteristics of Cr(VI)-Transformed Cells
There are no cell lines available from chromate lung tumors. Chronic exposure to
low doses of Cr(VI) has been shown to induce neoplastic transformation of human lung
cells (Kim et al., 2015; 2016, Pratheeshkumar et al., 2016; 2017). Additionally, acute
exposure to high doses of Cr(VI) can also induce neoplastic transformation (Xie et al.,
2007). Over the past decade these Cr(VI)-transformed cells have been investigated for
different cancer endpoints. These Cr(VI)-transformed cells have distinct properties when
compared to passage-matched control cells. EGFR overexpression and constitutive
activation have been shown to be important in these transformed cells (Kim et al., 2016).
Additionally, constitutive Nrf2, HIF-1a, and p62 expression have been shown to be
important in the cancer properties of these transformed cells (Kim et al., 2015, 2016;
Pratheeshkumar et al., 2016; 2017; Roy et al., 2016). Epigenetic changes have also been
reported in Cr(VI)-transformed cells (Pratheeshkumar et al., 2016; 2017; Wang Z et al.,
2018) Cr(VI)-transformed cells also have the ability to evade apoptosis ((Kim et al., 2015,
2016; Pratheeshkumar et al., 2016; 2017). Lastly, Cr(VI)-transformed cells have genomic
instability and altered DNA repair responses (Wise S et al., 2018; Xie et al., 2007). Given
the difficulty in assessing all endpoints in chromate tumors, these data from Cr(VI)transformed cells can be used to understand changes during Cr(VI)-induced transformation
and can be used to further understand the mechanism underlying Cr(VI) carcinogenesis.
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1.6.3. Cr(VI) and Epigenetic Modification
Epigenetics are modifications that are heritable changes that can alter cellular
function but do not require changes to genetic material. (Herman and Baylin, 2003).
Epigenetic modifications or changes to the epigenome suggested as an important
carcinogenic mechanism. The two main epigenetic modifications are DNA methylation
and histone modifications. Other reported epigenetic changes include histone variants,
microRNA (miRNA) expression, and nucleosome repositioning (Sharma et al., 2010).
These modifications can alter gene expression and last for several generations or the
lifetime of the cell. Changes can down- or upregulate pathways. Cr(VI) has been shown to
induce epigenetic changes in methylation of DNA and histone modifications and cause
gene expression changes and signaling pathway changes in cell culture studies. However,
studies in Cr(VI)-induced tumors and epigenetic alterations are limited.
Takahashi et al. (2005a) reported hMLH1 and hMLH2 expression was decreased in
chromate tumors due to hypermethylation of the promoter region. Additionally, these
tumors also were reported to have significant repression of the tumor suppressor
p16INK4a. This repression was correlated with DNA hypermethylation of the promoter in
patients with exposure to chromium for more than 15 years (Kondo et al., 2006). It was
also reported that tumor suppressor genes, APC and hMLH1 were hypermethylated in
Cr(VI)-exposed lung cancers (Ali et al., 2011). Wang et al. (2012) found that in individuals
actively exposed to Cr(VI) with Cr accumulation in their blood showed global DNA
hypomethylation which correlated with low levels of folate, DNA strand breaks, and
urinary 8-hydroxy-2'-deoxyguanosine. Similarly, other changes in gene expression in
chromate tumors have been observed, e.g. increased cyclin D1 and decreased survivin
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(Halasova et al., 2010; Katabami et al., 2000). Interestingly, 61.3% of chromate tumors
had surfactant B gene variants (deletion or insertion) (Ewis et al., 2006). Another study
found hypermethylation of CpG sites in DNA repair genes, including RAD51, increased
in Cr(VI)-exposed workers compared to non-exposed workers. Furthermore, these data
were correlated to blood Cr levels of the workers and this study confirmed their results in
human bronchial epithelial cells (16HBE cells) treated with Cr(VI) (Hu et al., 2018). A
study trying to develop a biomarker for Cr(VI) reported that mitochondrial DNA isolated
from the blood of chromate workers was hypomethylated (Yang et al., 2016). No studies
have investigated miRNAs in chromate tumors. Li et al. (2014) reported decreased miR3940-5p levels in the blood with Cr exposure from chromate workers.
Cell culture studies have addressed different epigenetic changes as a result of
chromium exposures. Some cell culture studies have shown significant changes in DNA
methylations (Klein et al., 2002; Lou et al., 2015). Other epigenetic modifications observed
in cell culture studies include histone acetylation and methylation (Hu et al., 2016;
Schnekenburger et al., 2007; Sun et al., 2009; Zhou et al., 2009). Acetylation of histone
tails is commonly associated with increased gene expression, while methylation is
associated with both increased and decreased repression (depending on where the
methylation site is). Sun et al. (2009) found changes in histone methylation leading to
tumor suppressor gene silencing events. Interestingly, Wei et al., 2004 found Cr(VI) could
crosslink a histone deacetylase to inducible promoters, which resulted in increased gene
expression. Similarly, acetylation of histone H4 of the stressor protein Nupr1 was
downregulated after Cr(VI) exposure in BEAS-2B cells which led to increased Nupr1
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protein expression. The overexpression of Nupr1 protein is associated with cancers (Chen
et al., 2016).
Another histone modification is biotinylation, the covalent binding of biotin to other
molecules. The biological role of histone biotinylation remains unclear but is believed to
be involved with histone acetylation and DNA damage response (Xia et al., 2014). Cr(VI)
treated 16HBE cells had differential histone biotinylation and differential distribution of
biotinidase depending on the Cr(VI) concentration (Xia et al., 2014). Furthermore, in
Cr(VI) treatments the authors reported histone deacetylation could play a role in histone
biotinylation further adding to the complexity of these histone modification mechanisms.
Human bronchial epithelial cells (BEAS-2B cells) were evaluated for gene
expression changes following a 2-month exposure to chromium. The authors utilized
single-cell RNA sequencing (Park et al., 2017). This study reported that Cr(VI) with or
without a CRISPR/cas9 deletion of Gene 33 (a protein involved in transformation) induced
differential expression of more than 80 genes. Some of these genes were included proteins
for epithelial-mesenchymal transition/metastasis, cell adhesion, oxidative stresses,
ubiquitination, and WNT signaling. Gene expression changes can be widely regulated by
epigenetic mechanisms. However, investigations on epigenetic changes in tumors are
limited and have been focused on methylation changes.
A limited number of cell culture studies have investigated the involvement of
miRNAs in Cr(VI) carcinogenesis. Li et al., 2016 reported that in 16HBE cells miR-39405p enhanced the HR response following treatment with Cr(VI). Similarly, He et al., 2013
found changes in miRNA expression associated with Cr(VI)-transformed BEAS-2B cells.
This reduction was associated with the up-regulation of proteins involved in angiogenesis
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and proliferation (He et al., 2013). Likewise, a study reported after Cr(VI)-induced
malignant cell transformation of BEAS-2B cells, transformed cells had increased miR-21
expression and inhibition of a tumor suppressor. Further blocking miR-21 suppressed
Cr(VI)-induced transformation (Pratheeshkumar et al., 2017).
These epigenetic investigations highlight the complexities and connectedness
between different mechanisms of carcinogenesis. Still, collectively these data provide
evidence that Cr(VI) has the ability to induce epigenetic changes. Nonetheless, it is unclear
precisely when some of these epigenetic changes happen and if they occur early or late
during Cr(VI) carcinogenesis. Additional studies are still warranted to determine if
epigenetic changes alone can induce carcinogenesis or occur in conjunction with the potent
DNA damaging effects of chromium. While the current studies provide strong evidence
that epigenetic changes are a key piece to the Cr(VI) carcinogenesis, the complete
epigenetic mechanisms are still unknown.
1.6.4. Cr(VI) and Multistage Carcinogenesis
The Multistage carcinogenesis mechanism is a stepwise progression and an
accumulation of mutations in tumor suppressor genes and oncogenes that leads to cancer
development (Volgelstein and Kinzler, 1993). The first step in multistage carcinogenesis
paradigm is initiation. Initiation involves some form of permanent genetic change or
mutation in an oncogene or a tumor suppressor gene. Next, this genetic change or mutation
is then promoted by selective clonal expansion of the initiated cell or cells. Further, this
promotion is then followed by more genetic changes which then lead to malignant
transformation and ultimately tumor progression (Volgelstein and Kinzler, 1993).
Therefore, for a chemical or compound to follow this paradigm for its carcinogenesis
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mechanism it must be able to induce significant mutations in oncogenes or tumor
suppressor genes.
Both animal studies and cell based studies suggest that Cr(VI) can be mutagenic.
One study examined Cr(VI)-induced mutation frequency in rodents using the Big Blue
transgenic mouse model (Cheng et al., 2000). These mice were treated with soluble
potassium dichromate via intratracheal instillation and the authors found a dose- and timedependent increase in mutation frequencies. Mutations observed were largely G:C base
substitution and minor deletions (Cheng et al., 2000). Inflammation alone has been
reported to induce mutations (Federico et al., 2007). Cr(VI) causes inflammation (Ding et
al., 2000; Roy et al., 2016). Since there were no measures in this aforementioned
mutagenesis study to account for inflammation, it is unclear if the mutations reported were
a direct result of the chromium exposure or secondary from the inflammatory response to
Cr(VI).
Cell culture studies applying a shuttle vector mutagenesis assay reported mutations
increase with Cr(VI) treatments (Zhitkovich et al., 2001, 2002; Quievryn et al., 2003,
2006). Additionally, these studies found that Cr(VI)-induced mutations resulted from
Cr(III)-DNA adducts and, importantly, were not from the reactive oxygen species or
reactive intermediates produced (Zhitkovich et al., 2001, Quievryn et al., 2006). More indepth studies found that Cr(III) forms binary and ternary adducts with DNA and these
ternary Cr(III) DNA-adducts were the most mutagenic (Zhitkovich et al., 2001, Quievryn
et al., 2003). Consistent with the Big Blue transgenic mouse study data, the predominant
mutations observed were single base substitutions of G:C (Zhitkovich et al., 2001) and
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interestingly, an additional study suggested that similar levels of base substitutions and
deletion mutations can occur from Cr(VI) exposure (Quievryn et al., 2003).
Additional cell culture studies used the method of focusing on an existing
chromosomal locus. One reported a 3 to 3.5-fold increase in mutation frequency with 3050% of these mutations being deletions when using a bacterial promoter in lung cells (Klein
et al., 2002). Another study found an increase in mutation frequency at the hprt locus in
Chinese hamster ovary cells, though this was only observed when cells were preloaded
with high (mM level) concentrations of ascorbate (reducing agent) and, notably, there no
increases in mutations were observed without ascorbate (Reynolds et al., 2004). Brooks et
al. (2008) reported an increase in Cr(VI)-induced mutations, but proficient nucleotide
excision repair was necessary for the induction of these mutations.
These studies suggest that Cr(VI) may induce G:C base substitution mutations. The
evidence is conflicting on the ability of Cr(VI) to induce deletion mutations and this
discrepancy may be due to the reducing agent present in the studies. For example, with
cysteine used as a major reducing agent, limited deletion mutations were observed
(Zhitkovich et al., 2001). Conversely, when ascorbate is the reducing agent similar levels
of both base substitutions and deletion mutations were found (Quievryn et al., 2003). These
reducing agent comparisons and the results from the in vivo Big Blue transgenic mouse
study, which showed a predominance of base substitutions with few deletions, further
support the observations by Liu et al. (1995) that ascorbate is not the principle in vivo
reductant for Cr(VI). Therefore it is reasonable to conclude that cysteine may be the more
important reducing agent in vivo. Thus, the increases in mutations observed in the ascorbate
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cell culture study may be experimentally derived and not occur in tissues and this
conclusion is consistent with the lower ascorbate levels in the lungs.
Cell culture studies and the animal study suggest that Cr(VI) is mutagenic. Yet,
these data suggest that these mutagenic events may only occur under non-exposure relevant
conditions, specifically may require a high dose, high toxicity, or experimentally contrived
systems. Furthermore, data from Cr(VI)-induced tumors from chromate workers show very
limited or no mutations in oncogenes such as p53 and ras. These results further support the
argument that Cr(VI) is either weakly or indirectly mutagenic. Thus there are insufficient
mutations to support Cr(VI) carcinogenic mechanism is through the multistage
carcinogenesis paradigm.
1.6.5. Cr(VI) and Genomic Instability
Genomic instability is a common event in lung cancers with both chromosome
instability and microsatellite instability and happening concurrently, and has been
extensively studied in Cr(VI)-induced tumors, which have microsatellite instability
(Holmes et al., 2008; Speer and Wise, 2018; Wise and Wise, 2018). Chromosome
instability comprises of both numerical and structural chromosome abnormalities.
Chromosome instability occurs in Cr(VI)-induced tumors evidenced by an increase in the
loss of heterozygosity, which is consistent with many cell culture studies that report a
significant effect on chromosome structure in cultured cells treated with Cr(VI) (Holmes
et al., 2008; Wise et al., 2010; Wise S et al., 2018). Numerical chromosomal abnormalities,
have not been measured in Cr(VI)-induced tumors, however, cell based studies report that
Cr(VI) dramatically alters chromosome number in cultured cells treated with Cr(VI) (Speer
and Wise, 2018; Wise and Wise, 2010; Wise and Wise , 2018).
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Epidemiology, animal, and cell culture studies demonstrate that the particulate form
of Cr(VI) is most potent with regards to carcinogenicity (IARC, 1990; Leonard and
Lauwerys, 1980). An evergrowing mechanism for particulate Cr(VI)-induced chromosome
instability has been proposed by the Wise Laboratory of Environmental and Genetic
Toxicology and supported by the literature (Speer and Wise, 2018) (Figure 1.4). Once the
particle dissolves, the Cr(VI) oxyanion crosses the cell membrane using sulfate/phosphate
transfer proteins aids and is rapidly transported into the cell (Leonard and Lauwerys, 1980;
Levy et al., 1986b; Patierno et al., 1988; Langard, 1990). Once Cr(VI) enters the cell,
Cr(VI) is rapidly reduced to Cr(III) which forms stable complexes with intracellular
structures (e.g., DNA, proteins, and other components) and will accumulate within the cell
(De Flora and Wetterhahn, 1989). This can lead to DNA adduct-based lesions and then
lead to stalled replication forks and ultimately DNA double strand breaks (Zhitkovich et
al., 2001, 2002; Quievryn et al., 2003, 2006; Reynolds and Zhitkovich, 2007; Brooks et
al., 2008). These double strand breaks will overwhelm the repair systems of the cells and
then go unrepaired or are mis-repaired and ultimately leading to translocations and other
structural chromosomal aberrations (Xie et al., 2007, 2008). The accumulation of double
strand breaks also causes a G2 arrest leading to centrosome amplification, spindle assembly
checkpoint bypass, premature centriole disengagement, centrosome amplification, and
eventually numerical chromosome instability (Holmes et al., 2006b; Martino et al., 2015;
Wise S et al., 2006). Epigenetic modifications may also contribute to structural and
numerical chromosome instability further contributing to neoplastic transformation (Wise
and Wise, 2018). Epigenetic modifications may change the DNA packaging and protein
and gene signaling and affect the genomic instability observed, however, more
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investigations are warranted. Reactive oxygen species produced during the reduction of
Cr(VI) to Cr(III) also contribute to oxidative damage in the cell, and if left unrepaired will
cause other problems and contribute to the neoplastic transformation (Xu et al., 2018).
Reports of patients with cobalt-chromium metal on metal hip implants have shown
increases in chromosome instability (measured in their peripheral blood) and increases in
chromosomal aberrations and translocations (was not overall statistically significant)
(Briggs et al., 2015; Dunstan et al., 2008). Interestingly, the first time point was at 1 year
follow up and patients had increased translocations (statistically significant), while the
aberrations had a strong linear relationship with Cr levels (not statistically significant)
(Briggs et al., 2015). However, the lasting consequences of these outcomes are uncertain.
To elucidate the impact that chromium may have on these results, Figgett et al. (2010)
examined the effects of physiologically relevant metal (cobalt and chromium) levels on
human primary skin fibroblasts. They reported that cells treated with these physiological
concentrations of Cr(VI), had both numerical and structural chromosome aberrations, and
complex aneuploidy.
Cr(VI)-induced DNA damage can be repaired by several mechanisms depending
on the type of damage. Base excision repair, crosslink repair, homologous recombination,
mismatch repair, nucleotide excision repair, and single strand break repair have all been
investigated in the repair of Cr(VI)-induced DNA damage as reviewed by Speer and Wise
(2018). All of the lesions types caused by Cr(VI) if left unrepaired or mis-repaired, can
have a direct negative impact on chromosome structure and overall genomic integrity of
the cell and ultimately lead to carcinogenesis (Figure 1.4).
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Figure 1.4. Mechanisms of Numerical and Structural CIN in Cr(VI) Carcinogenesis.
This figure shows some of the major mechanisms underlying CIN in our proposed
mechanism of Cr(VI) carcinogenesis. Particulate Cr(VI) dissolves extracellularly and if the
cation enters the cell there is no contribution to the effect. Similarly, if the Cr(VI) particle
enters the cell by phagocytosis there is also no contribution to the effect. When the Cr(VI)
oxyanion enters the cell it is reduced to Cr(III) and ROS are produced. The ROS can induce
oxidative damage which base excision repair (BER) attempts to repair. However, if it fails
double strand breaks form. Positively charged Cr intermediates and Cr(III) form as result
of the intracellular reduction process potentially binding to cellular elements including the
formation of DNA-Cr adducts or crosslinks and consequentially stalled replication forks
and the formation of a DNA double strand break. Crosslink repair or MMR can attempt to
resolve these effects, but if they fail will result in double strand breaks. The formation of
double strand breaks results in a G2 arrest as the attempts to repair the damage. Cr(VI)impaired HR repair leads to the use of a low fidelity repair mechanism and structural CIN.
At the same time, Cr(VI) induces spindle assembly checkpoint bypass and premature
centriole disengagement leading to centrosome amplification and numerical CIN.
Underlying structural and numerical CIN are Cr(VI)-induced epigenetic alterations have
yet to be elucidated. Finally, taken together structural and numerical CIN contribute to the
neoplastic transformation of Cr(VI) exposed and cancer. Reprinted from Reference Module
in Chemistry, Molecular Sciences and Chemical Engineering, 2018, Speer RM and Wise,
JP Sr. Current Status on Chromium Research and Its Implications for Health and Risk
Assessment, Pages No. 10, Copyright (2018), with permission from Elsevier [OR
APPLICABLE SOCIETY COPYRIGHT OWNER]." Also, Lancet special credit "Reprinted from The Lancet, 2018, Speer RM and Wise, JP Sr. Current Status on
Chromium Research and Its Implications for Health and Risk Assessment, Pages No. 10,
Copyright (2018), with permission from Elsevier."
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1.7 Dysregulated Cellular Energetics and Cancer
The seminal peer-reviewed article by Hanahan and Weinburg (2010), currently list
the hallmarks of cancer as self-sufficiency in growth signals, insensitivity to anti-growth
signals, evading programmed cell death, limitless replicative potential, sustained
angiogenesis, tissue invasion, and metastasis, deregulated metabolism, evading the
immune system, genome instability, and inflammation. Altered energy metabolism was
first purposed as an important part of carcinogenesis back in the 1920s by Otto Warburg
(Warburg et al., 1927). Typically, the major pathways affected are glycolysis, lactate
metabolism, lipid metabolism, mitochondrial respiration, pentose phosphate pathway, and
one carbon and nucleotide synthesis. It has also been reported that cancer cells and tumors
have increased glutamine and glucose uptake compared to normal cells or adjacent noncancerous tissues.
1.7.1 Increased Anaerobic Glycolysis or the “Warburg Effect”
Energy metabolism was first suggested as a vital to carcinogenesis back in the
1920s by Otto Warburg. In his initial publications and book Warburg noticed that cells
from cancer tissue slices had increased fermentation (we would later call this anaerobic
glycolysis or lactate fermentation) and some had increased respiration, but typically he
reported an increased in fermentation, similar to the Pasteur effect, while normal cells and
tissues had high levels of respiration and low fermentation levels. Subsequently, as our
understanding of normal cellular energetics evolved, so did Warburg’s interpretation of his
results grew. He would later in the 1950s refer to what he previously called fermentation
as anaerobic respiration or conversion of glucose to pyruvate and then pyruvate to lactic
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acid (lactate and H+) and refer to the conversion of pyruvate into the mitochondrial for use
oxidative phosphorylation as aerobic glycolysis or aerobic respiration (Warburg, 1956a,
1956b). Additionally, Warburg noted that most cancer cells or tumor tissues studied (when
compared to normal cells and tissues) had increases in their anaerobic respiration, he noted
this phenomenon stayed even in the presence on ambient oxygen and seemed to be a
permanent change of the cancer cells. Whereas normal cells will switch to an increase of
aerobic glycolysis or aerobic respiration in the presence of ambient or physiological
oxygen respiration (Warburg, 1956a, 1956b). Researchers in the 1970s would revisit
Warburg’s finding only briefly and it wasn’t until the technology evolved with our
understanding of cellular energetic at the turn of the century did cancer researchers really
go back and understand the impact of Warburg’s work (Weinhouse, 1976). Since his time,
the paradox Warburg described, of an increased of anaerobic glycolysis in the presence of
ambient and physiological oxygen, with a sometimes lower level of the oxidation of
pyruvate, has been termed the “Warburg effect” and is permanent energy metabolism shift
(Otto, 2016). Aerobic glycolysis with oxidative phosphorylation produces more ATP than
anaerobic glycolysis and it remains paradoxical that the cells do not revert back after
oxygen levels are increased. Glycolysis is 10 step process that converts glucose to pyruvate.
In the presence of oxygen, pyruvate then enters the mitochondria and is converted to
Acetyl-CoA by pyruvate dehydrogenase (PDH) and enters the Citric Acid Cycle
(TCA)/Kreb cycle, this is aerobic respiration. The process of glucose to acetyl-CoA is
called aerobic glycolysis. Conversely, in the absence of oxygen pyruvate is converted to
lactate, named anaerobic respiration. The process of glucose to lactate is termed anaerobic
glycolysis (Figure 1.5).
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There is now a growing body of literature in many cancer cells and tumor systems,
which supports, the increase of anaerobic glycolysis of cancer cells and tumors. This
change to an increase of anaerobic glycolysis over aerobic glycolysis is thought to provide
the cancer cells with a survival advantage in the harsh tumor microenvironment. However,
it remains unclear whether if the “Warburg effect” is a cause or consequence of tumor
development or a contributing of both (Otto, 2016).
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Figure 1.5. Glycolysis Overview. Glycolysis is 10 step process that converts glucose to
pyruvate. In the presence of oxygen, pyruvate then enters the mitochondria and is converted
to Acetyl-CoA by pyruvate dehydrogenase (PDH) and enters the Citric Acid Cycle
(TCA)/Kreb cycle, this is aerobic respiration. Conversely, in the absence of oxygen
pyruvate is converted to lactate, this is anaerobic respiration.
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1.7.2 Increased de novo Lipogenesis in Cancer
Remarkably, Warburg also noticed that tumors were very fatty compared to
adjacent normal tissue and appeared to be making more lipids. Most adult cells acquire
necessary lipids via exogenous sources; these lipids originate from dietary sources or are
synthesized in the liver and adipose (Otto, 2016; Santos and Schulze, 2012). De novo
lipogenesis occurs in the liver, adipose tissue, lactating breast, and at very low basal levels
in other tissues. Increased de novo lipogenesis and its proteins [ATP-citrate lyase (ACLY),
acetyl-CoA carboxylase alpha/1 (ACC1), and fatty acid synthase (FASN)] expressions
have been reported as key to carcinogenesis processes (Otto, 2016; Santos and Schulze,
2012).
In human cells, ACLY converts citrate into acetyl-CoA. The source of citrate can
be from acetate or glutamine metabolism, citrate uptake or citrate from the citric acid cycle.
Acetyl-CoA then has four ultimate destinations: (1) TCA/Kreb cycle; (2) cholesterol
synthesis; (3) acetylation of proteins or histones; (4) lipogenesis. In the case of lipogenesis,
Acetyl-CoA is then carboxylated by ACC1 to make malonyl-CoA. Finally, through a series
of steps involving NAPDH and more acetyl-CoA, malonyl-CoA is converted by FASN to
palmitate (the first free fatty acid produced by the cell) (Figure 1.6). Phosphorylation of
ACLY can increase its activity, while phosphorylation of ACC1 decreases its activity. This
palmitate can then be used to make triglycerides and phospholipids or for palmitoylation
of proteins.
Specifically, increases in lipogenesis and these proteins have been observed in
breast, colon, and lung, ovarian, pancreatic, and prostate cancers. Lipid increases in cancer
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cells are important for different aspects of cancer development; (1) they may be stimulated
by oncogenic signaling (e.g. EGFR, HER2, HIF-1α, etc.); and (2) they directly contribute
to the growth and proliferation of cancer cells, oxidative stress resistance, and survival
under energy stress, redox balance, and invasive properties of cancer (Menendez.and Lupu,
2007; Santos and Schulze, 2012). Furthermore, overexpression of ACC1 induced
neoplastic transformation in murine skin epidermal cells (Li et al., 2016). Overexpression
of FASN drove neoplastic transformation of human mammary epithelial cells (VazquezMartin et al., 2008; Yang et al., 2002). These studies show that these proteins when
overexpressed can induce neoplastic transformation and may be oncogenes when
overexpressed.
In human lung patients, these proteins increased expression is associated with
decreased patient survival. ACLY overexpression had a hazard ratio of 6.242 in lung cancer
patients (Osugi et al., 2015). In the case of ACC1, its phosphorylation (inactivity) is
associated with increased lung adenocarcinomas and squamous cell carcinomas patient
survival and risk ratio of mortality was 0.5 (95% CI, 0.06-0.7; P = .01) (Conde et al., 2007).
FASN tumor expression was linked to a decreased lung squamous cell carcinoma patient
survival (Visca et al., 2004).
Inhibition of ACLY, ACC1, and FASN causes a loss of many cancer cell properties,
e.g. decreased tumor growth and loss of growth in soft agar, programmed cell death and
decreased cancer cell proliferation, and increased drug sensitivity to chemotherapies
(Migita et al., 2008; Menendez.and Lupu, 2007; Orita et al., 2007; Santos and Schulze,
2012).
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Figure 1.6. De novo Lipogenesis. The source of citrate can be from acetate or glutamine
metabolism, citrate uptake or citrate from the citric acid cycle. ACLY converts citrate into
acetyl-CoA. Acetyl-CoA then has four ultimate destinations: (1) TCA/Kreb cycle; (2)
cholesterol synthesis; (3) acetylation of proteins or histones; (4) lipogenesis. In the case of
lipogenesis, Acetyl-CoA is then carboxylated by ACC1 to make malonyl-CoA. Finally,
through a series of steps involving NAPDH and more acetyl-CoA, malonyl-CoA is
converted by FASN to palmitate (the first free fatty acid produced by the cell) (Figure 1.4).
Phosphorylation of ACLY can increase its activity, while phosphorylation of ACC1
decreases its activity.
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1.7.3 Pentose Phosphate Pathway in Cancer
An elevation of the pentose phosphate pathway in cancer cells has been postulated
as a way to distinguish cancer cells from normal cells. Intermediates from pentose
phosphate pathway feed into other metabolism pathways (i.e., lipogenesis) and
intermediates from other energy pathways (i.e., glycolysis) can be used in the pentose
phosphate pathway. Increasing the pentose phosphate pathway leads to: (1) high NADPH
levels which can reduce ROS, high levels of nucleotides for DNA synthesis and repair; (2)
may promote resistance to therapies for increasing oxidative stress and DNA damage; (3)
drug resistance; (4) sustained high levels of glucose-6-phosphate dehydrogenase and
glutathione after drug resistance (Ferretti et al., 1993; Friesen et al., 2004; Gessner et al.,
1990; Patra and Nissim, 2015; Yeh et al., 1987). Multiple cancer cell lines studies have
been reported to have the acquisition of drug resistance accompanied by elevation of the
oxidative pentose phosphate pathway. Drug resistance could be reversed by treatment from
inhibition of early steps in the pentose phosphate pathway (Patra and Nissim, 2015).
Therefore, targeting the pentose phosphate pathway has also been proposed as a therapeutic
target for cancer (Patra and Nissim, 2015).
1.7.4. One-Carbon Metabolism and Nucleotide Synthesis in Cancer
One-carbon metabolism and nucleotide biosynthesis are important in one line with
such cancer-related metabolic alteration (Seyfried and Shelton, 2010; Shuvalov et al.,
2017). Increased one-carbon metabolism and nucleotide biosynthesis are found in many
different cancers (Locassale et al., 2013; Vazquez et al., 2013). One carbon metabolism
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can provide additional “building blocks” (e.g., nucleotides, some amino acids) and
contributes to epigenetic (e.g., DNA methyltransferases and protein methylation) and
redox homeostasis. There have been limited studies on developing drugs for the inhibition
of one-carbon metabolism enzymes Shuvalov et al., 2017). It is proposed due to the
necessity of some one-carbon metabolism pathways for normal cell functions, the targeting
of enzymes in these pathways can be difficult and may need to be used in combination with
other treatments.
1.7.5. Mitochondria and Cancer
Mitochondria changes in cancer have demonstrated as part of the dysregulated
energy metabolism reported in cancer. There are multiple endpoints of mitochondria to
investigate, this includes mitoDNA, mitochondrial respiratory function, mitophagy
(mitochondria autophagy), mitochondria membrane potential, fusion, and fission. There
are reports investigating mitochondrial respiration during transformation of human cell
lines. For example, one study found that mitochondrial dysfunction plays a pivotal role in
pancreatic carcinogenesis (Hardie et al., 2017). It was reported that mitochondrial
dysfunction is important in prostate carcinogenesis (Stueckle et al., 2012). However, most
studies are done in cancer cell lines and there still is needed for more studies for the role
of mitochondria dysfunction during the transformation process.
1.8. Chromium and Cellular Energetics
There remains limited reports on Cr(VI)-induced carcinogenesis and dysregulated
cellular energetics. One group reported that acute exposure to Cr(VI) in human skin
fibroblasts could upregulate cholesterol metabolism and SREBP-1 (Guo et al., 2013).
SREBP-1 is the main transcription factor for ACLY, ACC1, and FASN (Santos and
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Schulze, 2012). Another study, acute exposures to high concentrations of Cr(VI) to human
lung epithelial cells exhibited increased glycolytic function and decreased mitochondrial
respiration (Cerveira et al., 2014). Conversely, human skin cells that survived the toxicity
from exposure to high concentrations of Cr(VI) has elevated spare respiratory capacity of
their mitochondria (Nickens et al., 2012). These studies indicate that acute exposures to
Cr(VI) can induce dysregulated cellular energetics, but it is unclear from these data whether
these changes are due to a response to the toxicity of Cr(VI) or a permanent change.
Rationale for this study is supported by evidence from previous reports. First, as
mentioned above, some preliminary reports show that Cr(VI) exposure can alter cellular
energetics. Second, previous reports indicate that Cr(VI) can activate the PI3K/AKT
pathway and EGFR and dthat ownstream signaling of EGFR (Kim et al., 2015, 2016)
increases of both pathways have been implicated in upregulation of lipogenesis in cancer
cells (Bia et al., 2015; Lei et al., 2016; Migita et al., 2008; Orita et al., 2007; Otto, 2016;
Santos and Schulze, 2012) Next, HIF-1α is constitutively activated in Cr(VI)-transformed
lung cells (Kim et al., 2015, 2016; Wang et al., 2011) and HIF-1α is able to induce FASN
expression (Menendez et al., 2005) Lastly, nuclear factor (erythroid-derived 2)-like 2
(Nrf2) has been reported to be constitutively activated in Cr(VI)-transformed lung cells,
but has altered function (Kim et al., 2015, 2016; Pratheeshkumar et al., 2016, 2017; Wang
et al., 2011) and it was previously reported that Nrf2 may help control metabolic enzymes
and control ACLY expression in murine liver, however how Nrf2 is involved with ACLY
regulation remains unclear (Kitteringham et al., 2008; Liu.et al., 2018). These studies
suggest that in Cr(VI)-transformed cells, given the dysregulation of upstream factors,
lipogenesis may become activated and be a key to Cr(VI)-transformed cell survival and
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cancer properties and be a potential therapeutic target. Additionally, Cr(VI) causes acutely
to glycolysis and mitochondria, and thus Cr(VI)-transformed cells may have dysregulated
mitochondria. Further because most cancer cells exhibit a permanent shift to anaerobic
glycolysis or the “Warburg effect”, and increases in anaerobic glycolysis, which are
associated with increased lipogenesis (Santos and Schulze, 2012), it is plausible this
pathway will be upregulated in Cr(VI)-transformed cells.
1.9. Study Overview
Given, the lack of literature on energy metabolism in Cr(VI) carcinogenesis, we
chose to investigate some of these energy pathways in Cr(VI)-induced carcinogenesis.
Using the model Cr(VI)-transformed human lung cells, we chose to examine lipogenesis,
the “Warburg effect”, and mitochondrial respiratory dysfunction. We hypothesize: Cr(VI)induced transformation of human lung cells will cause altered cellular energetics,
specifically resulting in increased de novo lipogenesis, the “Warburg effect”, and
mitochondrial respiratory dysfunction.
For this study, we induced neoplastic transformation of human bronchial epithelial
airway cells (BEAS-2B cells) by exposing them to sodium chromate for 180 days and we
then isolated an individual colony from soft agar [BEAS-2B Cr(VI)-transformed cells].
Parallel untreated control BEAS-2B cells were passaged alongside the treatment dishes and
agar dish and used as a passage-matched control cell line. We compared the passagematched BEAS-2B cells and Cr(VI)-transformed BEAS-2B cells results to two other sets
of Cr(VI)-transformed lung cell line and their passage-matched, the two cell line sets used
were human bronchial epithelial airway cells (BEP2D cells) and human lung fibroblasts
(WTHBF-6 cells). We also performed a tumor growth assay using the xenograft nude
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mouse model for all sets of cells used. We isolated some xenograft tumor-derived cells
from the Cr(VI)-transformed fibroblasts. We then investigated three aims:
Specific Aim #1: Cr(VI)-transformed cells exhibit increased de novo lipogenesis,
which is important to their carcinogenic properties.
Specific Aim #2: Mitochondrial respiratory dysfunction does not occur during
Cr(VI)-transformation but rather during tumorigenesis.
Specific Aim #3: Cr(VI)-transformed cells do not exhibit increased anaerobic
glycolysis or the ‘Warburg effect’.
In brief, we observe increased lipogenesis enzymes and activity in the Cr(VI)transformed cells as compared to their passage-matched control cells. This pathway was
important for the Cr(VI)-transformed BEAS-2B cells. No mitochondrial respiratory
dysfunction in the Cr(VI)-transformed cells as compared to their passage-matched control
cells was observed. We did see mitochondrial respiratory dysfunction in xenograft tumorderived cells. We observed no increased anaerobic glycolysis or “Warburg effect” in the
Cr(VI)-transformed cells or the xenograft-tumor derived cells. Lastly, we show that human
chromate-induced lung cancer tissues had increased pACLY, ACLY, ACC1, and FASN
expressions and lung tumor tissues had no changes in LDHA expression.
1.10. Summary
The known mechanism of Cr(VI)-induced carcinogenesis include: (1) Cr(VI) is a
potent genotoxic agent that acts as a carcinogen by inducing DNA double strand breaks,
chromosome instability, altered DNA repair, and genomic alterations, epigenetics plays a
role with the genomic endpoints; (2) Cr(VI) induces reactive oxygen species that cause
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downstream changes in protein signaling and redox imbalance; and (3) Cr(VI) is able to
increase cell death evasion and growth signal expressions. (4) Lastly, growing evidence
suggests that Cr(VI) is able to induce altered cellular energetics.

Copyright © James Tate Fortin Wise 2019
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Chapter 2 Materials and Methods
2.1. Materials
2.1.1. Cell Culture
Phosphate

buffered

saline

(PBS),

Trypsin/EDTA,

sodium

pyruvate,

penicillin/streptomycin, LHC, LHC-8, LHC-9, and L-Glutamine were purchased from
Invitrogen (Carlsbad, CA). Dulbecco’s minimal essential medium and Ham’s F-12
(DMEM/F-12) were purchased from Mediatech (Herndon, VA). Cosmic calf serum was
purchased from Hyclone (Logan, UT). Tissue culture dishes, flasks, and plasticware were
purchased from Corning (Acton, MA). Moxi GO IITM and cassettes were purchased from
ORFLO Technologies (Ketchum, ID). Ethanol was purchased from VWR Life Science
(Radnor, PA).
2.1.2. Metals and Metal Preparation
Sodium chromate (NaCrO4), anhydrous 98%, was purchased from Alfa Aesar
(Haverhill, MA). 0.22 µM filters and syringes were purchased from VWR Life Science
(Radnor, PA).
2.1.3. Drug Preparation and Treatment
4-Methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid (C75) dimethyl
Sulfoxide (DMSO) were purchased from Millipore-Sigma (St. Louis, MO).
2.1.4. Antibodies
Primary antibodies for acetyl-CoA carboxylase 1 (ACC1), phosphorylated acetylCoA carboxylase (Ser79) (pACC), ATP-citrate lyase (ACLY) and phosphorylated ATPcitrate lyase (Ser455) (pACLY), fatty acid synthase (FASN), histone 3 (H3), hexokinase I,
hexokinase II, lactate dehydrogenase A (LDHA), phosphofructokinase (PFKP), pyruvate
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dehydrogenase (PDH), pyruvate kinase isozymes M1/M2 (PKM 1/2), and pyruvate kinase
isozymes M2 (PKM 2) were purchased from Cell signaling (Danvers, MA). Primary
antibodies for sterol regulatory binding protein 1 was purchased from BD Biosciences
(Franklin Lakes, NJ). Primary antibodies for acetyl-CoA carboxylase alpha, ATP-citrate
lyase, fatty acid synthase, and lactate dehydrogenase B (LDHB) were purchased from
Abcam (Cambridge, United Kingdom). Primary antibodies for phosphorylated acetyl-CoA
carboxylase alpha (Ser79) and phosphorylated ATP-citrate lyase (Ser455) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Primary antibody for β-actin were
purchased from Sigma-Aldrich (St. Louis, MO). Secondary antibodies for anti-mouse and
anti-rabbit HRP were purchased from Cell Signaling (Danvers, MA).
2.1.5. Protein Preparation and Quantification
PBS was purchased from Invitrogen (Carlsbad, CA). Cell lifters were purchased
from VWR Life Science (Radnor, PA). 10x RIPA buffer was purchased from Cell
Signaling (Danvers, MA). Protease inhibitor cocktail and phosphatase inhibitor were
purchased from Millipore-Sigma (St. Louis, MO). Phenylmethylsulfonyl fluoride (PMSF)
was purchased from RPI (Mt. Prospect, IL). Bradford assay reagents were purchased from
Bio-Rad (Hercules, CA). Albumin standards were purchased from ThermoFisher Scientific
(Waltham, MA).
2.1.6. Immunoblotting
3-8% tris-acetate gels, tris-acetate buffer, and gel cassettes were purchased from
Invitrogen (Carlsbad, CA). Bovine serum albumin (BSA) was purchased from Gemini
Bio-Products (West Sacramento, CA). 2-beta mercaptoethanol, bromophenol blue,
ponceau, and sodium azide was purchased from (St. Louis, MO). Acrylamide/bisAcrylamide (29:1 Ratio Solution), ammonium persulfate (APS), glycine, glycerol, sodium
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chloride, sodium dodecylsulfate (SDS) tris, and Tween 20 were purchased from RPI (Mt.
Prospect, IL). Precision Plus Protein Dual Color Standards was purchased from Bio-Rad
(Hercules,

CA).

Acetic

Acid,

hydrochloric

acid,

methanol

and

N,N,N',N'-

tetramethylethylenediamine (TEMED) was purchased from VWR Life Science (Radnor,
PA).
2.1.7. Immunofluorescence
Xylene and ethanol were purchased from VWR Life Science (Radnor, PA). Antigen
unmasking solution and Vectashield mounting medium containing 4,6-diamidino-2phenylindole (DAPI) were purchased from Vector laboratories Heat-Inactivated horse
serum was purchased from Invitrogen (Burlingame, CA). Secondary antibodies against
mouse and rabbit for Alexa Fluor 488 and Alex Fluor 568 were purchased from Invitrogen
(Carlsbad, CA).
2.1.8. Oil Red O Staining
Oil red O stain was purchased from Millipore-Sigma (St. Louis, MO). Ethanol, 0.22
µM filters and syringes were purchased from VWR Life Science (Radnor, PA).
Formaldehyde was purchased from Ricca Chemical (Batesville, Indiana).
2.1.9. Growth Curve
Moxi GO IITM and cassettes were purchased from ORFLO Technologies (Ketchum,
ID).
2.1.10. Metabolism Kits
The glycolysis cell based kit was purchased from Cayman Chemical Company
(Ann Arbor, MI). Free Fatty Acid Quantification Kit from BioVision (Milpitas, CA).
Chloroform and TRITON X-100 were purchased from VWR Life Science (Radnor, PA).
2.1.11. Seahorse Analyzer
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Antimycin A, L-carnitine, 2-deoxyglucose, glucose, glutamine, Etomoxir,
oligomycin, palmitate, rotenone, sodium pyruvate, ultra fatty acid free BSA were
purchased from Millipore-Sigma (St. Louis, MO). XF base medium, 96 well seahorse
plates, and seahorse cartridges were purchased from Agilent Technologies (Santa Clara,
CA).
2.1.12. Soft Agar Transformation Assay and Colony Isolation
Agar was purchased from Fisher Scientific (Hampton, NH). 4-Nitro blue
tetrazolium chloride (NBT) was purchased from Roche Holding AG (Basel, Switzerland).
2.1.13. Xenograft Tumor Studies
Athymic nude mice, NU/NU, 6–8 weeks old, were purchased from Jackson
Laboratories (Bar Harbor, ME). 22 gauge needles and syringes were purchased from VWR
Life Science (Radnor, PA). Matrigel™ GFR Membrane Matrix was purchased from
Corning Inc. (Corning, NY).
2.1.14. Cell Line Development
Collagenase type II was purchased from Stemcell Technologies (Vancouver, CA).
0.22 µM cell filters were purchased from BD Biosciences (San Jose, CA).
2.1.15. Statistics
Graphpad Prism 7 was purchased from GraphPad Software (La Jolla, CA).
2.2. Methods
2.2.1. Cells and Cell Culture
BEAS-2B, BEP2D and WTHBF-6 were used as model human lung cells,
respectively. BEAS-2B are SV40 immortalized human bronchial airway cells purchased
from ATCC (Ke et al., 1988). BEP2D cells are HPV E6 and E7 immortalized human
bronchial airway cells, which were gifted by Curtis Harris at the National Institute of
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Health (Wiley et al., 1991). WTHBF-6 cells are hTERT-expressing human lung fibroblasts
and were gifted by the Wise Laboratory of Environmental Health and Toxicology at the
University of Louisville (Wise et al., 2004b). These cells exhibit a diploid karyotype,
normal growth parameters and an extended lifespan. WHBF-6 and transformed WHTBF6 cell lines were cultured in a 50:50 mix of Dulbecco’s minimal essential medium and
Ham’s F12 medium plus 15% cosmic calf serum, 1% L-glutamine and 1%
penicillin/streptomycin. BEAS-2B and transformed BEAS-2B cell lines were cultured in
LHC-9 media. BEP2D and transformed BEP2D cell lines were cultured in LHC-8 media.
All cells were maintained in a 37oC, humidified incubator with 5 % CO2. At least once a
week, cells were subcultured using 0.25% trypsin/1mM EDTA solution and all
experiments were performed on logarithmically growing cells.
2.2.2. Metals and Metal Preparation
Sodium chromate is a soluble form of Cr(VI) and was dissolved as a solution in
ddH2O as 5 mM and filtered through a 0.22 μM filter. Then diluted further in water to
prepare final treatment concentrations in media as 0, 0.25, 0.5, 1, and 2.5 μM Cr(VI).
2.2.3. Inhibition Compound Preparation and Treatment
C75 was prepared aseptically in DMSO. DMSO was also used as a vehicle
treatment. 0, 1, 5, and 10 µM C75, and 0.1% DMSO treatments were used in fresh media.
2.2.4. Chronic Chromium Treatment
BEAS-2B cells were exposed to sodium chromate (0.25 and 0.5 μM) for 180 d (6
months) and routinely cultured with sodium chromate re-added during sub-culturing and
when media was refreshed (48-72 h). Passaged match control BEAS-2B were cultured
alongside the two treatment groups. Following 6 months of exposure, cells were seeded
into agar and a colony was isolated from the 0.5uM treatment group. Passage match control
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BEAS-2B cells were cultured alongside the agar dishes. Additionally, BEAS-2B cells,
BEP2D cells, and WHTBF-6 cells were seeded at 650,000 cells (BEAS-2B and BEP2D
cells) and 500,000 cells (WHTBF-6 cells) in 100 mm dishes 48 h prior to treatment. Then
cells were treated for 24 h with the 0, 0.25, 0.5, 1 or 2.5 µM sodium chromate. Dishes were
then harvested for protein for immunoblotting.
2.2.5. Protein Preparation and Quantification
Cells were washed with 4°C cold PBS 2x and scraped with a cell scraper on ice in
cold PBS. Pellets were collected in a microcentrifuge tube and centrifuged at 5,000 at 4°C
for 5 min. PBS was then aspirated. Pellets were homogenized in 60-100 μL of RIPA buffer
(RIPA buffer with protease cocktail inhibitors and phosphatase inhibitor). Pellets were
incubated on ice for 10 min and sonicated at 1 amplitude for 1 sec. Then pellets were
centrifuged at 16g for 10 min at 4°C. A Bradford assay was performed to measure the
protein concentrations against protein standards. Samples were then prepared at 30 μg/15
μL in RIPA buffer and 1x sample buffer.
2.2.6. Immunoblotting
Western blot analysis was carried out using standard laboratory procedures. Protein
samples were heated at 95°C for 10 min and then centrifuged at 16g for 10 min at 4°C. For
all glycolytic-related enzymes: 30 μg of protein samples were loaded into mini-prep trisglycine gels and run in a tris-glycine buffer. Running time was about 2 hours at -100 v. For
all lipogenesis related enzymes: 30 μg of protein samples were loaded into mini-prep 3-8%
tris-acetate gels and run in a tris-acetate buffer. Running time was about 90 min at -125 v.
Gels were transformed to nitrocellulose membranes overnight at 20 mAmps. To visualize
and confirm transfer, membranes were incubated in Ponceau S for 5 min. Membranes were
then blocked in 5% blocking buffer (BSA) for 1 h. Membranes were incubated in primary
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antibodies up to 72 h at 4°C. Primary antibodies were diluted at 1:1,000 for all except βactin (1:5,000) in 1% BSA in TBST + 200 μL sodium azide. Following primary antibody
incubation, membranes were washed 6 times with 1x TBST buffer over 1 h. Membranes
were then incubated with secondary antibodies (HRP antibodies) for 1 h in 2.5% blocking
buffer (BSA in TBST) at 1:5,000 (β-actin was 1:10,000). Following incubation with
secondary antibodies, membranes were washed 6 times with 1x TBST buffer over 1 h.
Membranes were then exposed to ECL reagent for up to 5 min and the developed on the
Azure c600 and bands were excised using Photoshop.
2.2.7. Patient Lung Sample Collection
Lung tumor tissue and adjacent normal lung tissue from three chromate workers
were obtained from the Tokushima University hospital, Tokushima, Japan. Worker 1 was
a male non-smoking chromate worker (Age 62) that had been exposed to a chromate
(Na2Cr2O7, K2Cr2O7, CrO3, and Cr2O3) in Hokkaido, Japan for 19 years. This worker was
diagnosed with stage I (T1N0M0) squamous lung carcinoma. Worker 2 was a male nonsmoking chromate worker (Age 61) that had been exposed to chromate (Na2Cr2O7,
K2Cr2O7, CrO3, and Cr2O3) in Hokkaido, Japan for 38 years. This worker was diagnosed
with stage II (T2N1M0) squamous lung carcinoma.
2.2.8. Immunofluorescence
Formalin-fixed tissue slices from the chromate workers were incubated at 60°C
overnight to dissolve the paraffin. Tissues then went through a series of xylene and ethanol
washes to remove the paraffin and rehydrate the tissue. Tissues were incubated with
unmasking solution for 30 minutes at 95°C then washed twice with TBS (with 0.025%
Trtion). Tissues were then blocked with 10% horse serum with 1% BSA in TBS (with
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0.025% Triton) and washed twice with TBS (with 0.025% Trtion). Tissues were then
incubated with primary antibodies overnight at 4°C. Primary antibodies were diluted 1:50
in TBS with 1% BSA. Primary antibodies were removed and tissues were washed twice
with TBS (with 0.025% Trtion) and re-probed with secondary antibody at room
temperature for 1 h. Secondary antibodies were removed and tissues were washed three
times with TBS. Slides were mounted with a cover slip and mounting solution containing
DAPI. Finally, the cells were visualized using Olympus BX53 fluorescence microscope
(Pittsburgh, PA).
2.2.9. Oil Red O Staining
Cells were seeded into 6 well plates and when cells reached 80-90% confluence
were processed for lipid droplet formation. Briefly, dishes were washed with PBS three
times and fixed with 4% formaldehyde for 40 min. Cells were then incubated in Oil Red O
solution (3 parts Oil Red O to 2 parts water) for 40 min. Following staining with Oil Red
O the dishes were washed 3 times with water and imaged on the Zeiss Observer A1
Microscope (Carl Zeiss AG, Germany). Following imaging cells were dissolved and
quantified. Quantification was carried out at 490nm on the BioTek EL800 plate reader
(Winooski, Vermont).
2.2.10. Growth Curve
BEAS-2B Cr(VI)-transformed cells (B2B-CrT cells) were treated with the FASN
inhibitor C75 for 24 h in a 100 mm dish. Cells were washed with PBS once and trypsinized
then centrifuged at 1000 rpm at 4C for 5 min and resuspended in media after collecting the
cell pellet. Cells were counted with the Orflo cell counter. Each concentration was seeded
into 3 wells of a 6 well plate at 12,500 cells (this was considered day 0). One well per
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concentration was harvested and counted per concentration every two days for up to six
days.
2.2.11. Metabolism Kits
2.2.11.1. L-Lactate Acid Levels
Cells were seeded in 96 well plates at the density to achieve 90% confluence after
24 h in appropriate growth medium. A blank well without cells was included as the control.
After 24 h incubation, L-Lactate concentrations in the culture medium were measured
using the glycolysis cell based kit purchased from Cayman Chemical Company.
2.12.2. Palmitic Acid Levels
Cells (1 x 106) were harvested for free fatty acids. Cells were homogenized by
pipetting in 200 μL of chloroform with 1% triton-x. Samples were centrifuged at 16g for 5
min at 4°C. Then the lower phase (non-polar) was transferred to a new tube and dried at
50°C, vacuum centrifuged for 30min and resuspended in 200 μL of sample buffer and 50uL
of sample was used per well. Then the manufactures’ instructions for the Free Fatty Acid
Quantification Kit from BioVision were followed and quantification was carried out at
560nm on the BioTek plate reader. Using a standard curve and correcting for the ¼ dilution
factor, palmitic acid levels were determined for all samples. Three independent
experiments were performed for each cell line.
2.2.12. Seahorse Analyzer
2.2.12.1. Fatty Acid Oxidation
The Seahorse XF96 Extracellular Flux Analyzer (Agilent Technologies, Santa
Clara, CA) was used to measure fatty acid oxidation in all cells. 24 h prior to the assays
BEAS-2B, BEP2D, and WTHBF-6 cells were seeded at a density of 4.0 x 104, 4.5 x 104,
and 3.5 x 104 cells per well in a XF96 plate, respectively. The seeding densities used for
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the Cr(VI)-transformed cells were the same as their passage-matched control cells. To
measure the rate of fatty acid oxidation, cells were incubated overnight in their normal cell
culture media with 0.5mM L-carnitine supplementation in XF96 cell culture plates. Fortyfive minutes prior to the beginning of OCR measurement, the cells were switched to the
Assay Medium (DMEM with 25 mM glucose, 0.5 mM carnitine, 2 mM glutamine, and 1
mM pyruvate). Etomoxir (40 µM) was added to one set of cells to reveal the amount of
FAO-associated OCR. The endogenous FAO-respiration was calculated by subtracting
OCR levels in ETO-treated cells receiving BSA from those in untreated cells receiving
BSA. The exogenous FAO-respiration was calculated by subtracting OCR levels in ETOtreated cells receiving BSA-palmitate from those in untreated cells receiving BSApalmitate. All Seahorse experiments were performed in at least triplicate by the Redox
Metabolism Shared Resource Facility at the University of Kentucky.
2.2.12.2. Glycolytic Rate Assay
The Seahorse XF96 Extracellular Flux Analyzer was used to measure glycolysis
activity in all the cells. 24 h prior to the assays BEAS-2B, BEP2D, and WTHBF-6 cells
were seeded at the density of 4.0x104, 4.5x104, and 3.5x104 cells per well in a XF96 plate
respectively. The glycolytic rate tests were performed per manufacturer’s protocol. For
injections 10mM glucose, 1uM oligomycin, and 50 mM 2-deoxyglucose were used. The
relative levels of non-glycolytic acidification, glycolysis, glycolytic capacity and
glycolytic reserve were calculated based on ECAR data obtained in the glycolysis stress
using Seahorse Wave software (Agilent Technologies) for XF analyzers. All Seahorse
experiments were performed by the Redox Metabolism Shared Resource Facility at the
University of Kentucky.
2.2.12.3. Glycolytic Stress Test
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The Seahorse XF96 Extracellular Flux Analyzer was used to measure glycolysis
activity in all the cells. 24 h prior to the assays BEAS-2B, BEP2D, and WTHBF-6 cells
were seeded at the density of 4.0x104, 4.5x104, and 3.5x104 cells per well in a XF96 plate
respectively. The glycolytic rate tests were performed per manufacturer’s protocol. For
injections 0.5mM antimycin A, 0.5 µM rotenone, and 50 µM 2-deoxyglucose were used.
The basal glycolysis and compensatory glycolysis were calculated based on the Proton
Efflux Rates using the Seahorse Wave software for XF analyzer. All Seahorse experiments
were performed by the Redox Metabolism Shared Resource Facility at the University of
Kentucky.
2.2.12.4. Mitochondrial Stress Test
The Seahorse XF96 Extracellular Flux Analyzer was used to measure
mitochondrial respiratory activity in all cells. 24 h prior to the assays BEAS-2B, BEP2D,
and WTHBF-6 cells were seeded at a density of 4.0 x 104, 4.5 x 104, and 3.5 x 104 cells per
well in a XF96 plate, respectively. The seeding densities used for the Cr(VI)-transformed
cells were the same as their passage-matched control cells. The mitochondrial stress tests
were performed per manufacturer’s protocol. For basal media for the experiments we used
XF base medium with 25 mM glucose, 2.0 mM glutamine, and 1.0 mM pyruvate. During
the assay, the values used for injections were 100 µM oligomycin and 50 mM 2deoxyglucose. For the injections of FCCP BEAS-2B control and Cr(VI)-transformed cell
lines received 0.3 µM FCCP and BEP2D and WTHBF-6 control, Cr(VI)-transformed cell
lines, and xenograft tumor-derived cells received 0.6 µM FCCP. Data were normalized to
baseline read for the third oxygen consumption read and is presented as a percentage (Wise
J et al., 2018). Coupling efficiency was not normalized to the baseline as it has an internal
normalization in its calculation. The basal respiration, coupled respiration, coupling
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efficiency, maximal respiration, proton leak, non-mitochondrial oxygen consumption and
spare respiratory capacity were calculated using the Seahorse Wave software for XF
analyzers. All Seahorse experiments were performed in at least triplicate by the Redox
Metabolism Shared Resource Facility at the University of Kentucky.
2.2.13. Soft Agar Transformation Assay and Colony Isolation
To confirm malignant transformation occurred of the Cr(VI) treated BEAS-2B
cells, an anchorage-independent cell growth assay was used. Soft agar colony formation
assays were performed as described (Wise J et al., 2018). Briefly, 2 mL of 0.67% agar in
LHC-9 media was placed into each well of a 6-well culture plate for the bottom layer. A
suspension (2 mL) containing 5 x 104 cells was mixed with 2 ml of 0.33% agar-LHC-9 and
placed on the bottom layer of the agar and grown for 8 weeks (24 h after seeding 1 mL of
media was put into each well to keep the agar from drying out). 24 h after plating, cultures
were examined microscopically to confirm an absence of large clumps of cells. Colonies
were stained with 5% 4-Nitro blue tetrazolium chloride and stained colonies were counted
following 24 h in stain. To establish cultures from anchorage-independent colonies, one
soft-agar colony was plucked under sterile conditions and then dispersed in trypsin and replated into culture dishes.
2.2.14. Xenograft Tumors
Animal studies were conducted in accordance with NIH animal use guidelines and
the animal usage protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Kentucky (Lexington, KY). Athymic nude mice were housed
in a pathogen-free room within the animal facilities at the Chandler Medical Center,
University of Kentucky (Lexington, KY). Cells (1 x 106 cells per mouse) from each cell
line were re-suspended in serum-free medium containing basement membrane matrix at a
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1:1 ratio (total volume of 100 μl) and subcutaneously (s.c.) injected into the flanks of nude
mice up and mice were maintained for up to 6 months post injection. A total of 8 injection
sites per cell line used. Each mouse received one s.c injection per side (8-12 mice were
used per experiment). Mice were checked weekly for tumor appearance. At the termination
of the experiment, mice were sacrificed; tumors were excised into pieces for cell line
development. Tumor weight and volume were also recorded. Tumor volume was
determined by Vernier caliper, using the formula of A x B2 x 0.52, where A is the longest
diameter of tumor and B is the shortest diameter.
2.2.15. Cell Line Development
Tumors were rinsed briefly with ethanol and then PBS, minced into small pieces
and then digested for 2 h with collagenase type II in PBS. Cells were then run through a 40
μM mesh cell filter and plated into T-25 flasks, media was replaced after 72 h and routine
culture was carried out once cells reached confluence.
2.2.16. Statistics
Graphpad Prism 7 was used to determine statistical relevance. The Student’s t-test
was used to calculate p-values to determine the statistical significance of the difference in
means. For tumor incidence, a chi-squared test was performed.
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Chapter 3 De novo Lipogenesis is Important for Hexavalent Chromium-Induced Lung
Carcinogenesis
3.1. Overview
The first aim of this project is the investigation of whether de novo lipogenesis is
important in Cr(VI)-induced lung carcinogenesis. The results in this chapter show Cr(VI)
treatment can induce lipogenesis-related cells in human lung cell lines. Further the results
report that three different sets of Cr(VI)-transformed lung cells have increased lipogenesis
related protein expression and increased lipogenesis as compared to their passage-matched
control cells. Furthermore, inhibit of a key lipogenesis protein provided evidence that this
energy metabolism pathway is important to Cr(VI)-transformed cells. Lastly, lipogenesis
protein expressions were higher in chromate-induced lung tumors than adjacent normal
lung tissue.
3.2. Prolonged Cr(VI) Exposure Induces Lipogenesis-Related Protein Expressions in
Human Lung Cell Lines
As mentioned in the introduction (chapter 1), a previous report shows that acute
exposures to Cr(VI) can induce SREBP-1 expression in human skin cells. Here, we
exposed human lung cell lines to sodium chromate for 120 h (sodium chromate
concentrations were chosen due to observed toxicity with higher concentrations). We saw
that pACLY, ACLY, and FASN expressions were increased and pACC expression was
decreased in BEAS-2B cells treated with Cr(VI) (Figure 3.1A). We observed that pACLY,
ACLY, ACC1, and FASN expressions were increased in BEP2D cells treated with Cr(VI)
(Figure 3.1B). Lastly, we reported that pACLY, ACLY, ACC1, and FASN expressions
were increased in WTHBF-6 cells treated with Cr(VI) (Figure 3.1C).
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Figure 3.1. Prolong Exposure to Cr(VI) Induces Lipogenesis-related Protein
Expressions in Human Lung Cells. This figure shows three preliminary western blots.
(A) BEP2D cells exposed to Cr(VI) for 120 h had increased ACLY, pACLY, ACC1, and
FASN expression compared to untreated control. While pACC expression was decreased.
(B) BEAS-2B cells exposed to Cr(VI) for 120 h had increased ACLY, pACLY, ACC1, and
FASN expression compared to untreated control. (C) WHTBF-6 cells exposed to Cr(VI)
for 120 h had increased ACLY, pACLY, ACC1, and FASN expression compared to
untreated control. β-actin and α-tubulin were used as loading controls.
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3.3. Chromium(VI)-Transformed BEAS-2B Cells Have Increased de novo
Lipogenesis
Using BEAS-B cells and Cr(VI)-transformed BEAS-2B Cells (B2B-CrT), we
investigated lipogenesis endpoints in these cells (protein and functional palmitic acid
levels). B2B-CrT cells had increased ACLY, pACLY, ACC1, and FASN protein
expressions compared to passage-matched control BEAS-2B cells. SREBP-1 protein
expression levels were not increased, indicating that the increase in protein expression is
not due to more transcription (Figure 3.2). Phosphorylation of ACC1 indicates decreased
activity. We observed that pACC protein expression was lower in the B2B-CrT cells
compared to the passage-matched BEAS-2B cells. B2B-CrT cells had increased palmitic
acid levels compared to passage-matched control cells (Figure 3.3), confirming a functional
change in the lipogenesis pathway. Typically, cancer cells increase lipid production for
various different endpoints (e.g. membrane synthesis, changing lipid profiles, protection
against oxidation, energy usage, and lipid droplet storage). We measured energy usage and
lipid droplet storage. We saw no major changes in endogenous or exogenous fatty acid
oxidation of the B2B-CrT cells compared to passage-matched control BEAS-2B cells
(Figure 3.4). Lastly, to measure lipid droplet formation, we employed Oil Red O staining.
No changes in lipid droplets were observed in the Cr(VI)-transformed cells compared to
passage-matched control cells (Figure 3.5).
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Figure 3.2. Chromium(VI)-Transformed BEAS-2B Cells Have Increased de novo
Lipogenesis Enzymes. Cr(VI)-transformed BEAS-2B cells (B2B-CrT cells) had increased
ACLY, pACLY, ACC1, and FASN protein expressions compared to passage-matched
control BEAS-2B cells. pACC expression was decreased in the B2B-CrT cells compared
to their passage-matched control BEAS-2B cells. β-actin was used as a loading control.
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Figure 3.3. Chromium(VI)-Transformed BEAS-2B Cells Have Increased Palmitic
Acid Levels. Cr(VI)-transformed BEAS-2B cells (B2B-CrT cells) had increased palmitic
acid levels compared to passage-matched control BEAS-2B cells (Data presented as
percent increase of passage-matched control BEAS-2B). Data represent 3 experiments,
errors bars represent the SEM, *p<0.05 compared to passage-matched control cells.
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Figure 3.4. Chromium(VI)-Transformed BEAS-2B Cells Do Not Have Increased
Fatty Acid Oxidation. Endogenous and exogenous fatty acid oxidation were measured on
the Seahorse Analyzer. Cr(VI)-transformed BEAS-2B cells (B2B-CrT cells) did not have
increased fatty acid oxidation as compared to their passage-matched control BEAS-2B
cells. Data represent 3 experiments, errors bars represent the SEM, *p<0.05 compared to
passage-matched control cells.
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Figure 3.5. Chromium(VI)-Transformed BEAS-2B Cells Do Not Have Increased
Lipid Droplets. Cr(VI)-transformed BEAS-2B cells (B2B-CrT cells) had no increases in
lipid droplet formation (Oil Red O staining) when compared to passage-matched control
BEAS-2B cells. Data represent 3 experiments, errors bars represent the SEM, *p<0.05
compared to passage-matched control cells.
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3.4. Chromium(VI)-Transformed BEP2D Cells Have Increased de novo Lipogenesis
Next we used BEP2D cells and Cr(VI)-transformed BEP2D Cells (BPD-CrT) from
a previous study. We investigated lipogenesis endpoints in these cells (protein and
functional palmitic acid levels). We aimed to confirm that our results with the BEAS-2B
cells were not cell line specific. BPD-CrT cells had increased ACLY, pACLY, ACC1, and
FASN protein expressions compared to passage-matched controls. SREBP-1 protein
expression levels were not increased, indicating that the increase in protein expression is
not due to more transcription (Figure 3.6). We also observed pACC expression was lower
in BPD-CrT cells (Figure 3.6). BPD-CrT cells had increased palmitic acid levels compared
to passage-matched control cells (Figure 3.8). We saw no changes in endogenous or
exogenous fatty acid oxidation of the BPD-CrT cells compared to passage-matched control
BEP2D cells (Figure 3.8) Lastly, no changes in lipid droplets were observed in the Cr(VI)transformed cells compared to passage-matched control cells (Figure 3.9).
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Figure 3.6. Chromium(VI)-Transformed BEP2D Cells Have Increased De Novo
Lipogenesis Enzymes. Cr(VI)-transformed BEP2D cells (BPD-CrT cells) had increased
ACLY, pACLY, ACC1, and FASN protein expressions compared to passage-matched
control BEP2D cells. pACC expression was decreased in the BPD-CrT cells compared to
their passage-matched control BEP2D cells. β-actin was used as a loading control.
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Figure 3.7. Chromium(VI)-Transformed BEP2D Cells Have Increased Palmitic Acid
Levels. Cr(VI)-transformed BEP2D cells (BPD-CrT cells) had increased palmitic acid
levels compared to passage-matched control BEP2D cells (Data presented as percent
increase of passage-matched control BEP2D). Data represent 3 experiments, errors bars
represent the SEM, *p<0.05 compared to passage-matched control cells.
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Figure 3.8. Chromium(VI)-Transformed BEP2D Cells Do Not Have Increased Fatty
Acid Oxidation. Endogenous and exogenous fatty acid oxidation were measured on the
Seahorse Analyzer. Cr(VI)-transformed BEP2D cells (BPD-CrT cells) did not have
increased fatty acid oxidation as compared to their passage-matched control BEP2D cells.
Data represent 3 experiments, errors bars represent the SEM, *p<0.05 compared to
passage-matched control cells.
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Figure 3.9. Chromium(VI)-Transformed BEP2D Cells Do Not Have Increased Lipid
Droplets. Cr(VI)-transformed BEP2D cells (BPD-CrT cells) had no increases in lipid
droplet formation (Oil Red O staining) when compared to passage-matched control BEP2D
cells. Data represent 3 experiments, errors bars represent the SEM, *p<0.05 compared to
passage-matched control cells.
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3.5. Chromium(VI)-Transformed WTHBF-6 Cells Have Increased de novo
Lipogenesis
Next, using WTHBF-6 cells (C52-2) and Cr(VI)-transformed WTHBF-6 Cells (T23-3 and
T73-3) from a previous study, we investigated lipogenesis endpoints in these cells. T23-3
and T73-3 cells had increased ACLY, pACLY, ACC1, and FASN protein expressions
compared to passage-matched controls. SREBP-1 protein expression levels were not
increased, indicating that the increase in protein expression is not due to more transcription
(Figure 3.10). We also found pACC expression was lower in T23-3 and T73-3 cells (Figure
3.10). T23-3 and T73-3 had increased palmitic acid levels compared to passage-matched
control cells (Figure 3.11). We observed no changes in endogenous or exogenous fatty acid
oxidation of the T23-3 and T73-3 cells compared to passage-matched control cells (Figure
3.12). Similarly, we did not observed no changes in lipid droplets in the Cr(VI)transformed cells compared to passage-matched control cells (Figure 3.13).

87

Figure 3.10. Chromium(VI)-Transformed WTHBF-6 Cells Have Increased De Novo
Lipogenesis Enzymes. Cr(VI)-transformed WTHBF-6 cells (T23-3 and T73-3 cells) had
increased ACLY, pACLY, ACC1, and FASN protein expressions compared to passagematched control WTHBF-6 cells (C52-2 cells). pACC expression was decreased in the
T23-3 and T73-3 cells compared to their passage-matched control WTHBF-6 cells. β-actin
was used as a loading control.
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Figure 3.11. Chromium(VI)-Transformed WTHBF-6 Cells Have Increased Palmitic
Acid Levels. Cr(VI)-transformed WTHBF-6 cells (BPD-CrT cells) had increased palmitic
acid levels compared to passage-matched control WTHBF-6 cells (C52-2 cells) (Data
presented as percent increase of passage-matched control). Data represent 3 experiments,
errors bars represent the SEM, *p<0.05 compared to passage-matched control cells.
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Figure 3.12. Chromium(VI)-Transformed WTHBF-6 Cells Do Not Have Increased
Fatty Acid Oxidation. Endogenous and exogenous fatty acid oxidation were measured on
the Seahorse Analyzer. Cr(VI)-transformed WTHBF-6 cells (T23-3 and T73-3 cells) did
not have increased fatty acid oxidation as compared to their passage-matched control
WTHBF-6 cells. Data represent 3 experiments, errors bars represent the SEM, *p<0.05
compared to passage-matched control cells.
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Figure 3.13. Chromium(VI)-Transformed WTHBF-6 Cells Do Not Have Increased
Lipid Droplets. Cr(VI)-transformed WTHBF-6 cells (T23-3 and T73-3 cells) had no
increases in lipid droplet formation (Oil Red O staining) when compared to passagematched control WTHBF-6 cells (C52-2 cells). Data represent 3 experiments, errors bars
represent the SEM, *p<0.05 compared to passage-matched control cells.
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3.6. Increased de novo Lipogenesis Is Important for Chromium(VI)-Transformed
Cells
To determine if the increases in lipogenesis is important in Cr(VI)-transformed cell
survival and cancer properties, we examined soft agar colony formation, proliferation, and
tumor growth after drug inhibition (C75) of FASN. We focused on just the BEAS-2B cells,
since all three cell types showed the same metabolism changes following neoplastic
transformation by chromium. Multiple reports have shown that inhibition of FASN leads
to decreased cancer cell and tumor growth. Following, a 24 h treatment with 0, 1, 5, and
10 µM C75, BEAS-2B and B2B-CrT, C75 treatment decreased FASN expressions (3.14).
Using a growth curve assay, we found that C75 negatively impacted the growth of B2BCrT more than the BEAS-2B cells (Figure 3.15). Treatment with C75 also decreased the
soft agar colony formation properties of B2B-CrT cells (Figure 3.16).
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Figure 3.14. Drug Inhibition Decreased FASN Protein Expression in Cr(VI)Transformed BEAS-2B Cells. 24 h treatment with 0, 1, 5, and 10 µM C75 (FASN
inhibitor) decreased FASN protein expression in Cr(VI)-transformed BEAS-2B cells
(B2B-CrT cells) and passage-matched BEAS-2B cells. DMSO was used a vehicle control
(VC). β-actin was used as a loading control.
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Figure 3.15. Increased De Novo Lipogenesis Is Important for Cr(VI)-transformed
Cells Growth. 24 h treatment with 0, 1, 5, and 10 µM C75 (FASN inhibitor) decreased
Cr(VI)-transformed BEAS-2B cells (B2B-CrT cells) growth as measured with a growth
curve [Data presented as number of cells (percent of untreated control)]. C75 reduced the
growth of B2B-CrT cells more than passage-matched BEAS-2B cells. DMSO was used a
vehicle control. Data represent 3 experiments, errors bars represent the SEM, *p<0.05
compared to untreated cells.
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Figure 3.16 Increased de novo Lipogenesis Is Important for Cr(VI)-transformed Cells
Growth in Soft Agar. 24 h treatment with 0, 1, 5, and 10 µM C75 (FASN inhibitor)
decreased BEAS-2B cells (B2B-CrT cells) soft agar colony formation. (A) Representative
soft agar image. (B) Average number of colonies per well for treatments. DMSO was used
as a vehicle control. Data represent 3 experiments, errors bars represent the SEM, *p<0.05
untreated cells.
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3.7. Chromate-Induced Lung Tumors Show Increased Lipogenesis Protein
Expressions
Formalin-fixed lung tissue slides from tumor and normal adjacency obtained from
a worked exposed to Cr(VI) were subjected to fluorescence immunostaining with
antibodies against pACLY (red), ACLY (red), ACC1 (green), and FASN (red) and DAPI
(nuclear control, blue). We observed increased staining of total ACLY and pACLY in
Cr(VI)-tumor lung tissues (Figure 3.17E,K and 3.18G,Q, respectively) as compared to the
adjacent normal lung tissues (Figure 3.17A,G and 3.18B,L, respectively). ACC1 and
FASN protein expressions were also increased in the Cr(VI)-induced lung tumor tissues
(Figure 3.18H,R and 3.19E,K, respectively) as compared to normal adjacent lung tissue
(Figure 3.18C,M and 3.19B,H, respectively). These results confirm our cell culture
findings and show that lipogenesis protein expressions are increased in Cr(VI)-induced
lung tumor tissues.
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Figure 3.17. Chromate Lung Tumors Show Increased ACLY Protein Expression.
Formalin-fixed normal lung tissue from a healthy patient and lung tumor tissue and its
adjacent normal tissue from a workers diagnosed with stage I and II lung adenocarcinomas
due to occupational exposure to Cr(VI) were subjected to immunofluorescence staining for
examination of expressions of ACLY (red) and DAPI (blue) was used for nuclear control.
Scale bar is 20 µM.
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Figure 3.18. Chromate Lung Tumors Show Increased pACLY And ACC1 Protein
Expressions. Formalin-fixed normal lung tissue from a healthy patient and lung tumor
tissue and its adjacent normal tissue from a workers diagnosed with stage I and II lung
adenocarcinomas due to occupational exposure to Cr(VI) were subjected to
immunofluorescence staining for examination of expressions of p-ACLY (red), ACC1
(green), and DAPI (blue) was used for nuclear control. Scale bar is 20 µM.
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Figure 3.19. Chromate Lung Tumors Show Increased FASN Protein Expression.
Formalin-fixed normal lung tissue from a healthy patient and lung tumor tissue and its
adjacent normal tissue from a workers diagnosed with stage I and II lung adenocarcinomas
due to occupational exposure to Cr(VI) were subjected to immunofluorescence staining for
examination of expressions of FASN (red) and DAPI (blue) was used for nuclear control.
Scale bar is 20 µM.
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3.8. Importance
The results from this aim demonstrate that during prolong Cr(VI) exposure can
induce lipogenesis-related proteins. Further, these resulted obtained for this chapter show
that Cr(VI)-induced malignant transformation of human lung cells (normal cells to
malignantly transformed cells) results in increased lipogenesis. Further, inhibition of a key
protein in this pathway demonstrated that this pathway is important for Cr(VI)-transformed
cells. Additionally, these results were not cell type specific (fibroblast versus epithelial
cells). Lastly, results obtained using chromate-induced lung tumor tissues from human
samples confirmed that these proteins were increased in this tumors compared to normal
adjacent tissue, indicating these results are translational to chromate exposures in humans.
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Chapter 4 Elucidating a Role of Mitochondrial Respiratory Dysfunction
During Hexavalent Chromium-Induced Lung Carcinogenesis
This chapter is reproduced with permission from Begell House Inc. The original text and
data can be found: Wise JTF, Wang L, Alstott MC, Ngalame NNO, Wang Y, Zhang Z, and
Shi X. Investigating the Role of Mitochondrial Respiratory Dysfunction During
Hexavalent Chromium-Induced Lung Carcinogenesis. Journal of Environmental
Pathology, Toxicology and Oncology. 37(4);317-329.
doi: 10.1615/JEnvironPatholToxicolOncol.2018028689.
4.1. Overview
The first part of this study investigates whether mitochondrial respiratory
dysfunction occurs during Cr(VI)-induced lung carcinogenesis. These data show that three
different sets of Cr(VI)-transformed lung cells do not have mitochondrial respiratory
dysfunction as compared to their passage-matched control cells. Furthermore, we observed
Xenograft tumor-derived cells did have mitochondrial respiratory dysfunction.
4.2. Chromium(VI)-Transformed BEAS-2B Cells Do Not Exhibit Mitochondrial
Respiratory Dysfunction
BEAS-2B cells chronically treated with 0.5 µM Cr(VI) [6 months (180 days)]
generated colonies in soft agar (data not shown). We developed Cr(VI)-transformed cells
(B2B-CrT) from an isolated colony collected from soft agar. Passage-matched control
BEAS-2B cells and B2B-CrT were analyzed for mitochondrial respiration using the
Seahorse Analyzer and the mitochondrial stress test assay. The basal respiration, maximal
respiration, and spare respiratory capacity of the Cr(VI)-transformed cells (B2B-CrT) were
not different from passage-matched control BEAS-2B cells (Figure 4.1A-C). The proton
leak, non-mitochondrial oxygen consumption and coupling efficiency were unchanged in
the transformed cells compared to the passage-matched control cells (Figure 4.1D-E).
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Interestingly, the transformed cells had a higher coupled respiration (Fig. 4.1E). These data
indicated that Cr(VI)-transformed BEAS-2B cells did not display mitochondrial
respiratory dysfunction and may be more metabolically active.

103

104

105

106

Figure 4.1. Chromium(VI)-Transformed Bronchial Airway Epithelial Cells (BEAS2B) Do Not Have Mitochondrial Respiratory Dysfunction. (A) Mitochondrial
Respiration Profile for BEAS-2B cells with the relevant injection strategy for the Seahorse
Analyzer Mitochondrial Stress Test. (B) Oxygen consumption data for the BEAS-2B and
B2B-CrT cells, presented as a baseline percentage to the third oxygen consumption read.
(C) Basal respiration, maximal respiration, and spare respiratory capacity for the BEAS2B and B2B-CrT cells. (D) Proton Leak, Non-mitochondrial oxygen consumption, and
Coupled respiration for the BEAS-2B and B2B-CrT cells. (E) Mitochondrial coupling
efficiency for the BEAS-2B and B2B-CrT cells. Data are the average of at least three
experiments ± the SEM. *P < 0.05.
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4.3. Chromium(VI)-Transformed BEP2D Cells Do Not Exhibit Mitochondrial
Respiratory Dysfunction
Since cancer cells usually display some mitochondrial respiratory dysfunction, we
tested whether our findings were cell-specific by comparing to other Cr(VI)-transformed
cell types. We received HPV (E6 and E8) immortalized bronchial epithelial airway cells
(BEP2D cells) and Cr(VI)-transformed BEP2D cells (BPD-CrT) from the laboratory of Dr.
John P. Wise, Sr. at the University of Louisville, KY (Xie et al., 2007). Passage-matched
control BEP2D cells and BPD-CrT were analyzed for mitochondrial respiration using the
Seahorse Analyzer and the mitochondrial stress test assay.
The basal respiration, maximal respiration, and spare respiratory capacity of the
transformed cells were not different from passage-matched control BEP2D cells (Figure
4.2A-C). The proton leak and non-mitochondrial oxygen consumption were unchanged in
the transformed cells compared to the passage-matched control cells (Figure 4.2D). The
coupled respiration and coupling efficiency were not statically different from passagematched control cells (Figure 4.2D and E). These data indicated that BPD-CrT cells did
not display mitochondrial respiratory dysfunction. These results are consistent with results
from BEAS-2B cells.
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Figure 4.2. Chromium(VI)-Transformed Bronchial Airway Epithelial Cells (BEP2D)
Do Not Have Mitochondrial Respiratory Dysfunction. (A) Mitochondrial Respiration
Profile for BEP2D cells with the relevant injection strategy for the Seahorse Analyzer
Mitochondrial Stress Test. (B) Oxygen consumption data for the BEP2D and BPD-CrT
cells, presented as a baseline percentage to the third oxygen consumption read. (C) Basal
respiration, maximal respiration, and spare respiratory capacity for the BEP2D and BPDCrT cells. (D) Proton Leak, Non-mitochondrial oxygen consumption, and Coupled
respiration for the BEP2D and BPD-CrT cells. (E) Mitochondrial coupling efficiency for
the BEP2D and BPD-CrT cells. Data for B-E are the average of at least three experiments
± the SEM. *P < 0.04.
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4.4. Chromium(VI)-Transformed Lung Fibroblasts Do Not Exhibit Mitochondrial
Respiratory Dysfunction
As mentioned before, we were surprised to find no major respiration changes in our
Cr(VI)-transformed cells. To further show that our findings were not unique to
immortalization factor or cell type, we compared our results to h-TERT immortalized
fibroblasts. We obtained immortalized human lung fibroblast cells (WTHBF-6 cells) and
Cr(VI)-transformed WTHBF-6 cells (T23-3 and T73-3) from the laboratory of Dr. John P.
Wise Sr. at the University of Louisville, KY (Wise, S.S. et al., 2018). These three different
cell lines allowed us to determine if immortalization or cell type plays a role in our observed
results. Passage-matched control WTHBF-6 cells (C52-2 cells), T23-3, and T73-3 cells
were analyzed for mitochondrial respiration using the Seahorse Analyzer and the
mitochondrial stress test assay. The basal respiration, maximal respiration, and spare
respiratory capacity of the Cr(VI)-transformed fibroblasts were not different from passagematched control fibroblast cells (Figure 4.3.A-C). The proton leak, non-mitochondrial
oxygen consumption, coupling efficiency, and coupled respiration were unchanged in the
transformed cells compared to the passage-matched control cells (Figure 4.3.D and E).
These data indicated that Cr(VI)-transformed fibroblasts did not display mitochondrial
respiratory dysfunction and confirmed the results of the epithelial cell lines, suggesting that
immortalization factors did not play any role.

113

114

115

116

Figure 4.3. Chromium(VI)-Transformed Human Lung Fibroblasts (WTHBF-6) Do
Not Have Mitochondrial Respiratory Dysfunction. (A) Mitochondrial Respiration
Profile for WTHBF-6 cells with the relevant injection strategy for the Seahorse Analyzer
Mitochondrial Stress Test. (B) Oxygen consumption data for the control WTHBF-6 cells
(C52-2 cells) and Cr(VI)-transformed WTHBF-6 cells (T23-3 and T73-3 cells), presented
as a baseline percentage to the third oxygen consumption read. (C) Basal respiration,
maximal respiration, and spare respiratory capacity for the C52-2, T23-3, and T73-3 cells.
(D) Proton Leak, Non-mitochondrial oxygen consumption, and Coupled respiration for the
C52-2, T23-3, and T73-3 cells. (E) Mitochondrial coupling efficiency for the C52-2, T233, and T73-3 cells. Data the average of at least three experiments ± the SEM. *P < 0.04.
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4.5. Cr(VI)-Transformed Cells Grow Tumors in Nude Mice
It was important to further demonstrate our Cr(VI)-transformed cells were
malignantly transformed because we did not observe any changes in mitochondrial
respiratory dysfunction and most cancer cell lines and tumors reported in the literature
exhibit mitochondrial dysfunction (Hsu et al., 2016). We used the xenograft tumor growth
assay to demonstrate that all sets of Cr(VI)-transformed cells were malignantly transformed
and were able to induce tumors in nude mice. We injected all sets of the transformed cells
and their passage-matched control cells into nude mice. Our results showed that B2B-CrT,
BPD-CrT, T23-3, and T73-3 cells were able to grow tumors in nude mice (Figures 4.44.6). None of the passage-matched control cells grew tumors in nude mice. These data from
the tumorigenesis experiments confirm that our Cr(VI)-transformed cells were malignantly
transformed.
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Figure 4.4. Chromium(VI)-Transformed Human Lung Bronchial Cells (BEAS-2B)
Grow Tumors in Nude Mice. Passage-matched control BEAS-2B cells and Cr(VI)transformed BEAS-2B cells (B2B-CrT) were injected into the flanks of 6-week old
athymic nude mice (1 x 106 cells per mouse) and checked weekly for tumor appearance.
There were 8 s.c. injection sites per cell line. (A) Tumor incidences. (B) Tumor volume
was measured after animal euthanasia. Tumor volume was determined by calipers,
following the formula A x B2 x 0.52, where A is the longest diameter of tumor and B is
the shortest diameter. (C) Tumor weights. These data are expressed as the mean ± SEM.
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Figure 4.5. Chromium(VI)-Transformed Human Lung Bronchial Cells (BEP2D)
Grow Tumors in Nude Mice. Passage-matched control BEP2D cells and Cr(VI)transformed BEP2D cells (BPD-CrT) were s.c. injected into the flanks of 6-week old
athymic nude mice (1 x1 06 cells per mouse) and checked weekly for tumor appearance.
There were 8 s.c. injection sites per cell line. (A) Tumor incidences. (B) Tumor volume
was measured after animal euthanasia. Tumor volume was determined by calipers,
following the formula A x B2 x 0.52, where A is the longest diameter of tumor and B is
the shortest diameter. (C) Tumor weights. These data are expressed as the mean ± SEM.
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Figure 4.6. Chromium(VI)-Transformed Human Lung Fibroblasts (WTHBF-6)
Grow Tumors in Nude Mice. Passage-matched control WTHBF-6 cells (C52-2 and
Cr(VI)-transformed WTHBF-6 cells (T23-3 and T73-3) were s.c. injected into the flanks
of 6-week old athymic nude mice (1 x1 06 cells per mouse) and checked weekly for tumor
appearance. There were 8 s.c. injection sites per cell line. (A) Tumor incidences. (B)
Tumor volume was measured after animal euthanasia. Tumor volume was determined by
calipers, following the formula A x B2 x 0.52, where A is the longest diameter of tumor
and B is the shortest diameter. (C) Tumor weights. These data are expressed as the mean
± SEM.
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4.6. Cr(VI)-Lung Fibroblast Xenograft Tumor-Derived Cells Have Mitochondrial
Respiratory Dysfunction
Carcinogenesis is considered a multi-step process. The mechanism of metalinduced carcinogenesis can be conceptualized into two stages. During the first stage,
normal cells undergo neoplastic transformation into malignantly transformed cells. In this
stage, Cr(VI)-induced cellular transformation did not induce mitochondrial respiratory
dysfunction. The second stage is the progression from malignantly transformed cells into
tumors (tumorigenesis) (Xu et al., 2017). We assessed if xenograft tumor-derived cells
have mitochondrial respiration changes. This would further provide evidence that the
tumor microenvironments may drive some of the mitochondrial dysfunctions found in
cancer cells reported in the literature. From the WTHBF-6 Cr(VI)-transformed cell lines’
xenograft tumor tissues we isolated cells. Specifically, we isolated six cell lines from the
T23-3 xenograft tumor tissues and two cell lines from the T73-3 xenograft tumor tissues.
Passage-matched control WTHBF-6 cells (C52-2) and the two Cr(VI)-transformed
colonies (T23-3 and T73-3), and the xenograft tumor-derived cell lines (T23-3-X2, T23-3X3, T23-3-X4, T23-3-X5, T23-3-X6, T23-3-X7, T73-3-X2, and T73-3-X3) were analyzed
for mitochondrial respiration. Again, mitochondrial respiration was measured using the
Seahorse Analyzer.
The basal respiration of xenograft tumor-derived cells was not different between
passage-matched control cells (C52-2 cells) and Cr(VI)-transformed cells (T23-3 and T733 cells) (Figure 4.7A, B, E, and F). Xenograft tumor-derived cells showed decreases in
maximal respiration and spare respiratory capacity compared to the passage-matched
control cells and the transformed cell lines (except T23-3-X3 which had increased
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respiration). The proton leak was higher in T23-3-X5, T23-3-X6, T23-3-X7, T73-3-X3,
and T73-3-X3 compared to passage-matched control cells (C52-2) (Fig. 7C and G). In most
of the xenograft tumor-derived cell lines (T23-3-X2, T23-3-X4, T23-3-X5, T23-3-X6,
T23-3-X7, T73-3-X2, and T73-3-X3) coupled respiration was higher than the passagematched control cells (Figure 4.7C and G). Non-mitochondrial oxygen consumption was
lower in all the xenograft tumor-derived cells except T73-3-X2. All of the xenograft tumorderived cells showed decreased mitochondrial coupling efficiency when compared to
passage-matched control fibroblasts and Cr(VI)-transformed cells. These data demonstrate
that xenograft tumor-derived cells showed mitochondrial respiratory dysfunction and
provided evidence that mitochondrial dysfunction observed in cancer may be, in part, due
to tumor microenvironments.
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Figure 4.7. Xenograft Tumor-derived Cells Have Dysfunctional Mitochondrial
Respiration. (A) Oxygen consumption data for the control WTHBF-6 cells (C52-2) and
Cr(VI)-transformed WTHBF-6 cells (T23-3) and xenograft tumor-derived cells (T23-3X2, T23-3-X3, T23-3-X4, T23-3-X5, T23-3-X6, and T23-3-X7) presented as a baseline
percentage to the third oxygen consumption read. (B) Basal respiration, maximal
respiration, and spare respiratory capacity for the C52-2, T23-3, T23-3-X2, T23-3-X3,
T23-3-X4, T23-3-X5, T23-3-X6, and T23-3-X7 cells. (C) Proton Leak, Non-mitochondrial
oxygen consumption, and Coupled respiration for C52-2, T23-3, T23-3-X2, T23-3-X3,
T23-3-X4, T23-3-X5, T23-3-X6, and T23-3-X7 cells. (D) Mitochondrial coupling
efficiency for the C52-2, T23-3, T23-3-X2, T23-3-X3, T23-3-X4, T23-3-X5, T23-3-X6,
and T23-3-X7 cells. (E) Oxygen consumption data for the control WTHBF-6 cells (C522) and Cr(VI)-transformed WTHBF-6 cells (T73-3) and xenograft tumor-derived cells
(T73-3-X2, and T73-3-X3) presented as a baseline percentage to the third oxygen
consumption read. (F) Basal respiration, maximal respiration, and spare respiratory
capacity for the C52-2, T73-3, T73-3-X2, and T73-3-X3 cells. (G) Proton Leak, Nonmitochondrial oxygen consumption, and Coupled respiration for C52-2, T73-3, T73-3-X2,
and T73-3-X3 cells. (H) Mitochondrial coupling efficiency for the C52-2, T73-3, T73-3X2, and T73-3-X3 cells. Data are the average of at least three experiments ± the SEM. *P
< 0.05 from C52-2. #P < 0.05 from either T23-3 or T73-3.
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4.7. Importance
The results from this aim demonstrate that during the early stages of metal-induced
carcinogenesis (normal cells to malignantly transformed cells) malignantly transformed
human lung cells [due to exposure to Cr(VI)] do not have mitochondrial respiratory
dysfunction. Additionally, these results were not cell type specific (fibroblast versus
epithelial cells). In the later stages of metal-induced carcinogenesis (transformed cells to
tumor), mitochondrial respiratory dysfunction was observed. These results suggest that
mitochondrial respiratory dysfunction occurs during the later stages of Cr(VI)-induced
carcinogenesis.

Copyright © James Tate Fortin Wise 2019
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Chapter 5 Anaerobic Glycolysis or the ‘Warburg effect’ is not Important for
Hexavalent Chromium-induced Lung Carcinogenesis
5.1. Overview
The first part of this study investigates whether the “Warburg effect” or increased
anaerobic glycolysis is important to Cr(VI)-induced lung carcinogenesis. These resulted
obtained for this chapter show that three different sets of Cr(VI)-transformed lung cells do
not increase anaerobic glycolysis as compared to their passage-matched control cells.
Furthermore, the same results were observed in xenograft tumor-derived cells.
5.2. Chromium(VI)-Transformed BEAS-2B Cells Do Not Exhibit the ‘Warburg
Effect’
Previously we developed a malignantly transformed cell lines from a colony
collected from agar for 6 month Cr(VI)-treated BEAS-2B cells (Wise, J et al., 2018). The
endpoints to measure properly investigate the “Warburg effect” or increased anaerobic
glycolysis include glycolysis measurements and extracellular lactate production. Therefore
to investigate this pathway we used passage match control BEAS-2B cells and the Cr(VI)transformed colony (B2B-CrT) and analyzed functional glycolysis (using the Seahorse
Analyzer) and L-lactate levels in the media. We also measured the rate-limiting glycolytic
enzymes by western blot analysis [hexokinase I, hexokinase II, lactate dehydrogenase a
(LDHA), phosphofructokinase (PFKP), pyruvate dehydrogenase (PDH), pyruvate kinase
isomers M1/M2 (PKM 1/2), and pyruvate kinase isomer M2 (PKM2)].
Using the glycolytic stress test, we observed that glycolysis, maximal glycolysis,
and glycolytic reserve were not increased in the B2B-CrT compared to BEAS-2B cells
(Figure 5.1A-C). To confirm this functional assay, we performed a second glycolytic test,
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the glycolytic rate assay. We found that basal glycolysis and compensatory glycolysis (this
is the glycolysis following mitochondrial inhibition) was not increased in the Cr(VI)transformed BEAS-2B cells compared to their passage-matched cells (Figure 5.1D-E).
Next, we measured the extracellular L-lactate levels in the media and found that these
levels were not statistically different in the transformed cells as compared to the passagematched control cells (Figure 5.1F). Lastly, we measured the rate-limiting enzyme of
glycolysis by western blot and saw no major increases in most the glycolytic enzymes in
the B2B-CrT cells, similarly, we did not observe in PDH, LDHA, and LDHB (Figure
5.1G). These data demonstrate that Cr(VI)-transformed BEAS-2B cells do not exhibit the
‘Warburg effect’.
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Figure 5.1. Chromium(VI)-Transformed BEAS-2B Cells Do Not Exhibit the
‘Warburg Effect’. (A) Glycolytic Function Profile for BEAS-2B cells with the relevant
injection strategy for the Seahorse Analyzer Glycolytic Stress Test. (B) Glycolytic stress
test data for the BEAS-2B and B2B-CrT cells. (C) Glycolysis, Glycolytic capacity, and
glycolytic reserve for the BEAS-2B and B2B-CrT cells. (D) Glycolytic Rate Profile for the
BEAS-2B cells with the relevant injection strategy for the Seahorse Analyzer Glycolytic
Rate Assay. (E) Basal glycolysis and compensatory glycolysis for the BEAS-2B and B2BCrT cells. (F) Extracellular L-lactate levels for BEAS-2B and B2B-CrT cells. (G)
Hexokinase I, Hexokinase II, phosphofructokinase (PFKP), pyruvate kinase isozymes
M1/M2 (PKM 1/2), PKM 2, pyruvate dehydrogenase (PDH), lactate dehydrogenase A and
B (LDHA, LDHB) protein expressions in BEAS-2B and B2B-CrT cells. Histone 3 (H3)
was used as a loading control. Data are the average of at least three experiments ± the SEM.
*P < 0.05. Data normalized to theoretical cell numbers based on doubling time in 96 well
plates.
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5.3. Chromium(VI)-Transformed BEP2D Cells Do Not Exhibit the ‘Warburg Effect’
Given, that most cancer cells exhibit increases to their anaerobic glycolysis. We
wanted to confirm our findings with the BEAS-2B Cr(VI)-transformed cells. Therefore
using immortalized bronchial epithelial airway cells (BEP2D cells) and a Cr(VI)transformed BEP2D cells (BPD-CrT) (from the Laboratory of Dr. John P. Wise at the
University of Louisville), these cells were previously described (Xie et al., 2007). Passage
match control BEP2D cells and the BPD-CrT cells were analyzed for functional glycolysis,
L-lactate levels, and glycolytic enzymes. Again, using the glycolytic stress test, we saw no
increase in glycolysis, maximal glycolysis, and the glycolytic reserve of Cr(VI)transformed BEP2D cells compared to the passage-matched control BEP2D cells (Figure
5.2A-C). Using the glycolytic rate assay, we observed no increase in basal glycolysis or
compensatory glycolysis of Cr(VI)-transformed BEP2D cells compared to the passagematched control BEP2D cells (Figure 5.2D-E). We also found no change in the L-lactate
levels of Cr(VI)-transformed BEP2D cells compared to the passage-matched control
BEP2D cells (Figure 5.2F). Lastly, we saw no increase in the rate-limiting glycolytic
enzymes, PDH, LDHA, and LDHB in the Cr(VI)-transformed BEP2D cells compared to
the passage-matched control BEP2D cells (Figure 5.2G). Combined with the Figure 5.1
data, these data indicate that Cr(VI)-transformed lung epithelial cells do not exhibit the
‘Warburg effect’.
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Figure 5.2 Chromium(VI)-Transformed BEP2D Cells Do Not Exhibit the ‘Warburg
Effect’. (A) Glycolytic Function Profile for BEP2D cells with the relevant injection
strategy for the Seahorse Analyzer Glycolytic Stress Test. (B) Glycolytic stress test data
for the BEP2D and BPD-CrT cells. (C) Glycolysis, Glycolytic capacity, and glycolytic
reserve for the BEP2D and BPD-CrT cells. (D) Glycolytic Rate Profile for the BEP2D cells
with the relevant injection strategy for the Seahorse Analyzer Glycolytic Rate Assay. (E)
Basal glycolysis and compensatory glycolysis for the BEP2D and BPD-CrT cells. (F)
Extracellular L-lactate levels for BEP2D and BPD-CrT cells. (G) Hexokinase I,
Hexokinase II, phosphofructokinase (PFKP), pyruvate kinase isozymes M1/M2 (PKM
1/2), PKM 2, pyruvate dehydrogenase (PDH), lactate dehydrogenase A and B (LDHA,
LDHB) protein expressions in BEP2D and BPD-CrT cells. Histone 3 (H3) was used as a
loading control. Data are the average of at least three experiments ± the SEM. *P < 0.05.
Data normalized to theoretical cell numbers based on doubling time in 96 well plates.
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5.4. Chromium(VI)-Transformed Lung Fibroblasts Cells Do Not Exhibit the
‘Warburg Effect’
We wanted to further demonstrate that our results were not cell line specific or that
immortalization factors affected our results. Immortalized lung fibroblasts (WTHBF-6)
and a Cr(VI)-transformed WHTBF-6 cells (T23-3 and T73-3 cells) (from the Laboratory
of Dr. John P. Wise at the University of Louisville) were used. These cells were previously
described (S.S. Wise et al., 2018). He Passage match control cells (C52-2 cells) and the
Cr(VI)-transformed cells (T23-3 and T73-3 cells) were analyzed for functional glycolysis,
L-lactate levels, and glycolytic enzymes. Using the glycolytic stress test, we observed no
increases in glycolysis, maximal glycolysis, and the glycolytic reserve of Cr(VI)transformed WTHBF-6 cells compared to the passage-matched control WTHBF-6 cells
(C52-2) (Figure 5.3A-C). With the glycolytic rate assay, we observed no increase in basal
glycolysis or compensatory glycolysis of T23-3 and T73-3 cells compared to the passagematched control C52-2 cells (Figure 5.3D-E). Similarly, we also found no change in the Llactate levels of Cr(VI)-transformed WTHBF-6 cells compared to the passage-matched
control WTHBF-6 cells (Figure 5.3F). Lastly, We did not observe any change in the ratelimiting glycolytic enzymes, PDH, LDHA, and LDHB in the Cr(VI)-transformed WHTBF6 cells compared to the passage-matched control WHTBF-6 cells (Figure 5.3G).
Combined with the Figure 1 and 2 data, these data demonstrate that Cr(VI)-transformed
lung cells do not exhibit the ‘Warburg effect’ and further shows that cell type and cell
immortalization did not affect our results.
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Figure 5.3. Chromium(VI)-Transformed WTHBF-6 Cells Do Not Exhibit the
‘Warburg Effect’. (A) Glycolytic Function Profile for WTHBF-6 cells with the relevant
injection strategy for the Seahorse Analyzer Glycolytic Stress Test. (B) Glycolytic stress
test data for the WTHBF-6 cells (C52-2 cells) and Cr(VI)-transformed WTHBF-6 cells
(T23-3 and T73-3 cells). (C) Glycolysis, Glycolytic capacity, and glycolytic reserve for the
C52-2, T23-3, and T73-3 cells. (D) Glycolytic Rate Profile for the WTHBF-6 cells with
the relevant injection strategy for the Seahorse Analyzer Glycolytic Rate Assay. (E) Basal
glycolysis and compensatory glycolysis for the C52-2, T23-3, and T73-3 cells. (F)
Extracellular L-lactate levels for C52-2, T23-3, and T73-3 cells. (G) Hexokinase I,
Hexokinase II, phosphofructokinase (PFKP), pyruvate kinase isozymes M1/M2 (PKM
1/2), PKM 2, pyruvate dehydrogenase (PDH), lactate dehydrogenase A and B (LDHA,
LDHB) protein expressions in C52-2, T23-3, and T73-3 cells. Histone 3 (H3) was used as
a loading control. Data are the average of at least three experiments ± the SEM. *P < 0.05.
Data normalized to theoretical cell numbers based on doubling time in 96 well plates.
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5.5. Cr(VI)-WTHBF-6 Xenograft-derived Cells Do Not Exhibit the “Warburg Effect”
Since we saw did observe increases in anaerobic glycolysis in Cr(VI)-transformed
cells compared to passage-matched control cells, we wanted to establish that the ‘Warburg
effect’ is a factor from the tumor microenvironment. Therefore using a mouse xenograft
tumor model, we isolated 6 cell lines from the T23-3 xenograft tumors and 2 cell lines from
the T73-3 xenograft tumors (Wise J et al., 2018). Passage match control WTHBF-6 cells
(C52-2) and the two Cr(VI)-transformed colonies (T23-3 and T73-3), and the xenograftderived cell lines (T23-3-X2, T23-3-X3, T23-3-X4, T23-3-X5, T23-3-X6, T23-3-X7, T733-X2, and T73-3-X3) were analyzed for functional glycolysis, glycolytic rate, L-lactate
levels, and rate-limiting glycolytic enzymes. Results from the glycolytic stress test revealed
that some xenograft tumor-derived cells (T23-3-X5 and T23-3-X6) had an increase in their
glycolysis, maximal glycolysis, and glycolytic reserve compared to the C52-2, T23-3, and
T73-3 cells (Figure 5.4A-D). Interestingly, we observed no major increase in basal
glycolysis or compensatory glycolysis when using the glycolytic rate assay (Figure 5.4EF). The L-lactate levels in the media were unchanged in the xenograft tumor-derived cells
as compared to transformed cell counterparts (Figure 5.4G-H). Lastly, we found no overall
increase in the expressions of glycolytic rating limiting enzymes, PDH, LDHA, and LDHB
(Figure 5.4I). These data indicate that Cr(VI)-xenograft tumor-derived cells do not exhibit
the ‘Warburg effect’ but have some xenograft tumor-derived cells had increased glycolysis.
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Figure. 5.4. Xenograft Tumor-Derived Cells Do Not Exhibit the ‘Warburg Effect’.
(A) Glycolytic stress data for the control WTHBF-6 cells (C52-2) and Cr(VI)-transformed
WTHBF-6 cells (T23-3) and xenograft tumor-derived cells (T23-3-X2, T23-3-X3, T23-3X4, T23-3-X5, T23-3-X6, and T23-3-X7). (B) Glycolysis, glycolytic capacity, and
glycolytic reserve for the C52-2, T23-3, T23-3-X2, T23-3-X3, T23-3-X4, T23-3-X5, T233-X6, and T23-3-X7 cells. (C) Glycolytic stress test data for C52-2 cells and Cr(VI)transformed WTHBF-6 cells (T73-3) and xenograft tumor-derived cells (T73-3-X2, and
T73-3-X3). (D) Glycolysis, glycolytic capacity, and glycolytic reserve for the C52-2, T73-3, T73-3-X2, and T7-3-X3 cells. (E) Basal glycolysis sand compensatory glycolysis for
C52-2, T23-3, T23-3-X2, T23-3-X3, T23-3-X4, T23-3-X5, T23-3-X6, and T23-3-X7 cells.
(F) Basal glycolysis sand compensatory glycolysis for C52-2, T73-3, T73-3-X2, and T733-X3, cells. (G) Extracellular L-lactate levels for C52-2, T23-3, T23-3-X2, T23-3-X3, T233-X4, T23-3-X5, T23-3-X6, and T23-3-X7 cells. (H) Extracellular L-lactate levels for
C52-2, T73-3, T73-3-X2, and T73-3-X3 cells. (I) Hexokinase I, Hexokinase II,
phosphofructokinase (PFKP), pyruvate kinase isozymes M1/M2 (PKM 1/2), PKM 2,
pyruvate dehydrogenase (PDH), lactate dehydrogenase A and B (LDHA, LDHB) protein
expressions in the different cells listed above. Histone 3 (H3) was used as a loading control.
Data are the average of at least three experiments ± the SEM. *P < 0.05 from C52-2. #P <
0.05 from either T23-3 or T73-3.
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5.6. Chromate-induced Lung Tumors Do Not Show Increased Lactate Dehydrogenase
A Protein Expression
Formalin-fixed lung tissue slides from tumor and normal adjacency obtained from
a worked exposed to Cr(VI) were subjected to fluorescence immunostaining with
antibodies against lactate dehydrogenase A (LDHA) in green and DAPI (nuclear control,
blue). The LDHA expression was not increased in Cr(VI)-tumor lung tissues (Figure 5.29E
and K) as compared to adjacent normal lung tissues (Figure 5.29B and H). These results
confirm our cell culture findings and show that LDHA protein expression is not increased
in Cr(VI)-induced lung tumor tissues.
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Figure 5.5. Chromate Lung Tumors Compared Do Not Show Increased LDHA
Protein Expression. (A-F) LDHA expression in normal tissue as compared to stage I lung
tumor tissue (chromate-induced). (G-L) LDHA expression in normal tissue as compared
to stage II lung tumor tissue (chromate-induced). LDHA expression is in red, DAPI is blue
and was used for nuclear control. Scale bar is 20 µM.
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5.7. ATP Production
Recently, it has been proposed that cancer cells normally do not produce more ATP,
but rather are upregulating energy metabolism pathways for producing building block for
cellular components. To tell if Cr(VI)-transformed cells have increased ATP production as
compared to their passage-matched control cells, we used the ATP production assay on the
seahorse analyzer to measure the ATP production. Surprisingly the total ATP production
results were mixed. We observed that the Cr(VI)-transformed BEAS-2B cells had lower
total ATP production when compared to their passage-matched control BEAS-2B cells
(Figure 5.6A). Conversely, we found that the Cr(VI)-transformed BEP2D and WTHBF-6
cells had no differences in their total ATP production when compared to their passagematched control cells (Figures 5.6B-C). We continued in the investigation of the ATP
production assays and measured the ATP production of the xenograft tumor-derived cells
and compared them to the Cr(VI)-transformed cells (T23-3 and T73-3 cells) and the
passage-matched control cells (C52-2). When examining the total ATP production, we saw
a variation between the Xenograft tumor-derived cells (Figure 5.7A-B). Not all of the cell
lines had increased total ATP production when compared to the passage-matched control
cells. We found that T23-3-X2, T23-3-X3, T23-3-X4, and T23-3-X6 had increased total
ATP, while T23-3-X7, T73-3-X3, T73-3-X2, and T73-3-X3 cells had decreased total ATP
production. Interestingly, the Cr(VI)-transformed cells when used in these experiments
showed lower total ATP when compared to the passage-matched control cells. This is
different then what we noted in the section above. We propose this difference is likely due
to subtle metabolic variations in the cells. It is important to note is the breakdown of their
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ATP production does not change and matches the glycolysis and mitochondrial respiratory
results (Wise J et al., 2018).
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Figure. 5.6. ATP Production of Chromium(VI)-Transformed Cells. (A) Total ATP
production for the BEAS-2B and B2B-CrT cells as measured by the Seahorse Analyzer.
(B) Total ATP production for the BEP2D and BPD-CrT cells. (C) Total ATP production
for the WTHBF-6 Cells (C52-2) and Cr(VI)-transformed WTHBF-6 cells (T23- and T733 cells). Data are the average of at least three experiments ± the SEM. *P < 0.05.
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Figure 5.7. ATP Production of Xenograft Tumor-Derived Cells. (A) Total
ATP production for control WTHBF-6 cells (C52-2) and Cr(VI)-transformed
WTHBF-6 cells (T23-3) and xenograft tumor-derived cells (T23-3-X2, T23-3-X3,
T23-3-X4, T23-3-X5, T23-3-X6, and T23-3-X7). (B) Total ATP production Total ATP
production for control WTHBF-6 cells (C52-2) and Cr(VI)-transformed WTHBF-6 cells
(T73-3) and xenograft tumor-derived cells (T73-3-X2 and T73-3-X3). Data are the
average of at least three experiments ± the SEM. *P < 0.05 from C52-2. #P < 0.05 from
either T23-3 or T73-3.
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5.8. Importance
The results from this aim demonstrate that during Cr(VI)-induced carcinogenesis
(normal cells to malignantly transformed cells), malignantly transformed human lung cells
due to exposure to Cr(VI) do not exhibit increased anaerobic glycolysis (“Warburg effect”).
Additionally, these results were not cell type specific (fibroblast versus epithelial cells).
Also, xenograft tumor-derived cells did not have increased anaerobic glycolysis (“Warburg
effect”). These data are consistent with results from the chromate-tumor data. The lack of
observed “Warburg effect” is important, because these data suggest the possibility that not
all energy metabolism dysfunction occur for all forms of cancer. Further these cells could
be used to investigate changes independent of the “Warburg effect”.
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Chapter 6 Discussion
6.1. Overview
Hexavalent chromium is a well-established human carcinogen and has been shown
to cause respiratory cancers including lung cancer. After decades of research, the
underlying mechanisms for its carcinogenicity remain elusive, though many hypotheses
have been proposed and multiple pieces of the mechanism are known (Figure 1.4). It is
clear from the literature that ROS, redox imbalances, Cr(III)-DNA adducts, Cr(III) and
cellular components interactions, epigenetics, genomic instability, cell death pathway
evasion, and altered DNA are all key to the mechanism underlying Cr(VI) carcinogenesis.
However, other hallmarks of cancer such as dysregulated cellular energetics, remain under
investigated. This project investigated the hypothesis that Cr(VI)-induced transformation
of human lung cells will cause altered cellular energetics, specifically resulting in
increased de novo lipogenesis, the “Warburg effect”, and mitochondrial respiratory
dysfunction. The rational for these aims were the limit of literature on energy metabolism
in Cr(VI) carcinogenesis and the ability of Cr(VI) to activate upstream pathways of energy
metabolism. Similarly, some report in the literature suggested acute exposures to Cr(VI) in
cell culture studies could alter cellular energetics. Therefore we chose to investigate some
of these prominent energy pathways in carcinogenesis in an applied setting, in Cr(VI)induced carcinogenesis. Using the model Cr(VI)-transformed human lung cells, we chose
to examine three specific aims:
Specific Aim #1: Cr(VI)-transformed cells exhibit increased de novo lipogenesis,
which is important to their carcinogenic properties.
Specific Aim #2: Mitochondrial respiratory dysfunction does not occur during
Cr(VI)-transformation but rather during tumorigenesis.
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Specific Aim #3: Cr(VI)-transformed cells do not exhibit increased anaerobic
glycolysis or the ‘Warburg effect’.
In brief, we studied malignant transformed [due to Cr(VI) exposures] human lung
cells. Human bronchial epithelial airway cells (BEAS-2B cells) were treated to sodium
chromate for 180 days to induced transformation and we isolated an individual colony from
soft agar [BEAS-2B Cr(VI)-transformed cells]. Parallel untreated control BEAS-2B cells
were passaged in parallel. We then compared the results from BEAS-2B Cr(VI)transformed cells to two other sets of Cr(VI)-transformed lung cell line sets, human
bronchial epithelial airway cells (BEP2D cells) and human lung fibroblasts (WTHBF-6
cells). Further, we also employed a tumor growth assay using the xenograft nude mouse
model and isolated xenograft tumor-derived cells from the Cr(VI)-transformed fibroblasts.
We observed increased lipogenesis enzymes and activity in all Cr(VI)-transformed cells as
compared to their passage-matched control cells. This pathway was demonstrated to be
important for the Cr(VI)-transformed BEAS-2B cells. We reported no mitochondrial
respiratory dysfunction in the Cr(VI)-transformed cells as compared to their passagematched control cells, but observed mitochondrial respiratory dysfunction in xenograft
tumor-derived cells. We found no increased anaerobic glycolysis or “Warburg effect” in
the Cr(VI)-transformed cells or the xenograft-tumor derived cells. Lastly, we found that
human chromate-induced lung cancer tissues had increased pACLY, ACLY, ACC1, and
FASN expressions and lung tumor tissues had no change in LDHA expression. These
results suggest that some energy metabolism changes (reported in cancers) occur from
Cr(VI)-induced malignant transformation but others require the tumor microenvironment
and some may not occur during the transformation process.
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6.2. Chromium and Lipid
In chapter 3, we reported on lipid metabolism changes in Cr(VI)-induced
transformation, these results are also summarized in table 6.1. We reported that key
lipogenesis proteins (ACLY, ACC1, and FASN) were increased in Cr(VI) treated human
lung cells for 120 h. We observed that key lipogenesis proteins (ACLY, ACC1, and FASN)
were increased in three sets of Cr(VI)-transformed lung cells when compared to their
passaged matched control cells. Functionally, we saw these cells were increasing free fatty
acid levels (palmitate). Additionally, we observed no changes in lipid droplet formation or
fatty acid oxidation of the Cr(VI)-transformed cells. Lastly, we confirmed this pathway
was important to Cr(VI)-transformed BEAS-2B cells and these proteins were increased in
chromate lung tumors.
Our data in Cr(VI)-transformed cells is consistent with the literature, showing
cancer cells have increased lipogenesis proteins (Santos and Schulze et al. 2012). Some
studies have implicated that overexpression of these lipogenesis proteins (ACC1 and
FASN) are important to the carcinogenesis mechanism and can induce neoplastic cellular
transformation. In murine skin cells overexpression of ACC1 drove the neoplastic
transformation of these cells (Li et al., 2016). Further, using withaferin A, the authors were
able to block the cancer properties from the overexpression of ACC1 (Li et al., 2016).
Similarly overexpression of RAS or EGFR led to increased FASN in mammary epithelial
cells which drove neoplastic transformation furthermore, this FASN overexpression has
been shown to be important to the carcinogenesis of mammary epithelial cells (Yang et al.,
2002). A study from Vazquez-Martin et al. (2008) reported that overexpression of FASN
activated the HER1/HER2 tyrosine kinase receptors in human mammary epithelial cells
and these cells underwent neoplastic transformation. Additionally, Zaytseva et al. (2014)
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demonstrated that in colorectal cancer cells with a low expression of FASN, overexpression
of FASN led to increased angiogenesis properties. In prostate epithelial cells
overexpression of FASN caused neoplastic transformation and transgenic expression of
FASN in mice resulted in prostate intraepithelial neoplasia (Miigita et al., 2009).
Our prolonged (120 h) Cr(VI) treatment of human lung cells increased lipogenesis
protein expressions, pACLY, ACLY, ACC1, and FASN (Figure 3.1.). It appears that there
is a dose dependent increase, additional work is needed to see if this is also time dependent.
Guo et al. (2013) reported that acute Cr(VI) treatment of human skin fibroblasts could
induce SREBP-1 proteins and change the cholesterol profile of these cells. Additionally, it
has been reported that Cr(VI) induced ROS can cause lipid oxidation, specifically causing
lipid peroxidation (Leonard et al., 2004). In humans, chromate workers exposed had
increased lipid peroxidation in their blood plasma (Elis et al., 2001).
During acute and prolonged exposures to Cr(VI), the cell may respond to upregulate
lipogenesis related proteins due to endoplasmic reticulum stress, as endoplasmic retriculum
stress can lead to lipid accumulation (Fang et al., 2013). Along with this, it may be
upregulating the lipogenesis pathway to increase the amount of free fatty acids to increase
the amount of saturated and monounsaturated fatty acids to protect against lipid
peroxidation from the acute toxicity of ROS. Polyunsaturated acyl-chains easily undergo
peroxidation as compared to saturated and monounsaturated fatty acids. Increased rates of
de novo lipogenesis in cancer cells has been linked to a high rate of saturated and
monounsaturated fatty acids (Santos and Schuzle, 2012). However more studies are needed
to clarify if the cells are upregulating lipid proteins in response to Cr(VI) exposure in order
to make more saturated and monounsaturated fatty acids.
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Following neoplastic transformation with Cr(VI), we found that Cr(VI)transformed BEAS-2B, BEP2D, and WTHBF-6 cells compared to their passage-matched
control cells had increased pACLY ACLY, ACC1, FASN protein expression and increased
free fatty acid levels (palmitic acid). Given, that cancer cells may upregulate de novo
lipogenesis for energy usage or energy storage, we measured β-oxidation for energy usage
and lipid droplet formation for energy storage. We saw no increases in either endpoint in
the Cr(VI)-transformed cells as compared to their passage-matched control cells.
Additional investigations are needed to determine if these Cr(VI)-transformed cells are
upregulating de novo lipogenesis for changing the lipid profile or for stabilizing EGFR.
The literature supports a positive feedback loop between EGFR and FASN
overexpression in cancer. Specifically, a palmitate attached to the EGFR receptor to
stabilize it on the membrane and leading to palmitoylation, the EGFR then upregulates the
FASN and a positive feedback loop is achieved (Ali el al., 2018; Bollu et al., 2015). Cr(VI)transformed cells have increased FASN and EGFR expressions and therefore this feedback
loop may be highly probable. Cancer cells will change the lipid profile of the cellular
membrane for multiple reasons, one being protection against lipid peroxidation (discussed
above). Previous reports have implicated lower ROS in Cr(VI)-transformed cells compared
to passage-matched control cells (Xu et al., 2018), it is possible this is due to a change in
the lipid profile. Future investigations are aimed at examining these two endpoints in
Cr(VI)-transformed cells.
Next, we demonstrated that drug inhibition (C75) of FASN caused FASN protein
expression, cell proliferation, and soft agar colony formation of Cr(VI)-transformed
BEAS-2B cells. These results established that increased de novo lipogenesis is important
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for Cr(VI)-transformed cells and overexpression of FASN is a key protein for some cancer
properties of these cells. Relat et al. (2012) reported that in A549 cells C75 inhibition
inhibited FASN and cancer properties of these cells, our data match these results. C75 has
the potential to have an off target effect on the carnitine transporter and negatively affect
fatty acid oxidation and therefore is not appropriate for animal studies. These data match
reports in lung cancer where overexpression of these lipogenesis proteins is seen in lung
cancer cell lines and in patient tumors (Conde et al; 2007; Hess and Igal 2011; Jin et al.,
2014; Migita et al., 2008; Orita et al., 2007; Osugi et al., 2015; Piyathilake et al., 2000;
Relat et al., 2012; Visca et al., 2004). From the C75 inhibition data it is not clear if the lack
of growth in the growth curve experiments is due to cell death or cell cycle arrest. However,
it has been reported that inhibition of overexpressed FASN in cancer leads to a cytotoxic
buildup of malonyl-CoA (Swinnen et al., 2006). Additionally, C75 treatment was shown
to induce apoptosis of human melanoma cells, human breast cancer cells, and human lung
cancer cells, (Ho et al., 2007; Puig et al., 2008; Relat et al., 2012). Therefore, it is likely
that the inhibition of FASN in Cr(VI)-transformed cells is resulting in cell death. Further,
it has been demonstrated that FASN is important for lung cancer cells’ tumorigenesis (Relat
et al., 2012). Therefore in our future experiments, we will investigate shRNA knockdown
of FASN to demonstrate that FASN is important for Cr(VI)-transformed cell
tumorigenesis.
In lung cancer patients overexpression of ACLY and FASN in tumor tissues has
been observed and associated with a poor post treatment survival rate (Migita et al., 2008;
Orita et al., 2007; Osugi et al., 2015; Piyathilake et al., 2000; Visca et al., 2004). Similarly,
increased human lung tumor expression of p-ACC (phoysphoyrlation of ACC1/ACC2
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leads to inhibition) is linked to increased patient survival (Conde et al; 2007). These studies
demonstrate that the change in lipogenesis as measured in cell culture studies translates to
lung cancer patients. We stained tumor and adjacent normal tissue from 2 chromateinduced lung cancers from chromate workers. One subject was stage I and one subject was
stage II, both tumors with squamous cells. We observed that total ACLY, pACLY, ACC1,
and FASN expressions were increased in the Cr-tumor tissue as compared to the normal
adjacent tissues. We did see the possibility of a link between lung cancer staging and ACC1
and FASN expressions, unfortunately our sample size for these two stages is 1, and
therefore a clear link remains unknown. Furthermore these visual protein expression data
are important because they demonstrate our cell culture results are consistent with
chromate-induced lung cancers in humans.
Additional future studies are needed to investigate the interactions of upstream
factors and the change in lipogenesis in Cr(VI)-transformed cells. Specifically, the role of
Nrf2 in the lipogenesis changes needs to be investigated, given that Nrf2 is upstream of
certian metabolism pathways and that this transcription factor becomes constitutively
activated in Cr(VI)-transformed cells compared to passage-matched control cells (Kim et
al., 2015; Kim et al., 2016; Kitteringham et al., 2008; Pratheeshkumar. et al., 2016; Wang
Y et al., 2018). When Nrf2 becomes constitutively activated, it plays an oncogenic role in
cancer development (Wang Y et al., 2018). It is likely that Nrf2 may not properly regulate
lipid metabolism endpoints as previously described in the literature and may be a major
cause for lipogenesis enzyme shifts (Kitteringham et al., 2008; Wang Y et al., 2018).
However, given lipid signaling is different in murine livers as compared to humans, it adds
further complexity to the role Nrf2 is playing here (Bergen and Mersmann 2005). Lastly,
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as discussed above, EGFR and FASN form a positive feedback loop in cancer cells and
this positive feedback loop needs to be investigated in Cr(VI)-transformed lung cells (Ali
et al., 2018; Bollu et al., 2015).
In conclusion for lipogenesis endpoints, we found that Cr(VI)-transformed cells
have increased lipogenesis proteins and increased lipogenesis as compared to passagematched control cells. These cells are not producing more lipids for energy usage or energy
storage. This pathway change is not unique to lung cell type and immortalization factor for
the lung cell line does not affect the results. Drug inhibition demonstrated that FASN
overexpression is important for Cr(VI)-transformed cells’ survival and cancer properties.
Lastly, we saw that pACLY, ACLY, ACC1, and FASN expressions were increased in
chromate-induced human lung tumors as compared to adjacent normal lung tissue.
Increased lipogenesis and associated enzymes may be a potential therapeutic target in
Cr(VI)-induced lung carcinogenesis.
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Table 6.1 Results of Lipogenesis Experiments

Endpoint

120 h
Cr(VI)
Exposure

BEAS-2B
BEP2D
WTHBF-6
Chromate
Cr(VI)
Cr(VI)
Cr(VI)
Lung
Transformed Transformed Transformed
Tumors
Cells
Cells
Cells

Growth in Agar

---

Yes

Yes

Yes

---

pACLY/ACLY
Expressions

Increased

Increased

Increased

Increased

Increased

FASN Expression

Increased

Increased

Increased

Increased

Increased

ACC1 Expressions

Increased

Increased

Increased

Increased

Increased

Fatty Acid Oxidation

---

No Change

No Change

No Change

---

Lipid Droplets

---

No Change

No Change

No Change

---

FASN inhibition –
Soft Agar Colonies

---

Decreased

---

---

---

FASN Inhibition Cell
Growth

---

Decreased

---

---

---
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6.3. Chromium and Mitochondria
In chapter 4, we reported on mitochondrial respiratory changes in Cr(VI)-induced
transformation, these results are also summarized in table 6.2. Interestingly, we found that
xenograft tumor-derived cells have mitochondrial respiratory dysfunction but Cr(VI)transformed cells did not exhibit mitochondrial respiratory dysfunction.
Currently, there is limited literature on the role of mitochondrial dysfunction during
the process of malignant cell transformation. In one report, it was shown that human skin
fibroblasts treated with a high concentration (5 µM) of Cr(VI) generated a small number
of cell populations that were resistant to Cr(VI) toxicity and survived this acute high Cr(VI)
treatment. These survivor cells exhibited no mitochondrial DNA damage compared to
control passage-matched cells. Interestingly, these cells had a decreased spare respiratory
capacity compared to control (Nickens et al., 2012). It is important to note that it was a
very small number of cells that had resistance to high dose acute Cr(VI) exposure.
Additionally, in Cr(VI)-transformed cells, we did not observe major changes in their spare
respiratory capacity as was found with skin fibroblasts in the aforementioned study. There
are a couple of possible explanations for these differences: (1) the previous study focused
on acute, high-Cr(VI) exposures and the respiration change could be related to survival
during acute Cr(VI) exposure; and (2) another report found that human lung fibroblasts and
skin fibroblasts have different sensitivities to acute Cr(VI) exposures (Xie et al., 2015).
In chapter 4, we reported on mitochondrial respiration endpoints in multiple sets of
Cr(VI)-transformed lung cells as compared to their passage-matched control cells. We also
described the same mitochondrial respiration endpoints of xenograft tumor-derived cells.
It was found previously, that Cr(VI) cancer stem-like cells had decreased oxygen
consumption when compared to passage-matched control BEAS-2B cells and BEAS-2B
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Cr-(VI)-transformed cells (Dai et al., 2017). It is recognized from multiple studies that
cancer stem cells have different metabolism compared to cancer cells, which would explain
the difference in results obtained from Cr(VI) cancer stem-like cells and our current results
(Deshmukh et al., 2016; Dong et al., 2017; Peiris-Pagès et al., 2016). Another report found
that acute exposures to Cr(VI) could cause mitochondrial dysfunction (Abreu et al., 2013),
this difference from our results could be due to toxicity of Cr(VI) at 48 h. Further, these
mitochondrial dysfunction response may represent a survival response to acute Cr(VI)
toxicity or the changes reported are early response part of Cr(VI)-induced carcinogenic
mechanism.
Our results indicate that mitochondrial respiration is not affected negatively after
malignant transformation from Cr(VI) exposures, as evident from comparing Cr(VI)transformed lung cells to their passage-matched control cells. We found a general trend
that some of Cr(VI)-transformed cells have increased coupled respiration, yet some Cr(VI)transformed cells do not. The differences in some of the respiration functions between the
transformed cells could be due to some mitochondrial changes in the cells that are not
uniform during cellular transformation and other metabolic endpoints (e.g., increased
lipogenesis, mitochondrial membrane potential, alterations to mitochondrial complexes,
and mitochondrial DNA changes) may also be involved. We reported that xenograft tumorderived cells had significant inhibition of their max mitochondrial respiration (following
FCCP treatment) and their spare respiratory capacities. These xenograft tumor-derived
cells also had decreased coupling efficiency, another important endpoint showing
mitochondrial respiratory dysfunction, as it shows these cells are making less ATP to total
oxygen used. Interestingly, xenograft tumor-derived cells have increased coupled

185

respiration compared to their Cr(VI)-transformed cells. Contrary to these results, one
xenograft tumor-derived cell line (T23-3-X2) showed increased mitochondrial respiration,
providing evidence that not every cell from a tumor undergoes mitochondrial dysfunction.
These data indicate that cellular transformation does not cause mitochondrial dysfunction,
rather it may be due to the tumor microenvironment.
Ethidium bromide treatment of immortalized prostate epithelial cells caused a
depletion of mitochondrial DNA, which is critical factor in various cancer endpoints (e.g.
glycolytic metabolism, migration, and survival (Moro et al., 2009). Mutations in
mitochondrial DNA were found in patient-derived pancreatic cancer cell lines and further
examination of the metabolic profiling led to the finding that complex I, III, and IV were
inhibited in some of these patient-derived pancreatic cell lines (Hardie et al., 2017). In the
same study, the Hardie et al. (2017) showed that, that in the patient-derived pancreatic cell
lines (with complex I inhibition) oxygen consumption was lower than immortalized
pancreatic cells. These patient-derived xenografts cell line results are in agreement with
our results using the xenograft tumor-derived cells. In human lung cells (BEAS-2B)
chronically (6 month) exposed to arsenic were reported to have mitochondrial dysfunction.
Additionally, the authors measured the endpoints of gene expressions and found multiple
genes associated with mitochondrial dysfunction were lower in the chronically arsenictreated cells compared to the passage-matched control BEAS-2B cells. Specifically, the
expressions of genes associated with the electron transport chain were lower (Stueckle et
al., 2012). Although the authors did not isolate a single phenotype in their study of chronic
arsenic treatment, these data do indicate a possible difference in mitochondrial response
between arsenic and chromium. However, it is possible that there may be mitochondrial
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gene changes in Cr(VI)-transformed cells, but more investigations are warranted to confirm
this.
Even though there was no mitochondrial respiratory dysfunction in Cr(VI)transformed cells, other endpoints of mitochondrial dysfunction may be present, including
mitochondrial DNA damage, mitophagy dysfunction, and mitochondrial membrane
potential changes. However, respiration is unaffected in these cells so it is plausible that
the mitochondrial membrane potential is also unaffected. Additional studies are warranted
to examine the cause of mitochondrial respiration changes in the xenograft tumor-derived
cells. Specifically, Nrf2 role in mitochondrial changes needs to be studied, given that Nrf2
is upstream of many metabolism pathways and Nrf2 becomes constitutively activated in
Cr(VI)-transformed cells compared to passage-matched control cells (Kim et al., 2015,
2016; Pratheeshkumar et al., 2016, 2017; Wang Y et al., 2018). Nrf2 when constitutively
activated, will play an oncogenic role in cancer development. It is likely that Nrf2 may not
properly regulate its metabolism endpoints and may be a major contributing factor for
metabolism shifts (Wang Y et al., 2018). Further investigation on the changes in the
mitochondrial membrane potential, mitochondrial DNA and mitophagy (mitochondria
autophagy) during Cr(VI)-transformation and in Cr(VI)-transformed cell tumorigenesis
remains to be investigated.
The results from the chapter 4 demonstrate that during the early stages of metalinduced carcinogenesis (normal cells to malignantly transformed cells) malignantly
transformed human lung cells [due to exposure to Cr(VI)] do have mitochondrial
respiratory dysfunction. As with the lipogenesis results, these results were not cell type
specific (fibroblast versus epithelial cells). In the later stages of metal-induced
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carcinogenesis (transformed cells to tumor) we observed mitochondrial respiratory
dysfunction. Thus, these results suggest that mitochondrial respiratory dysfunction occurs
late in Cr(VI)-induced carcinogenesis.
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Table 6.2 Results of Mitochondria Respiration Experiments
BEAS-2B
Cr(VI)
Transformed
Cells

BEP2D Cr(VI)
Transformed
Cells

WTHBF-6
Cr(VI)
Transformed
Cells

Xenograft
Tumorderived
Cells

Yes

Yes

Yes

---

Basal Respiration

No Difference

No Difference

No Difference

Decreased

Maximal Respiration

No Difference

No Difference

No Difference

Decreased

Spare Respiratory
Capacity

No Difference

No Difference

No Difference

Increased

Proton Leak

No Difference

No Difference

No Difference

Decreased

Non-Mitochondrial
Respiration

No Difference

No Difference

No Difference

Decreased

Coupled Respiration

No Difference

No Difference

No Difference

Decreased

Coupling Efficiency

No Difference

No Difference

No Difference

Decreased

Endpoint

Growth in Nude Mice
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6.4. Chromium and ‘Warburg Effect’
In chapter 5, we reported on the glycolysis and L-lactate levels in chromiumtransformed lung cells as compared to their passaged match control cells. These results are
summarized in table 6.3. Our results clearly indicate through functional glycolysis and
glycolytic rates that glycolysis is not increased in Cr(VI)-transformed lung cells as
compared to passage matched control cells. We also observed no changes in extracellular
lactate levels. The same results occurred in Cr(VI)-transformed fibroblast xenograft
tumor-derived cells. We also observed a general trend of no increases in expressions in the
glycolytic rate-limiting enzymes (Hexokinase, PFKP, PKM 1, and PKM 2), PDH, LDHA,
LDHB. These data indicate that that there are no increased in anaerobic glycolysis or
‘Warburg effect’ during Cr(VI)-induced lung carcinogenesis in vivo.
In previous report, it was shown that Cr(VI)-cancer stem like cells had increased
anaerobic glycolysis as compared to the normal-stem cells and Cr(VI)-transformed cells
(Dai et al., 2017). Differences have been found between the energy metabolism of cancer
stem like cells and cancer cells (Deshmukh et al., 2016; Peiris-Pagès et al., 2016).
Moreover, cancer stem like cells have been shown to have higher levels of anaerobic
glycolysis, specifically have higher glycolysis levels, glycolytic enzymes, and L-lactate
levels compared to cancer cells (Deshmukh et al., 2016; Hammoundi et al., 2011; Liu et
al., 2013; Palorini et al., 2014). We suspect if we isolated Cr(VI)-cancer stem like cells for
these Cr(VI)-transformed cell lines that we would see a similar trend as reported by Dai et
al. (2017).
It has become well established that most cancer cells and tumors have permanent
shift towards anaerobic glycolysis versus aerobic glycolysis, even in the presence of
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oxygen, which has been termed the ‘Warburg effect’. Previous studies have looked at Llactate levels and glycolysis intermediate levels during transformation of mammary
epithelial cells and reported increases in lactate levels and glycolysis sugars (Chang et al.,
2016; Janzer et al., 2014; Zou et al., 2017). In human lung epithelial cells transformation
from radon was shown to increase lactate in late passages (Liu et al. 2016). In human
fibroblasts transformation from RAS mutations resulted in increased glycolysis measured
by the Seahorse Analyzer but no increases in lactate. In neural stem cells, causing
transformation by interfering with metabolism proteins results in increases in glycolysis
and lactate (Peruzzo et al., 2016). While, these studies state the “Warburg effect” is result
of carcinogenesis (excluding the fibroblast study). They all have their shortcomings when
looking at experimental design and their results are over-stated. Each study used a mixed
phenotype population of cells when measuring endpoints of anaerobic glycolysis. It is
important to use a single phenotype when investigating transformation, by either isolating
colonies from soft agar or sub-cloning and selecting colonies that are transformed and grow
in agar. Otherwise within the cells tested some not transformed and it is not clear if the
results seen in these studies are due to changes in the stably transformed cells in their
studies or cells that have a non-stable phenotype. In our study, transformed cells tested
were either selected from soft agar or sub-clones that grew in soft agar, we also confirmed
transformation of all our transformed cell lines by xenograft tumor growth. Therefore, we
consider from our results that increased anaerobic glycolysis in the presence of oxygen or
the “Warburg effect” (as measured by functional glycolysis assays, glycolytic enzymes,
and lactate levels) does not occur in Cr(VI)-induced carcinogenesis and this may be true
for carcinogenesis as a whole in vivo. Interestingly, using chromate lung tumor tissues and
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immunofluorescence, we noticed LDHA was not increased in the tumor tissues as
compared to the normal lung tissue. We can speculate that it is possible chromate lung
tumors do not have the ‘Warburg effect’, however more studies using fresh patient samples
are need to measure L-lactate levels and functional glycolysis to confirm this finding. We
also found that LDHB (responsible for conversion of pyruvate to lactate) was not increased
in the Cr(VI)-transformed cells as compared to the passage-matched control cells, these
data provide evidence that the lactate is not being used differently between the Cr(VI)transformed cells and passage-matched control cells, however using stable isotope labeled
lactate is needed to confirm these results.
ATP production was not increased in the Cr(VI)-transformed cells as compared to
their passaged matched control cells. There was variability in ATP production and the
source of ATP for the xenograft tumor-derived cells. We suspect this variability is likely
due to the fact that not all cells in a tumor have the same access to ATP. At this time
without further investigation a pattern cannot be discerned. However, overall these ATP
data fit with the hypothesis that cancer cells’ dysregulated cellular energetics is for
‘building blocks’ versus increasing total ATP.
A future study is aimed at using the Cr(VI)-transformed cells from this aim to solve
a fundamental cancer biology question on if the ‘Warburg effect’ is a consequence or a
contributing factor for tumor development. We will aim to knockout LDHA and block the
ability of these transformed cells to upregulate anaerobic glycolysis and investigate this
chicken or egg question. Furthermore, these cells that don’t overexpress LDHA allow us
to investigate dysregulated cellular energetics that are independent of the ‘Warburg effect’.
Additionally, isolating cancer stem like cells from these malignantly transformed cells may
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show that the cancer stem like cells have undergone ‘Warburg effect’. We may also
investigate if the ‘Warburg effect’ occur after putting these malignantly transformed cells
in physiological oxygen. Liu et al. (2016) reported their radon-transformed cells handled
lower oxygen environments more efficiently than passage-matched control cells and had a
higher upregulation of L-lactate.
Lastly, our data demonstrated that in a laboratory setting, the ‘Warburg effect’ does
not occur during Cr(VI)-induced transformation of lung cells and does not occur during
Cr(VI)-transformed cells’ tumorigenesis. Interestingly, these results may carry over to
chromate lung tumors. More studies are needed to establish if the ‘Warburg effect’ occurs
in chromate lung tumors in humans or if using a chromate exposure in mice, does the
‘Warburg effect’ occur.
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Table 6.3 Results of Anaerobic Glycolysis Experiments

Endpoint

BEAS-2B
Cr(VI)
Transformed
Cells

BEP2D
WTHBF-6
Cr(VI)
Cr(VI)
Transformed Transformed
Cells
Cells

Glycolysis

No Change

No Change

Maximal
Glycolysis

No Change

Glycolytic
Capacity

Xenograft
Tumorderived Cells

Chromate
Lung
Tumors

No Change

No Change

---

No Change

No Change

No Change

---

No Change

No Change

No Change

No Change

---

L-Lactate
Levels

No Change

No Change

No Change

No Change

---

Glycolytic Rate

No Change

No Change

No Change

No Change

---

Variable

Variable

Variable

Variable

---

LDHA
Expression

No Change

No Change

No Change

No Change

No Change

Total ATP
Production

No Change

No Change

No Change

No Change

---

Rate Limiting
Glycolytic
Enzymes
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6.5. Overall Role of Dysregulated Cellular Energetics in Cr(VI) Carcinogenesis
Reports have shown that acute exposure to Cr(VI) can alter cellular energetics in
human cells. Specifically, acute exposure to Cr(VI) can alter the cholesterol proteins and
SREBP-1 (Guo et al., 2013), increase glycolysis (Abreu et al., 2014), and alter
mitochondrial respiratory function (Abreu et al., 2014; Nickens et al., 2012). Additionally,
ROS from Cr(VI) could cause lipid peroxidation (Leonard et al., 2004) and in chromate
exposed humans, blood plasma had increased levels of lipid peroxidation (Elis et al., 2001).
The data presented in chapters 3, 4, and 5 demonstrated that dysregulated cellular
energetics occur for Cr(VI) carcinogenesis. First in prolonged (120 h) exposures we saw
that Cr(VI) could induce lipogenesis protein expression in a concentration dependent
manner. Next, we found increased lipogenesis related protein expressions (ACLY, ACC1,
and FASN) in Cr(VI)-transformed cells and chromate lung tumors. Additionally, we
demonstrated the overexpression of FASN was important for Cr(VI)-transformed cell
cancer properties. Interestingly, we also found that Cr(VI)-transformed human lung cells
(BEAS-2B, BEP2D, and WTHBF-6 cells) had no major changes in their glycolytic
function, glycolytic rate, L-lactate levels or mitochondrial respiration when compared to
their passaged matched control cells. Similarly, xenograft tumor-derived cells did not
exhibit the ‘Warburg effect’, but did have mitochondrial respiratory dysfunction.
Combined with the literature and our data presented in chapter 3, 4, and 5 it is clear
that Cr(VI) exposure and Cr(VI)-induced carcinogenesis results in dysregulated cellular
energetics. Acute or prolonged exposures to Cr(VI) elicits a cellular response in the form
of an increase in glycolysis, mitochondrial respiration response, and increased lipogenesis,
the reasons for which are unclear. These data show that certain energy pathways
(lipogenesis and mitochondria respiration) have dysregulated function after malignant
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transformation from Cr(VI) exposure. In the case of increased de novo lipogenesis, it is an
early carcinogenesis step, while mitochondrial respiration occurs in later steps in Cr(VI)
carcinogenesis.
In Warburg’s original findings, he speculated that an insult would cause a cellular
energetic response, which later would become permanent after prolonged exposure to this
insult and would result in a permanent phenotypic change in energy metabolism. It is
possible that this occurs in Cr(VI) carcinogenesis, given the initial changes in energy
metabolism due to acute or prolonged Cr(VI) exposures. Then some of these changes in
energy metabolism become permanent after malignant transformation from Cr(VI) and
further drive the dysregulated cellular energetics. Future studies are needed to investigate
other metabolism pathways in Cr(VI)-induced carcinogenesis and to confirm these energy
changes are an initial response to Cr(VI) exposures and later become permanent. To
conclude some metabolism pathways are important to Cr(VI)-induced carcinogenesis,
while others appear not to be.
6.6. Proposed Cr(VI) Carcinogenesis Mechanism
When using models in the laboratory, different changes in human cells occur at
different times during Cr(VI) carcinogenesis (figure 6.1). It has been established that after
Cr(VI) exposures human lung cells upregulate p62, Nrf2, HIF-1a, and EGFR in response
to the Cr(VI) (Kim et al., 2015, 2016; Pratheeshkumar et al., 2016, 2017). Cells also
upregulate Nrf2 in response to the ROS from Cr(VI) (Wang et al., 2011; Wang et al., 2016).
Additionally, reports have shown that acute exposure to Cr(VI) leads to responses from
energetic pathways (Abreu et al., 2014; Nickens et al., 2012, Guo et al., 2013), however
the reasons for this is unclear. Acute Cr(VI) exposures also cause genomic instability,
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epigenetic changes, and altered DNA responses (Wise and Speer, 2018; Wise and Wise,
2018). Following chronic exposure to Cr(VI), cells undergo neoplastic transformation to
malignantly transformed cells. These cells have constitutively activated p62, Nrf2, HIF-1a,
and EGFR protein expressions, cell death evasion, and epigenetic changes (Kim et al.,
2015, 2016; Pratheeshkumar et al., 2016, 2017). Additionally, Cr(VI)-transformed cells
have altered DNA repair and genomic instability (Wise S et al., 2018). In chapters 3, 4,
and 5 we found Cr(VI)-transformed cells have dysregulated cellular energetics. Next,
following tumorigenesis using a xenograft tumor model in nude mice, Cr(VI)-transformed
cells developed tumors. Cell lines insulated from these tumors (xenograft tumor-derived
cells) had additional cancer properties, including dysregulated cellular energetics (chapter
4 and 5) and preliminary data suggests a near-tetraploid karyotype (data not shown).
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Figure 6.1. Chromium(VI) Transformation Changes.
Human lung cells have basal or physiological levels of p62, Nrf2, HIF-1α , and EGFR.
Additionally, these cells have regulated cellular energetics, functional DNA repair, and a
normal karyotype. Following Cr(VI) exposure inducing transformation, transformed cells
have constitutively activated p62, Nrf2, HIF-1α , and EGFR. These cells also have ability
to exhibit epigenetic changes, genomic instability, altered DNA repair, and dysregulated
cellular energetics, and evade cell death pathways. Following Cr(VI)-transformed cell
tumor development in nude mice, these xenograft tumor-derived cells have a small increase
in glycolysis, mitochondrial respiratory dysfunction, and a near tetraploid karyotype.
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Next, updating proposed Cr(VI) carcinogenesis mechanism from the Wise
Laboratory of Environmental Health and Toxicology, we propose two additional parallel
mechanism to be included in this over mechanism: cell death pathway evasions and
dysregulated cellular energetics (figure 6.2). The steps between and how the cells are
evading cell death and responding with dysregulated cellular energetic remains to be
determined. In the case of increased lipogenesis protein the Cr(VI) treated cells may be
upregulating the level of monounsaturated and saturated fatty acids to protect against lipid
peroxidation. It is also possible that dysregulated energetics may have interactions with
cell death, epigenetics, and genomic instability by providing signaling materials or other
important molecules (e.g., nucleotides, amino acids, carbohydrates, etc.). However, more
studies are needed to investigate this.
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Figure 6.2. Updated Cr(VI) Carcinogenesis Mechanism.
Using the mechanism slide from the introduction, here is an updated proposed Cr(V)
carcinogenesis mechanism. Two other mechanisms may occur in parallel to the genomic
instability and DNA repair changes. Cr(VI) treated cells with damage may evade cell death
pathways. Additionally, Cr(VI) appears to induced dysregulated cellular energetics.
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6.7. Potential Future Directions
Future directions could be used to address the chicken and egg question in cancer
research on dysregulated cellular energetics, what comes first the ‘Warburg effect’ or the
tumor? Using the Cr(VI)-transformed cells in this study, we could knockout lactate
dehydrogenase A and determine if malignantly transformed cells not relying on this
pathway are able to still grow tumors. We will also examine if the ‘Warburg effect’ occur
after putting these malignantly transformed cells in physiological oxygen. Additionally,
we can investigate metabolism changes independent of the ‘Warburg effect’. Investigating
other energy metabolism pathways in Cr(VI)-induced carcinogenesis would be
worthwhile, as well as determining FASN and EGFR have a positive feedback loop in
Cr(VI)-transformed cells like other cancer cells and examining if Nrf2 has a role in the
increased de novo lipogenesis of Cr(VI)-transformed cells. Other investigative avenues
include determining other reasons for the increases in lipogenesis aside from signaling (i.e.,
lipid peroxidation) and what is causing the mitochondrial respiratory dysfunction. Lastly,
more investigations with Cr(VI) exposures and energy pathways and key proteins are
needed to further establish the role dysregulated cellular energetics are playing in the
Cr(VI) carcinogenic mechanism.
6.8. Importance
Multiple studies have established that ACLY, ACC1, and FASN over expression
are crucial to the increase in lipid of cancer cells and some malignant features of cancer
cells. Additionally, changes in mitochondrial respiration and increased anaerobic
glycolysis are characteristics of cancer cells and tumors. Our results to reveal metabolic
reprogramming as a key piece in Cr(VI) carcinogenesis. Interestingly, some changes
reported in cancer and cancer cells require the tumor microenvironment and may require
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xenograft tumor cell lines when doing transformation studies for proper investigation.
These results also further indicate dysregulated cellular energetics as a possible parallel
mechanism in the proposed Cr(VI) carcinogenesis mechanism (Figures 1.4 and 6.2),
however more detailed investigations are required as well as further studies to understand
the overlap between the mechanisms. Lastly, these data open the door for the lipogenesis
proteins as therapeutic targets in chromate induced cancers and in addition, chromium may
be involved in other diseases involving dysregulated cellular energetics.
6.9. Conclusions
Our data demonstrated that increased lipogenesis occurs in malignant
transformation of human lung cells [due to Cr(VI) exposure]. Our data also showed that
mitochondrial respiratory dysfunction requires the tumor microenvironment for Cr(VI)transformed cells and is a later event in Cr(VI) carcinogenesis. Lastly, increased anaerobic
glycolysis does not occur in Cr(VI)-transformation. The lipogenesis results were able to
translate to chromate lung tumors in humans. These data established that dysregulated
energy metabolism occurs after Cr(VI)-induced cellular transformation.
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